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Personalised polypills, which includes multiple drugs in a single pill tailored for individual patients, has 
gained a lot of research interests with the emergence of pharmaceutical 3D printing. A distinct feature of 
polypill is to be able to release each drug in a controlled manner. However, currently, there are limited tools 
to aid the design of such solid dosage forms with desired drug release kinetics. In this work, the drug release 
mechanisms of a wide range of solid dispersions formed using polymers and model drugs covering a wide 
range of physicochemical properties were investigated to generate a large dataset with an attempt to 
develop a simulation strategy for achieving a desired drug release profile.  
 
Building a dataset and using the dataset toward simulation building the data to be reproducible and reliable. 
The sources of errors throughout the manufacturing and the performance measurements of 3D printed 
example solid dosage forms were first investigated to assess the reproducibility and reliability of the 
experimental data generated to build the dataset. This was the focus of chapter 3. Thereafter, chapter 4 
systematically investigated the behaviour of a wide range of pure polymers to enable the prediction of the 
behaviour of polymer blends. The polymer behaviour studied include hydration, swelling, and erosion. 
Addition of the drug and investigating the effect on formulation behaviour was the focus of chapter 5. 
Chapter 6 used statistical approaches such as principal component analysis as a factor reduction technique 
and K-means clustering to classify the behaviour of the polymer-drug dispersions. These statistical 
approaches successfully demonstrated that correlating polymer behaviours and drug release profiles can be 
used to predict the selection of polymer(s) for a given drug to achieve a desired drug release profile. Further 
upscaling of the dataset is crucial to enhance analysis. 
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Chapter 1: Introduction 
Since the 1950s, there has been accumulative evidence indicating a substantial account of variability for 
drug response is genetically determined with age, nutrition, health status, environmental exposure, 
epigenetic factors, and concurrent therapy was proposed and formed the foundation of the modern 
practice of personalised therapy (1). Therefore, a new discipline arose from genetics, biochemistry, and 
pharmacology known as pharmacogenetics. The continuous development of this new field led to and guides 
the modern practice of personalized medicine. The aim of personalized medicine is simply to tailor drug 
therapy with the best response and safety margin to ensure the most effective clinical outcome for each 
patient (2). While much of the vision of personalized medicine can be attributed to advancement in 
genetics, the implementation of personalized medicine requires the advancements in the pharmaceutical 
materials science and processing to enable viable methods to cost-effectively produce small batch 
personalised medicine to meet each patient’s needs. Additive manufacturing methods such as fused 
deposition modelling 3D printing has demonstrated the potential as a manufacturing tool to enable such 
small batch production. The process is operated by using a 3D digital design to guide the layer-by-layer 
production of each single dosage form (3). However, for the pharmaceutical field, currently, there is no 
systematic formulation approach that can rapidly provide the design that can tailor the drug and the drug 
release pattern to the needs of each patient.  
 
This project initiated by examining the accuracy of the FDM 3D printing process. The research then moved 
the focus on to developing a prediction approach which allows the formulation scientists to rapidly develop 
suitable solid dispersion based formulation tailored for each patient’s clinical needs (i.e. a particular drug 
with a particular type of controlled release pattern).  
 
The Introduction chapter is divided into two main sections, Background and Main Scope of this project. The 
Background section provides relevant information on the scientific concepts related to the type of 
formulations (solid dispersions) and the processing methods (FDM 3D printing and hot melt extrusion) used 
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in this project. This information is used as a knowledge foundation of experimental Chapter 3.  The Main 
scope of this project section reviewed and discussed the fundamental knowledge on the behaviour of 
polymer behaviour and drug release kinetics from polymer-based solid dispersions. This information forms 
the foundation for the research development of Chapter 4, 5 and 6.     
1.1 Background  
1.1.1 Hot Melt Extrusion (HME) 
HME is the process wherein raw materials are heated and mixed by applying shear stress and forced to exit 
through a die under controlled conditions (4). Originally and still widely used by the plastic industry, HME 
was introduced to and has been rapidly adopted by pharmaceutical manufacturing. The most frequent 
application of HME in the pharmaceutical industry is as a manufacturing process to produce solid dispersion 
based products.  
1.1.1.1 Types of extruders & Extrusion process 
Screw extruders are one of the three types of extrusion machines. The other two types are ram and radial 
screen extruders (5). Screw extruders are the most importantly used in the pharmaceutical industry (6). 
Within the screw types, there are three classifications: Single-screw extruders (SSE) with a smooth barrel, 
twin-screw extruders (TSE) with corotating or counter-rotating with intermeshing screws, and multi-screw 
extruders (MSE) with a rotating or static shaft. SSE is the most widely used due to its mechanical simplicity. 
SSE consists of one rotating screw in a smooth barrel that yields in a good melt, stable pressure, and 
temperature in the barrel. It is also characterized by a long residence time which provides good mixing but 
is itself a disadvantage (7). Excessively long residence time can lead to degradation of the material due to 
the prolonged exposure to heat. TSE was introduced with having two agitator assemblies on two parallel 
shafts. The use of two screws allows different conditions along the zones of the extruder. The screws can be 
either co-rotating or counter-rotating and can be intermeshing or non-intermeshing (8). Intermeshing TSE is 
the most used as the design allows for self-cleaning which prevents raw materials from being in the barrel 
and overheating (6). Non-intermeshing is less used due to their design but capable of producing high torque 
which is used for processing of highly viscous material (9, 10). TSE has two advantages over SSE; the first 
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being reduced residence time typically between 5-10 mins and second being enhanced mixing due to the 
design of screws which employ a disruptive mixing and dispersive mixing (11). In disruptive mixing, the 
materials are blended evenly while, in dispersive mixing, the material is broken down into finer 
morphologies (6). Hence, the enhanced mixing. TSE is preferred over SSE especially for thermolabile drugs 
(9). In this work, TSE was used. Figure 1-1 shows SSE, TSE, and the different screw types. 
 
Figure 1-1: (a) SSE with one screw and one shaft and TSE two screws on two shafts. (b) the two types of twin screws for TSE. (c) top: 
intermeshing screws, middle: intermeshing counter-rotating, and bottom: non-intermeshing counter-rotating screws. Adapted from 
reference (6, 8). 
The various types of extruders have three common distinct zones of operation. The first is the feeding, the 
second is the transition, and the third is the metering zone (6, 10-12). The material is fed through the 
hopper which is the feeding section. The material is then transported to the transition zone where it is 
melted, compressed, and mixed. As the compression takes effect, the pressure is increased, and the 
material moves along the barrel until it reaches the metering zone in the form of homogeneous plastic melt 
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ready for extrusion. The metering zone reduces the non-uniformity by minimizing the thickness variation, 
ensuring laminar flow, and smooth exit through the die cavity (11). The typical HME is shown in Figure 1-2.  
 
Figure 1-2: HME schematic (6). 
1.1.1.2 Materials for HME 
The materials used for HME should possess the following characteristics. They must meet the same levels of 
purity and safety as materials used in traditional oral dosage, must be able to deform easily inside the 
extruder and solidify on exiting it, must be thermostable and maintain an acceptable physical and chemical 
stability during the HME process and afterwards during long-term storage, and lastly, the desired in vitro 
release and in vivo performance should be achieved by the product. The pharmaceutical materials used for 
HME are a combination of drug and functional excipients. The functional excipients are classified as matrix 
carriers, release modifying agents, plasticizers, antioxidants, and thermal lubricants (6, 10).  
• Active Pharmaceutical Ingredients (APIs) 
Some of the advantages are that HME is an anhydrous process which avoids degradation due to hydrolysis 
by aqueous media often added in the granulating media. The drug has to be thermally stable during the 
HME process and as such, pre-characterization of the drug chemical and physical properties is crucial. 
Crystalline drugs, characterized by their lattice structure, are thermodynamically more stable compared to 
their counterpart amorphous forms (6). However, poorly-soluble crystalline drugs have a much slower 
dissolution rate than the amorphous form of the drug. HME is often used with an attempt to form a 
molecular dispersion of the drug in the polymer matrices to improve the dissolution rate of the drug. The 
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state of the drug in HME such as fully dissolved (molecular dispersion), or fully undissolved (phase separated 
solid dispersion with crystalline drug), or a combination of both, can impact the performance (i.e. drug 
release rate) and the stability of the oral dosage form (13).  
• Carriers 
Carriers are used during HME as embedding component for the drug. These carriers are melt-capable and 
are classified into polymeric carriers containing polymers and non-polymeric carriers containing low melting 
point wax. The polymeric carriers can be hydrophilic polymers such as polyethylene oxide or hydrophobic 
carriers such as zein and ethyl cellulose (14, 15). Reports of non-polymeric carrier have included the use of 
sugars and acids (12, 16). The choice of carriers depends on drug-polymer miscibility, polymer stability, the 
desired release mechanism, and function of the final dosage form (6). 
• Plasticizers 
Plasticizers are low molecular weight compounds that can affect in one or more of the three ways. They can 
cause the carrier to be less rigid, lower the processing temperature which can avoid the degradation of 
thermolabile drug, and reduce the shear forces needed for extrusion (6, 10, 17). The plasticization 
phenomenon occurs because plasticizers increase the free volume between polymer chains which lead to 
lower melt viscosity so that less heat (lower HME operational temperature) and shear forces are required to 
make the polymer chains move in the direction of the flow (18). Additionally, plasticizers ease the fusion 
process (melting) of semi-crystalline polymers (19). Common plasticizers, approved by the FDA, in 
pharmaceutical dosages are enlisted in Table 1-1. The materials used in HME is discussed next. 
Table 1-1: Common plasticizers used in oral dosage (10). 
Type Examples 
Citrate esters triethyl citrate, tributyl citrate, acetyl, triethyl citrate, acetyl tributyl citrate 
Fatty acid esters butyl stearate, glycerol monostearate, stearyl alcohol 
Sebacate esters dibutyl sebacate 
Phthalate esters diethyl phthalate, dibutyl phthalate, dioctyl phosphate 
Glycol derivatives Polyethylene glycol, propylene glycol 
Vitamin E TPGS D-α-tocopheryl polyethylene glycol 1000 succinate 
Others triacetin, mineral oil, castor oil 
 
6 
1.1.2 Fused Deposition Modeling 3D printing (FDM 3DP) 
According to statistics, FDM has been the most common 3D technology used for prototyping accounting for 
36% in 2017, 46% in 2018 (20), 57% in 2019 (3), and most commonly used for pharmaceutical applications 
until 2018 (21). FDM 3DP is a type of the material extrusion 3DP process (22, 23) wherein, a heated nozzle is 
used (24). The feeding material, in the form of filaments, is fed via rollers into the nozzle. Filaments are then 
heated by heating elements into a molten state to allow for extrusion through the nozzle tip (25). The 
nozzle can move in the x, y-direction while the platform is movable in the z-directions to produce the final 
desired geometry layer by layer, which fuses as the printed filament cools (26, 27). Upon deposition, the 
material cools and solidifies onto a platform. The schematic illustration of FDM is shown in Figure 1-3. 
 
Figure 1-3: Schematic illustration of the FDM 3D printing technology. Adapted from reference (28). 
In terms of loading drug into the FDM filaments, currently in use, are two common methods of preparation: 
impregnation and hot melt extrusion (29, 30). For impregnation, the filament is immersed (soaked) in a 
solution of the drug for an extended duration, usually a minimum of 24 hours. This method was used by 
Goyanes et al (31) but the drug loading achieved in such cases is quite low, approximately 15% at most (32). 
The alternate method is by preparing the custom made drug loaded filament using hot melt extrusion which 
has better drug loading capacity than the impregnation and is discussed next (33). 
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1.1.2.1 Pharmaceutical applications of HME coupled with 3D printing  
A major advantage of HME is to form solid dispersions with suitable polymeric excipients that provide the 
solubility enhancement for poorly soluble drugs (34). The different mechanisms proposed in the literature 
on how solid dispersions can improve drug solubility are improving wettability, preventing recrystallization, 
and stabilizing amorphous formulations (35). The melt and mixing process during HME converts crystalline 
drugs to the amorphous form by dispersing it in a carrier and prevents drug recrystallization through the 
formation of non-covalent bonds between the drug and the carrier chain or through the steric hindrance 
phenomenon (10). Due to the drug dissolved in the hydrophilic carrier, dissolution in gastrointestinal fluids 
is enhanced compared to that of the native crystalline form of drugs. Review of HME made oral solid dosage 
form from 1990 to 2015 has been given by Major et al (36). 
 
As discussed previously, for FDM 3DP, the filaments can be created using HME (37, 38). All pharmaceutical 
filaments have to be custom made using HME as all of the commercially available filaments are not made of 
pharmaceutical grade materials (39). The use of HME is to create a filament that incorporates the drug in a 
polymer and extruded via the use of a modified die to match the circumferential dimensions of the FDM 
3DP nozzle. HME is capable of producing thermoplastic filaments that can withstand tensile and 
compression forces of the printing process (40, 41). Coupling HME with 3D printing has shown the 
advantage of producing tablets with high drug loading capacities as high as 40% of the oral dosage (6, 38). 
For research, higher drug loading has received attention due to the potential of increasing patient 
compliance (42). Increased patient compliance is one of the benefits, which has been demonstrated in 
clinical trials of polypills for cardiovascular disease with 81% adherence vs 46% adherence when taking the 
medications separately (43). A Polypill is the combination of two or more drugs in one pill designed to 




Figure 1-4: Schematic of HME followed by 3DP as a single continuous process. The output can be FDM 3D printed tablets (right) or 
polypill (left). Adapted from reference (38). 
The oral solid dosage forms that have been printed using this approach reported in the literature are of four 
types. They are controlled release dosage forms (CRDFs), sustained release dosage forms (SRDFs), 
immediate release dosage forms (IRDFs), and polypills (37). CRDFs aim to control the plasma concentration 
of the drug after administration (44). SRDFs aim to maintain the rate of drug release over a sustained period 
(44). IRDFs aim to release the drug as fast as possible, generally with first order kinetics so that a fast 
therapeutics onset can be achieved (44).  
1.1.2.2 Commercialization Limitations 
FDM 3D printing is still a prototype machine and in its infancy stages in pharmaceutics. As such, it is 
expected that limitations and issues may exist. Such limitations and issues have been mentioned in 
literature (24, 25, 45-48). Alhijjaj et al reported the impacts of processing parameters on the 3D printed 
dosages by looking at the physical variations such as weight, dimensions, and individual stand width and 
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deduced correlations of one or more parameters to the physical variations using principal component 
analysis (48). In the case of oral solid dosage forms, the microstructure is an important key feature if 
polypills are to be made in the standard size of traditional tablets (24). This was shown by works of Goyanes 
et al wherein a polypill was printed. Since the polypill had two formulation filaments to be printed, it 
required precision of printer resolution at microscale to match the theoretical dimensions, which was not 
best achieved. This was evident by observing the high variations in the drug release profiles of 
approximately ±40% among some formulation replicates (49) but ±5% in others. This indicates the 
inconsistency in FDM 3DP currently in use. Weeren et al focused on quality of parts printed by FDM 
exported computationally as STL files by investigating deformities between designed specification and 
printed object, and categorized as surface and internal defects (50). Increasing print speed is challenging, as 
there is generally a trade off between feature resolution and print speed (51). The high temperatures 
required for printing has been recognized as a barrier limiting the materials available for FDM printing, as 
many materials degrade at higher temperatures (52). Okwuosa et al focused on 3DP at lower temperatures 
and using thermofillers to avoid degradation (53). 
 
There are also works citing economical issues that suggest 3D printing is still not feasible for mass 
production. Injection molding (another manufacturing method) is more cost effective per parts as 
production rates rise but 3D printing cost per part remains the constant (54). However, printing reduces 
time of production significantly but increases the number of steps to the final OSDF (21). There are great 
benefits to 3DP and additive manufacturing in general, which have already been discussed. Another casing 
point of a benefit possibly, is the manufacturing of orphan drugs which are very cost ineffective on mass 
production scale (55). Mazzanti et al has reviewed the challenges of using filaments and outlined specifically 
the problems of using natural polymers for FDM printers by diving them into two categories of processing 





Figure 1-5: Natural fiber filament problems that may be encountered in FDM 3DP and the possible solutions (56). 
The melting through HME results in obtaining a solid molecular dispersion. The types and controlling factors 
of solid dispersions are an important factor, which is discussed next. 
1.1.3 Solid dispersions 
The term solid dispersion refers to the distribution of one or more drug in a carrier at solid state by melting 
(fusion), solvent, or melting solvent method to improve the solubility of poorly soluble drug (57). Sekiguchi 
et al were the first to report the melting (fusion) method in the early 1960s (58). Sekiguchi et al initially 
proposed that solid dispersion can only exist as a eutectic mixture in a microcrystalline state but Goldberg et 
al subsequently reported this to not necessarily exist in microcrystalline state but also in other molecular 
arrangements (58, 59). Based on the molecular arrangement, Chiou and Riegelman classified six different 
types of solid dispersion (60), shown in Table 1-2. The state of matrix or the drug is one of the three: 
crystalline, amorphous, or molecularly dispersed, shown in Figure 1-6. In this project, the main kind of solid 
dispersion is amorphous solid dispersions often referred to as glass solution in the original six classifications. 





Figure 1-6: The different states of drug molecule in the polymer (61). 
Due to observations of monotectic, peritectic structures, Vasconcelos et al proposed a different 
classification system based on carrier properties: the first generation consisting of crystalline polymer, 
second generation consisting of amorphous carriers, and third generation consisting of surfactant carriers 
(62). Vo et al modified this by adding a fourth generation of insoluble and swellable polymers (63). 
Furthermore, Meng et al classified binary solid dispersion into six categories based on the state of the API 
which is similar to the classification proposed by Chiou and Riegelman (64). All classification schemes are 
equally valid, and here the first of them, proposed by Chiou and Riegelman, will be discussed. Figure 1-7 
illustrates the different classification categories. Recently, multicomponent solid dispersion systems have 
been cited as an efficient drug delivery system to improve bioavailability and drug solubility (65, 66). In such 
systems, as the name suggests, different compartments contain different solid dispersion systems with the 





Table 1-2: Classification of the six solid dispersion types. For the states, C=crystalline, A=amorphous, and M=molecularly dispersed. 
Adapted from reference (57). 
Solid dispersion type Matrix state Drug state 
Number 
of phases 
I Eutectics C C 2 
II Amorphous precipitation  C A 2 
III Solid solutions  
 Continuous solid solution C M 1 
 Discontinuous solid solution C M 2 
 Substitutional Solid Solution C M 1 or 2 
 Interstitial Solid Solution C M 2 
IV Glass suspension A C 2 
V Complex formation  A A 2 





Figure 1-7: Solid dispersion classification based on properties and number of categories in each in brackets (67). 
 
1.1.3.1 Eutectic Type 
Eutectic mixtures are made from rapid solidification of fused liquid of two components which show 
complete liquid miscibility and almost no solid-solid solubility (68). The phase diagram for the eutectic 
mixture is shown in Figure 1-8. Such systems are regarded as an intimately blended physical mixture of the 
two crystalline components (69, 70). 
Solid Dispersion Classification Basis
Physicochemical structures 
by Chiou and Riegelman in 
1971
(six categories) 
Carrier properties by 
Vasconcelos et al in 2007
(three categories)
Modified by Vo et al in 2013
(+1, totalling four categories) 






Figure 1-8: Phase diagram of Eutectic mixtures of substance A and B. Adapted from reference (60). 
The liquid miscibility is attained in the liquid solution phase of both A and B. In the adjacent phase, either A 
or B exist as a solid while the other is liquid. Point E is known as the eutectic temperature where the mixture 
freezes or melts and lower than either of the constituents (71). As the temperature is decreased, both A and 
B become solid and crystallized particles. The crystals, with their increased surface area and reduced 
particle size increase the dissolution rates along with other factors. This increase drug solubility with very 
small crystallite sizes, solubilization effect of the carrier in a microenvironment surrounding the drug 
particle in initial stages of dissolution, absence of agglomeration between fine crystallites of API that hinder 
dissolution, excellent wettability and dispersibility of API in a water-soluble matrix, and crystallization in the 
metastable form which has higher solubility leading to faster dissolution (60). Use of eutectic mixture is to 
form solid dispersion of a crystalline API in a crystalline polymer to enhance the dissolution of the drug. 
Carrier may be either hydrophilic or hydrophobic. Law et al demonstrated increased dissolution of insoluble 
fenofibrate in a eutectic mixture of PEG 8000 (hydrophilic polymer) of ratio 25:75 (API:polymer), while 
Figueirêdo et al demonstrated increased dissolution for both insoluble benznidazole (an antichagasic API) in 
eutectic mixture with insoluble posaconazole (an antifungal hydrophobic API) or ratio 80:20 (API BNZ:API 
PCZ) (72, 73). 
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1.1.3.2 Amorphous precipitation 
In this state, the API precipitate out in amorphous form within the crystalline carrier. This is the main 
difference between the eutectic mixture and amorphous precipitation. The amorphous form has the highest 
energy of the pure form of API and produces faster dissolution compared to the crystalline form (60). 
Mullins et al showed that amorphous novobiocin has a tenfold higher solubility than its crystalline form 
(74). The principle of crystalline carrier is the same as a eutectic mixture. The crystalline carrier, being 
water-soluble, exhibit forming small particles, reducing aggregation, increased wettability, decreasing 
crystallinity, and transforming metastable polymorph (75). Crystalline carriers such as urea (76), organic 
acids (77), and sugars have been used (78).   
1.1.3.3 Solid solutions 
A solid solution is made of solid solute dissolved in a solid solvent and often called mixed crystal due to the 
crystals of two component being homogenously distributed as a one phase system (79). It was suggested 
that due to solid in a solid medium, the molecular size of the solid solute is at a minimum, and can have 
faster dissolution than eutectic mixtures (80). Solid solutions can be classified into two categories either 
based on the level of miscibility or the crystalline structure of the solid solution (81, 82). Based on 
miscibility, the categorization is either continuous or discontinuous and based on the crystal structure, the 
categorization is either substitutional or interstitial solid solutions. In continuous solid solution, the 
components are miscible across all proportions. It has been theorized that total lattice energy of the 
continuous solid solution at various compositions should be greater than that of either pure components 
because the strength of the bond between the two different components at the solid state should be 
greater than that between the same species of molecules (79). Such solid solution has not been reported in 
pharmaceutics but has been reported to be made in engineering for lithium batteries by Noh et al (83). In 
contrast, discontinuous solid solutions, there is limited solubility of the two components above the eutectic 
temperature. This is more possible in reality a one component is capable of dissolving the other component 
to a certain degree. As the temperature is lowered, the solubility decreases, and the solid solution exists in a 




Figure 1- 9: (Left) Continuous solid solution. (Right) Discontinuous solid solution (84). 
In terms of crystalline structure, one group is substitutional solid solutions. In substitutional solid solutions, 
the solvent molecule is substituted by solute molecules in the crystal lattice structure. The resultant can be 
a continuous or discontinuous solid solution. Such substitution is possible if the molecular sizes of the two 
components do not differ more than 15% according to Hume-Ruthery rule (82, 85). In contrast, in interstitial 
solid solutions, the solute molecule occupies the interstitial space between the solvent molecules in the 
crystal lattice. For interstitial solid solutions to form, three factors must be present. The first is the diameter 
of the solute molecule should be less than 59% of the solvent molecule diameter. The second is the volume 
of the solute molecule should be less than 20% of the solvent molecule. The third is the pattern in which the 
solute and solvent molecule is arranged should favour the formation of an interstitial solid solution (60). 
Figure 1-10 shows the difference in the lattice structure of the substitutional and interstitial solid solution.   
 
Figure 1-10: (Left) Substituitional solid solution  crystal lattice and (right) interstitial solid solution. Black circles=Solute molecule and 
white circle=solvent molecules (60).  
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1.1.3.4 Glass suspension and Glass solutions 
The concept of the formation of a glass solution as another potential modification of a dosage form which 
can increase drug dissolution by Chiou and Riegelman (60). The term ‘glass’ is used to describe a pure 
chemical or a mixture of chemicals in a glassy state. A glass solution is a homogenous system in which the 
glassy or vitreous form of the carrier solubilizes the drug molecule in its matrix (86). Glass suspension is a 
mixture wherein the precipitate is suspended in glass solvent. The glassy state is achieved by rapid 
quenching of the melt (87). This glassy state is characterized by transparency and brittleness below the Tg. It 
continuously softens upon heating and gives a broad melting point. Heating the glassy state of pure 
compounds can transform it into a crystalline state. Various physicochemical properties such as viscosity, 
refractive index, thermal conductivity, compressibility, etc. change within the glass transition region when a 
substance is heated or cooled (60). Simonelli et al were the first to demonstrate high dissolution rates for 
glass suspensions using PVP with saphathiazole (88). 
1.1.3.5 Complex formation 
Complex formations are modified particles that are a conjugate of the drug and carrier molecules forming a 
binary system. The complex formation is common. Sekiguchi et al found eleven cases of compound 
formations out of twelve-phase diagrams while Guillory et al found four compound formations out of nine 
phase diagrams investigated (89, 90). Furthermore, If the complex forms during the preparation method, it 
does not indicate they will re-form in the liquid phase and vice versa. The formation of the drug from the 
complex formed depends on stability, dissociation constant, solubility and intrinsic absorption rate of the 
complex (60). In one study by Benet et al, the dissolution rates increased by onefold for a complex of 
griseofulvin and polyethylene glycol 6000 (91).  
 
The physical state of the drug and the excipients are vitally important for impacting on the stability and drug 
release behaviour of the solid dispersions. Therefore, the phase behaviour of solid dispersions is discussed 




1.1.3.6 Phase behaviour of solid dispersions 
Despite the potentials of solid dispersions for improving the dissolution of the poorly soluble drug, the 
number of research articles for solid dispersion outweighs the number of commercial products of solid 
dispersion (92). The low number is due to physicochemical instability in the manufacturing process or during 
storage with the eventual effect of the solid dispersion exhibiting phase separation or recrystallization (93, 
94). Understanding the phase behaviour of a solid dispersion is critical for predicting the stability of the solid 
dispersion. The phase behaviour of a solid dispersion can be probed by a range of thermodynamic 
parameters such as glass transition temperature and molecular mobility. These all can be used to predict 
the storage stability of solid dispersions. Here the glass transition temperature is discussed in detail as it was 
used directly in this project to identify the physical state and the phase behaviour of the solid dispersions 
studied. It is also one of the most widely used parameters to predict stability and to help identify the 
appropriate storage conditions of amorphous dispersions (95, 96). 
• Theories of Glass transition 
Previously, it was stated that Tg is dependant on the thermodynamics (cooling/heating rate). This raised a 
hypothetical question about how much Tg can be slowed if the rates are slowed. Furthermore, Tg is effected 
by the crosslink density, by the molecular weight, copolymerization, crystallinity, chemical structure groups, 
tacticity, and by pressure (97). Therefore, three main theories of glass transitions were proposed to explain 
at a molecular level, which is outlined in Table 1-3. 
Table 1-3: Tg theory with advantages and disadvantages (97). 
Theory Advantage Disadvantage 
Free volume 
theory 
1. Time and temperature of viscoelastic 
events related to Tg.  
2. Coefficients of expansion above and below 
Tg related 
1. Actual molecular 
motions poorly defined 
Kinetic theory 
1. Shifts in Tg with time frame quantitively 
determined 
2. Heat capacities determined 
1. No Tg predicted at 
infinite time scales 
Thermodynamic 
theory 
1. Variation of Tg with molecular weight, 
diluent, and cross-link density predicted 
2. Predicts true second-order transition 
temperature 






Free volume theory was introduced by Eyring et al primarily states free volume in the form of segmented 
voids as a vital part for the onset of molecular motion (98). Secondly, it relates the coefficient of expansion 
above and below the Tg, and third, it relates the viscoelastic motion to the variables of time and 
temperature.  
 
The kinetic theory defines Tg as the temperature at which the relaxation time for the segmental motions in 
the main polymer chain is of the same order of magnitude as the time scale of the experiment. The theory 
approaches the rate of equilibrium of the system accounting for the motion of the voids and molecules.  The 
kinetic theory also provides numerical information about the heat capacities below and above the Tg.  There 
are various models or method postulated pertaining to the kinetic theory such as Vol'kenshtein–Ptitsyn 
relaxation theory (99), Tool–Narayanaswamy–Moynihan method (100), Kovacs method (101), and Adam–
Gibbs theory (102). A comprehensive review of all these theories/models is given by Tropin et al (103). The 
thermodynamic theory introduces the notion of equilibrium and the requirement for true second-order 
transition, even at infinitely long scales which was proposed by Gibbs and DiMarzio (104).  It successfully 
predicts the variation of Tg with molecular weight, crosslink density, and diluent content (97). 
 
The free volume needed for calculations in these theories is found by subtracting the occupied volume from 
the total volume (105). The free volume numbers have different estimations due to different definitions of 
the occupied volume. Therefore, there are variations in the free volume number fraction. Table 1-4 outlines 
the various theories that estimate the free volume fraction. 
Table 1-4: Summary of free volume numbers from four models (97). 
Theory Free volume fraction Reference  
WLF 0.025 (106) 
Hirai and Eyring 0.08 (107) 
Miller 0.12 (108) 






• Glass transition (Tg) 
The glass transition is a phenomenon that is observed when an amorphous material is supercooled rapidly 
(no nucleation or crystallization), the material forms a glass whereby the macroscopic dynamics either 
ceases or is infinitesimally slower than the characteristics measurement time. The temperature at which 
this occurs is the Tg (110). The same holds true when heating that the glassy material changes into a 
rubbery material indicating it is a reversible process. The transition is a kinetic process and the Tg is 
dependent upon the cooling rate for a given material (111). Faster cooling result in higher Tg and slower 
cooling result in lower Tg. Figure 1-11 shows the volume changes as a function of temperature. Generally, 
an amorphous polymer has a single Tg (112). Blends can exhibit one or two Tg depending on their miscibility 
or immiscibility, which is discussed later (113). Tg is a second-order phase transition, unlike melting, which is 
a first-order transition whereby latent heat is involved. At Tg, there are changes in derivative 
thermodynamic properties such as heat capacity, coefficient of thermal expansion, mechanical modulus, 
and dielectric constant. (114, 115). There are also other physical changes in entropy, rigidity and viscosity 
(111). As viscosity is one of the indicators, Tg has also been noted as the temperature, at which the shear 
viscosity is equal to 1013 Poise or 1012 Pa s (116). 
 
Figure 1-11: Volume of various states of materials as affected by temperature (117). 
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Based on the derivative thermodynamic property changes mentioned, there are different methods to 
characterize the Tg of a material. The first is volumetric methods operating based on volume changes using 
dilatometry and thermal mechanical analysis (118). The second is mechanical or dielectric methods 
operating based on changes in storage modulus or changes in dielectric loss constant using dynamic 
mechanical analysis and dielectric analysis (119). The third is a moisture sorption technique operating based 
on changes in moisture uptake which switches from adsorption to absorption (120). The fourth is 
thermodynamic analysis operating based on changes in specific heat capacity using a differential scanning 
calorimetry (121).  
• Glass transition for Blends 
Polymeric blends can have three instances of Tg depending on the miscibility (122). For miscible blends 
which are a single phase, a single Tg is observed which can be calculated using the Fox equation or Gordon-
Taylor equation, shown by equation 1-1 and 1-2 respectively. For immiscible blends, the original two 
individual Tg of the constituting materials is observed. Thermodynamically, there is always some degree of 
molecular mixing of one component in another component but this negligible, and therefore still taken as 
an immiscible blend. For partially miscible blends, there are two separate Tg but both are more shifted 
toward the Tg of the other polymer (97, 122, 123). The Tg behaviours are shown in Figure 1-12. Such shifted 
Tg was observed in the works of using epoxy and acrylate polymer in a ratio of 60/40%, weight-wise, where 
the Tg of pure epoxy was 120oC, which shifted down (inward towards acrylate) to 95oC, while the Tg of pure 
acrylate was -40oC which shifted up (also inward toward epoxy) to -10oC, indicating a partial blend (often 










 (125) Equation 1-1 
Gordon-Taylor Equation 𝑇𝑔 =
𝑊1𝑇𝑔1 + 𝑘 ⋅ 𝑊2 ⋅ 𝑇𝑔2
𝑊1 + 𝑘 ⋅ 𝑊2
 (121) Equation 1-2 
where W1 is the weight fraction of homopolymer 1, W2 is the weight fraction of homopolymer 2, Tg1 





Figure 1-12: Schematic plots of shifts expected in Tg for the three blend scenarios (123). 
It is seen that miscibility is an important factor that affects the Tg. In this work, the Tg was used to assess the 
polymer blends in chapter 4. Two cases of polymer blends were prepared: miscible and semi-miscible blend. 
1.2 Main scope of this project 
1.2.1 Polymer behaviour in aqueous media 
Polymer dissolution is wherein the polymer immersed in a solvent undergoes two transport processes, one 
being solvent diffusion and the other being chain disentanglement (126). Ueberreiter describes the process 
being initiated by the solvent as it pushes into the polymer. As the solvent pushes into the polymer, the 
polymer may or may not swell. In either case, the most outer layer of the polymer is disentangled and flows 
in the bulk of solvent direction (solution medium). As time passes and the solvent penetrates further, a 
quasi-stationary equilibrium is reached where the transport rate of polymer into the solvent is balanced by 
ingress rate of solution into the polymer (127). Ueberreiter also first summarized regions of a glassy 
swellable polymer based on layering composition shown in Figure 1-13. The infiltration layer, next to the 
pure polymer, is characterized by many intermolecular spaces through which molecules from the pure 
 
22 
polymer layer can penetrate, starting the diffusion process. The solid swollen layer has been described as a 
build up layer which is still in the glassy state. The gel layer contains the polymer material that is eroded but 
held in this state due to the rubbery state of this layer. The final layer before the pure solvent is a liquid 
layer which encapsulated the entire polymer system (127). 
 
Figure 1-13: Schematic of the surface layer of a polymer during dissolution. The chain disentanglement is in opposite direction to 
solvent diffusion. Adapted from reference (126). 
Factors affecting polymer dissolution can be polymer related or external. Polymer related factors are 
molecular weight (127), polydispersity (128), structure (129), composition (130), stereochemistry (131), and 
solvent and additives (132). External factors include agitation (133), temperature (128), and radiation (134).  
 
Regarding molecular weight, the dissolution rate decreases with increasing polymer weight in a nonlinear 
trend. It was observed that the dissolution rate was inversely related up to a critical molecular weight and 
thereafter, the dissolution rate plateaus. Below this critical molecular weight, dissolution occurred by stress 
cracking. Parsonage et al. concluded that the dissolution is controlled by chain disentanglement, which is a 
function of polymer molecular weight (135). Larger molecular weights yield higher levels of entanglement. 
Therefore, these molecular weights have a higher degree of swelling before dissolution occurs. 
 
In addition to the molecular weight of the polymer, the dissolution process can also be affected by chain 
chemistry, composition, and stereochemistry. A polymer dissolves either by exhibiting a thick swollen layer 
or by undergoing extensive cracking, depending on how fast the osmotic pressure stress that builds up in 
the polymer matrix is relieved. Therefore, the nature of the polymer’s differences in free volume, and 
segmental stiffness are responsible for behaviour variations from polymer to polymer. It was also found that 
 
23 
the dissolution behaviour is profoundly affected by the tacticity of the polymer (129). Gipstein et al 
observed variations of dissolution behaviour with stereochemistry in that the solubility rate of isotactic 
PMMA is much greater than that for the syndiotactic and heterotactic stereo forms (131). 
 
The type of penetrating solvent can also have a profound effect on polymer dissolution. Ouano and 
Carothers studied the dissolution of PMMA in several solvents and found that crack occurred quicker with 
the smaller, better solvents than bulky and poorer solvent (129). This was because of higher diffusion rates 
and swelling power of these solvent molecules. They concluded that if the internal pressure builds up faster 
than the glassy matrix can relax, through gradual swelling, a fracture can result. It was also pointed out that 
polymer morphology at the molecular level has a strong influence on the kinematics of dissolution. 
 
External parameters such as agitation and temperature as well as radiation exposure can influence the 
dissolution process. It was found that the rate of dissolution increases with the agitation and stirring 
frequency of the solvent due to a decrease of the thickness of the surface layer, and the dissolution rate 
approaches a limiting value if the pressure of the solvent against the surface of the polymer is increased at 
all temperatures (127). Drummond et al studied the effects of radiation with samples of P(MMA-co-MAH) 
with Methyl ethyl ketone, it was shown that the dissolution process is a function of radiation dose (134). 
 
It is noted that the underlying phenomenon of the polymer behaviour can be divided into three processes, 
which consists of the solvent diffusion(known as hydration), the expansion of polymeric network (known as 
swelling), and the polymer chain disentanglement into the solvent (known as erosion).  
1.2.1.1 Hydration 
Hydration refers to the penetration of the solvent into the matrix through the free volume in the material. 
The rate of penetration of liquid into a porous matrix is driven by the interplay between the capillary forces 
that promote fluid movement towards the interior and the viscous forces that oppose the liquid movement 
(136). It was noted that the process of sorption/desorption has been noted to be complex and non-linear 
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depending on the polymer morphology and chemistry. For example, two distinct hydration profiles were 
observed for the same polymer by Moy et al (137). The overall response of hydrated polymers is further 
influenced by factors such as water induced relaxation in the host polymer (138, 139). McBrierty et al 
summarized the factors that impact hydration of polymers (140). In summary, the behaviour of water is 
influenced by physical/spatial as well as chemical interactions. Chemical effects include hydrogen bonding 
to binding sites such as ion clusters, ester, amide, carboxyl and polar sites (141). A hierarchy of interactions 
has been proposed in order of decreasing energy. They are as such: ion-ion > water-ion > water-polar = 
polar-polar = water-water > water-hydrophobic (142).  
 
Experimentally, hydration was measured in this work by measuring mass changes. For mass changes to infer 
hydration, equation 1-3 has been used (143). In this equation, the moisture absorption is simple ratio-wise 
change equation which describes the absorption as an incremental increase in wet weight (polymer+water) 
as a ratio to the initial weight in terms of percentage. Other techniques such as NMR and Magnetic 
Resonance Imaging (MRI) has been used to measure hydration in the event of swelling and erosion 
occurring simultaneously. NMR has been used to obtain the diffusion coefficient of solvent and NMR 
imaging has been used to construct a time evolution of hydration (144, 145). Alternative to NMR imaging, 
once the diffusion coefficients are gathered, substituting into appropriate diffusion equations can produce a 
time evolution of hydration. The MRI does this by mapping 1H nuclei associated with mobile water (146).  
                        Hydration % = 
𝑀𝑡−𝑀0
𝑀0
× 100 Equation 1-3 
 
where M0 is the initial mass and Mt is the mass at sample time. In this work, hydration was measured for 
placebo polymers and formulation using the above equation in chapter 4 and 5.  
1.2.1.2 Swelling 
There have been multiple theories to describe swelling in polymers. The kinetics of swelling is a continuous 
process of transition from un-solvated glassy to a relaxed rubbery region. Fick's law of diffusion describes 
solute transport from polymeric matrices. In rubbery polymers, hydration is described by Fickian transport 
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and a concentration dependent diffusion coefficient. Fickian transport refers to the solute transport process 
in which the polymer relaxation time (tr) is much greater than the solvent diffusion time (147). In glassy 
polymers, the lagging reorientation of polymer molecules leads to anomalous effects if conducted near or 
below the Tg.  
 
According to the Bajpai classification, two basic categories arise (148). The first category is the Fickian or 
Case I transport which appears when the Tg of polymer is well below the ambient temperature. Here, the 
polymer chains are very mobile and the solvent penetrates easily. The hydration rate, Rhyd is slower than 
the polymer chain relaxation rate, Rrelax, (Rhyd << Rrelax), as shown by the first (top) scenario of Figure 1-14.  
 
The second category is non-Fickian diffusion, which occurs when the Tg of the polymer is above the ambient 
temperature. For non-Fickian diffusion, the polymer chains are less mobile than in Case I transport causing 
slower hydration into the polymer (149). Two subtypes arise in non-Fickian diffusion, depending on the 
hydration rates. They are Case II transport and anomalous transport. If the Rhyd is much faster than the 
Rrelax, Case II transport arises distinguishable by a sharp boundary between the hydrated and non-hydrated 
parts (Rhyd >> Rrelax). This is shown in the third (bottom) scenario in Figure 1-14. In this case, the drug 
molecules penetrate the swollen layer much more in the same amount of time compared to Case I 
transport. In contrast, anomalous transport arises when the hydration rate and relaxation rates are similar 




Figure 1-14: Illustrations of swelling cases. The top is Case I transport, the middle is anomalous transport, and the bottom is Case II 
transport (143). 
Experimentally, swelling is measured by volume changes. Ratio-wise percentages volume changes are 
calculated using Equation 1-4 (150). In this work, the swelling was measured for placebo polymers and 
formulation using the equation in chapter 4 and 5. 
                     Swell % = 
𝑉𝑡−𝑉0
𝑉0
× 100     Equation 1-4 
where V0 is the initial volume and Vt is the volume at sample time. 
 
1.2.1.3 Erosion 
Erosion is defined as the loss of mass through the physical dissolution of a polymer. This can result either 
due to dissolution and diffusion of the polymeric chains or via chain scission, followed by dissolution and 
diffusion (151). The chain scission is also referred to as chemical degradation that occurs due to hydrolysis 
for biodegradable polymers (152, 153). This degradation is reflected by loss of molecular weight while 
erosion is reflected by mass loss (154). In the case of degradation, hydration must occur before hydrolysis 
can occur. Polymer erosion is a more complex process as it depends on many other processes besides 
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degradation, such as morphological changes and characteristics of the oligomers formed (155). The 
resultant oligomers and monomers are more soluble than the polymers. The dissolved products eventually 
diffuse away from the polymer system shown in Figure 1-15.  
 
Figure 1-15: The combination of processes leading to erosion (153). 
There are two macroscopic mechanisms via which erosion occurs: bulk erosion (homogeneous erosion) or 
surface erosion (heterogeneous erosion). In bulk erosion, the solvent hydrates (Rhyd) into the polymer faster 
than polymer scission (Rsci) causing the polymer to degrade at the same rate throughout the bulk of the 
system (Rhyd >> Rsci). Bulk eroding polymer retains the original geometry and size during most of the 
dissolution process but the chain scission occurs throughout the material. The molecular weight and the 
mechanical strength of the specimens decrease in time during the erosion process. The decrease in 
molecular weight occurs essentially from the beginning of the degradation process, whereas loss of mass is 
much delayed. The external dimensions of the polymer material remain essentially unchanged until the 
material disintegrates at a critical time point. (156). Conversely, if the polymer scission is faster than the 
hydration, then erosion only occurs at the areas closest to the surface (Rhyd << Rsci). Size and mass of the 
device decrease in time, whereas molecular weight and mechanical properties of the polymer device 
remain unchanged. In surface erosion, the rate of mass loss is proportional to the surface area (156, 157). In 
drug delivery, such polymeric systems are favourable due to the predictability of the erosion process which 
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can be related to the drug release directly (158). The two mechanisms of erosion along with the loss of 
mass, molecular weight, and strength are shown of the polymer system are shown in Figure 1-16. In this 
work, erosion was studied for the placebo polymers in chapters 4 and 5 which include Hypromellose acetate 
succinate (HPMCAS), Poly-ethylene oxide (PEO), Poly-vinyl alcohol (PVA), Poly-ε-caprolactone (PCL), Poly-
(vinylpyrrolidone-co-Vinyl Acetate (PVPVA), Soluplus, and xanthan gum. More details about these polymers 
are given in chapter 2. Some polymers such as PCL have been well studied to show surface erosion while 
others cannot be assigned one route exclusively (159, 160).  
 
Whether a polymer undergoes surface or bulk erosion cannot be unequivocally assigned. Erosion model has 
been prepared by Burkersroda et al using an erosion number (ε). Erosion number is an expression which is 
the ratio between diffusion time and chemical chain scission time. For ε >>1, surface erosion occurs while 
for ε << 1, bulk erosion occurs, and ε = 1, prediction cannot be made (161). A list of the driving factors of 
erosion was stated in the works of Burkersroda et al which are a multifactorial and complex dynamic 
interplay of degradation, swelling, dissolution, diffusion of oligomers and monomers, and even more factors 
for electrically erodible polymer or pH changes for pH-sensitive polymers (153, 155). Furthermore, the 
morphology of the polymer (crystalline vs amorphous) was shown to have different erosion rates (162). 
 
Experimentally, erosion has been measured by dry mass changes shown by Equation 1-5 (163). The 
difference between hydration and erosion in terms of the sampled weight used is that the hydration 
measures wet mass including the weight of the solvent and erosion uses dry mass which is the weight 
material only after drying.  
                           Erosion % = 
𝑀𝑡−𝑀0
𝑀0
× 100     Equation 1-5 
where M0 is the initial dry mass and Mt is the dry mass at sample time. Predicting polymer dissolution 





Figure 1-16: A) Surface erosion and (B) Bulk erosion. The strength, mass, and MW due to erosion in both cases are shown (156, 164). 
1.2.2 Drug release behaviour of solid dispersions 
Drug release is the process in which the drug is released from the polymeric matrix. Polymeric matrices 
release the drug in one of two ways: diffusion or erosion (151). In the case of diffusion-controlled release, 
the drug molecules translocate from the initial position in the matrix to the outer surface and onto the 
solvent through dissolution (165). The drug concentration gradient in the polymer matrix is the driving force 
for the molecules to diffuse into the surrounding medium. The highest concentration of the drug is in the 
non-hydrated dry regions of the matrix and the lowest is in the bulk of the solvent (166). The factors that 
impact the diffusion of a drug molecule is dependent upon the solubility of the drug in the polymer matrix, 
the concentration of drug in the matrix, and the diffusional pathlength. Many polymeric matrices have drug 
molecules on the surface of the matrix. Upon immersion into a solvent, the release of these drug molecules 
is controlled by the rate of diffusion of the drug into the surrounding environment. This can lead to “burst 
release” phenomenon (167). 
 
For erosion controlled release, the two types of erosion discussed earlier are possible to be exhibited. If 
water is confined to the surface of the matrix, as in the case of hydrophobic polymers, polymer hydration 
will occur only on the surface and drug will be released as the surface of the polymer matrix erodes. 
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Alternatively, if the water penetrates the polymer matrix faster than dissolution at the surface, then erosion 
will occur throughout the entire material and the drug will be released by bulk erosion (151). Based on the 
type of controlled release kinetics, three types of drug release model have been formulated. They are as 
follows (147):  
• Diffusion controlled models 
• Dissolution based models 
• Erosion based models 
Diffusions controlled models are derived from Fick’s I and II law of diffusion. To predict drug release profiles, 
the diffusion coefficient of the solute within the polymer matrix should be available, which could be 
measured by NMR and fluorescence correlation spectroscopy (168). Such models have many assumptions. 
They assume diffusion takes place only in one dimension, have a constant drug diffusion coefficient for the 
entire duration, have no matrix swelling or erosion of the bulk material, the drug is initially homogeneously 
distributed within the matrix, mass transfer resistance due to liquid unstirred boundary layers at the surface 
of the matrix is negligible compared to mass transfer resistance due to diffusion within the matrix, and drug 
dissolution is rapid and complete upon exposure to the solvent (147, 169, 170). Examples of diffusion 
models are the Higuchi model, Noyes-Whitney equation, Nernst–Brunner equation (165, 171). In this work, 
there are no polymeric matrix formulations that do not erode nor swell. In other words, all matrix 
formulations either swell or erode. For example, zein formulations used in this work do not erode but do 
swell significantly. As such, diffusion-controlled models only are not appropriate for describing release 
kinetics from zein formulations.  
 
The second type of model is dissolution based models. Narasimhan and Peppas developed a model for 
polymer dissolution based on the molecular mechanism (172). These models assume a constant drug and 
solvent diffusion coefficient and moving boundaries (147). Moving boundaries indicate volume changes. 
Such models have shown to successfully capture Fickian and Case II type behaviour in the works of 
Narasimhan and Peppas wherein release profile of cimetidine hydrochloride from PVA tablet and sodium 
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diclofenac from a PVA tablet were fitted to the experimental data and the equation (172). Examples of 
dissolution based model are the Narasimhan-Peppas model and the Gompertz model (172, 173). 
 
The third type of model is erosion based models. Such erosion based models are divided into two main 
groups based on the approach of erosion evolution. The first group is the diffusion-and-reaction model, 
which suggests the description of the erosion process as a combination of polymer diffusion and reaction. 
Majority of models in this group have been used to model bulk eroding process but there is also Monte 
Carlo technique that has been used for bulk eroding systems (174, 175). The second group is the cellular-
automata model, assumes the erosion process as a random event (169). Majority of the second group of 
models assume the matrix surface detachment is commonly the rate-controlling step, and therefore the 
models are applied for the surface-eroding system. The erosion models, in general, assume constant 
material erosion rate and constant surface detachment of drug. Examples of erosion based models are the 
Weibull model, Hopfenberg model, and Hixson-Crowell model (170, 171, 176). 
 
There are additional numerous empirical models that have been established may help explain the transport 
mechanism. Examples are Ritger-Peppas, Peppas-Sahlin, and Alfrey equations (147). However, these models 
do not provide additional insights into a more complex transport mechanism. Furthermore, these models 
may yield misinformation when there is a need for taking into account specific physicochemical processes 
(177). For example, Ritger-Peppas and Peppas-Sahlin equations have been applied to describe the release of 
sodium salicylate from HPMC tablets, indicating a non-Fickian drug release mechanism. The study also 
revealed that polymer erosion, swelling and dissolution were all involved in the release process and the 
authors suggested that the conclusion of a non-Fickian drug release mechanism, based on the diffusional 
exponent (n) of the Peppas models was misleading (178). One particular empirical model, being used 
frequently, is the Korsmeyer-Peppas model, shown by equation 1-6 (179, 180). Korsmeyer-Peppas has been 
successful in explaining 60% (or more in some cases) of the drug release profile of formulations that contain 
soluble and insoluble APIs and poorly soluble polymers. In such cases, significant swelling of the insoluble 
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polymer occurs after the partial dissolution of polymers and the drug, leading to the quick appearance of 
pores or even large cavities full of liquid through which the drug diffuses (169). Release from those systems 
was not well described by any other empirical models (181). Korsmeyer-Peppas has been successfully 
employed in cases wherein the rate of drug release follows neither the process of diffusion nor that of 
erosion (182). An exception to the application of this model is for mucoadhesive erodible formulations 
(183). Since Korsmeyer-Peppas is well suited to fit the drug release profile, this model was used for all the 
drug release profiles for all the formulations in chapter 3 and 5.  
                       
𝑀𝑡
𝑀∞
= 𝑘𝑡𝑛  Equation 1-6 
where Mt is mass at time t, 𝑀∞ is the total drug mass at infinite time, k is the drug release constant, and n is 
the drug release index. These empirical models have been used generally for three major geometries 
(shown in Figure 1-17) as all geometries can be simplified to three underlying geometries: slabs, spheres, 
and cylinders (184). Within the matrix system, there exists monolithic solutions and monolithic dispersions. 
Monolithic dispersions are polymeric matrices where the drug concentration in the matrix is higher than 
drug solubility. All polymeric matrices in this work were monolithic dispersions and of cylindrical geometry. 
 
Figure 1-17: Diffusion controlled monolithic geometries. Cini is the initial concentration and Cs is the saturation concentration (184). 
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1.2.3 Predicting drug release profiles 
The aim of controlled release systems in the context of personalized medicine is to achieve a drug release 
profile that is tailored to the patient’s clinical needs. The aim of sustained release, extended release, and 
immediate release dosage has been explored extensively in pharmaceutics (44). The factors affecting drug 
release are the drug, the release medium, and the matrix material. Of the three factors, the drug and 
release medium is not alterable. The drug is required by the patient and the release medium in the body is 
fixed to be either in pH 1.2 or 6.8. This leaves only the matrix material alterable. Of the existing works 
undertaken for controlled release, there is a plethora of literature that focuses on chemical modifications 
(185-193), and physical modifications (194-197). Such works for chemical modifications have included 
manipulation of pH-sensitive interactions between polymers by Chen et al to enhance the drug release 
profile (185) and using different polymer MW by Maggie et al to achieve an altered drug release profile 
(190), while physical modification includes the creation of pores in the formulation by Ghasemi et al (197). 
In recent years with the advancement of technology, the mathematical modelling aspect has been 
witnessed more in pharmaceutics (161, 170, 198). The benefits of such mathematical modelling with 
regards to controlled release systems have been discussed. One of the advantages that mathematical 
models provide is that they yield quantitative information about the system. This characteristics information 
can be combined with statistics which can give rise to the classification of polymers and drug (199).  
 
An existing commercial software named GastroPlus® aims to be able to simulate a desired drug release 
profile of the formulated product based on the input information of the excipients used and geometry of 
the dosage form. The input information for this operation from the user consists of start and end times of 
the dissolution, the buffer media pH, the paddle speed, and dissolution media volume (200). The drug 
release profile is generated using one of the three options. The first of these is using the classical Nernst-
Brunner model (Equation 1-7) while the second and third options are using the Johnson model (200). 
Depending on the particle shape, either spherical or cylindrical, the appropriate Johnson-spherical (Equation 












)] 𝑀𝑈 Equation 1-7 
where 𝑀𝑈 is the amount of undissolved drug, 𝑀𝐷 is the amount of dissolved drug, 𝛾 is a unitless calibration 
constant, V is the volume of dissolution medium, ρ is the density of the drug, D is the diffusion coefficient, h 












1∕3 Equation 1-8 
where 𝑀𝑈𝑖 is the amount undissolved drug of the ith particle, 𝑀𝑈𝑜 is the initial amount of undissolved drug, 















 Equation 1-9 
 
where s is the shape factor is (L/D) obtained by dividing L(length) by diameter (D). GastroPlus has been used 
for a wide variety of pharmacodynamic and pharmacokinetic modelling in humans and animals including the 
prediction of in Vitro drug release profiles for the development of extended release doxazosin tablets (201), 
correlating In Vitro profile with In Vivo absorption of efavirenz tablets to develop generic medications (202). 
1.2.4 Objectives of the research 
FDM 3DP is most commonly advocated for the development of polypills which can be personalized. The 
method of drug impregnation for drug loading into filament has shown low yielding. Therefore, HME 
coupled with FDM is an alternate method of filament preparation that allows great flexibility during 
manufacturing with drug loading, carrier polymer blending, and molecular dispersion of drug. HME, being in 
the pharmaceutical industry, has been well studied. However, no literature on sources of errors of HME-
FDM as a coupled process exists. Therefore, the first objective of this project (Chapter 3) is to probe the 
sources of errors during a pharmaceutical HME-FDM 3DP coupled process which can then be used to 
improve the precision when FDM 3DP is used for pharmaceutical applications.  
 
To achieve personalization, precision in drug release from oral dosage is inevitable. Developing a tool to 
guide the design of the dosage form that can deliver the desired drug release profile to suit each patient will 
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move the field closer to its intended clinical application. Therefore, understanding the formulation 
behaviour for polymers and drug is important at the macroscale. Understanding the macroscale behaviour 
in terms of hydration, swelling, and erosion of the polymer can help predict the drug release for a given 
class or type of drug in a pre-experiment scenario. Furthermore, the quantitative information deduced from 
applying the appropriate mathematical model to the appropriate geometry can be combined with statistics 
to create a classified dataset, which can be the beginnings of a database. This classification can aid in the 
creation of personalised dosage form that exhibits the desired release profile. Thus, the following specific 
objectives are the focus of Chapter 4-6: 
1. Investigate the predictability of pharmaceutical polymers and polymer blends behaviour (swelling, 
hydration, and erosion) in aqueous media.  
2. Investigate the effects of the key physicochemical properties of the drug on drug release and the 
significance of the role that the polymer plays in controlling the drug release.  
3. Build a classification approach to describe the characteristic drug release profiles of polymeric 
based dispersions.  
4. Use the information generated by the classification approach to build a dataset, with the attempt to 
enable the guided selection of the appropriate polymer to achieve a desired drug release profile for 




Chapter 2: Materials and Methods 
2.1 Introduction 
This chapter provides the specific characteristic information of the materials, the working principles, and 
general methodologies of the processing and characterisation techniques used throughout the project. The 
materials consist of polymers and drugs. The polymers used in this work were a copolymer of acrylic & 
methacrylic acid esters & quaternary ammonium groups (Eudragit RS), Xanthan gum, Polycaprolactone 
(PCL), Poly1-vinylpyrrolidone-co-Vinyl Acetate (PVPVA), Poly(vinyl caprolactam-polyvinyl acetate-
polyethylene glycol) graft copolymer (PCL-PVAc-PEG) also known as Soluplus, polyvinyl alcohol (PVA), 
polyethylene oxide (PEO), Hypromellose acetate succinate (HPMCAS), and purified zein. The model drugs 
used in this work were paracetamol, lidocaine, and ibuprofen. The reason for using these drugs was that the 
drugs exhibit different ionized charges at pH 1.2 and pH 6.8 as well as different levels of solubility. 
 
The samples in this work were prepared by hot melt extrusion and/or FDM 3D printing. Once the solid 
dispersion based filaments or dosages were prepared, characterization was performed to understand their 
physiochemical properties by using differential scanning calorimetry (DSC), thermogravimetric analysis 
(TGA), attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR). Ultraviolet 
spectrometer (UV) was used to evaluate in vitro drug release performance. Finally, the statistical techniques 
used to analyse the data is also discussed in detail in this chapter.  
2.2 Materials 
2.2.1 Paracetamol (PCM) 
Paracetamol, also known as Acetaminophen, is an antipyretic, non-opioid analgesic, and non-steroidal anti-
inflammatory drug of Biopharmaceutics Classification System (BCS) class III. The IUPAC name of PCM is N-(4-
hydroxyphenyl)acetamide (203). PCM used in the thesis was brought from Sigma Aldrich (CAS Number: 103-
90-2) with a purity of ≥ 99% (204). The structure and the physical properties are summarised in Table 2-1. 
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2.2.2 Lidocaine (LID) 
Lidocaine, also known as lignocaine, is an amide-type local anaesthetic and Class 1b antiarrhythmic 
frequently used for its anaesthetic and antiarrhythmic benefits and in the treatment of chronic pain (205, 
206). It is of BCS class I. The IUPAC name of lidocaine is 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide 
(207). LID was selected as a model drug due to the positive ionized state in the ranges below PH 7. LID used 
in the thesis was brought from Sigma Aldrich (Dorset, UK) (CAS Num: 137-58-6) with a purity of ≥ 98% (208). 
The structure and the physical properties of LID are presented in Table 2-1. 
2.2.3 Ibuprofen (IBU) 
Ibuprofen is an NSAID with anti-inflammatory, analgesic, and antipyretic properties commonly used to treat 
fever, pain arising from inflammation and post-surgery, and rheumatoid arthritis (209). It is of BCS class II. 
The IUPAC name for IBU is 2-(4-isobutylphenyl)propionic acid (210). IBU was selected as an opposing 
charged API to LID for the anionic charge it posses in the identical pH and its hydrophobic nature (211, 212). 
IBU, used in the thesis, was brought from Sigma Aldrich (Dorset, UK) (CAS Num: 15687-27-1) with a purity of 
≥ 98% (213). The structure and physical properties are enlisted in Table 2-1. 








Formula CH3CONHC6H4OH C14H22N2O C13H18O2 
Molecular Weight (g/mol) 151.16 (214) 234.34 (208) 206.28 (213) 
Solubility (g/L) 17.39 at 300C (215) 22 at 370C (216) 0.021 at 250C (210) 
pKa 9.38 (203) 8.01 (207) 5.3 (210) 
LogP 0.46 (203) 2.44 (207) 3.97 (210) 
Density (g/cm3) 1.31 (203) 1.01 (217) 1.08 (218) 




2.2.4 Hypromellose acetate succinate (HPMCAS) 
HPMCAS is a pH-responsive cellulose derivative, in particular a cellulose ester, containing acetyl and 
succinoyl groups (223). Cellulose derivatives are generally categorized into three groups based on pH-
responsiveness and chemistry as pH responsiveness, hydrophilicity, and hydrophobicity shown in Figure 2-1. 
 
Figure 2-1: The classification of cellulose based polymers. HPMCAS is categorized as cellulose succinate encircled in red (224). 
The structure of HPMCAS is shown in Figure 2-2. HPMCAS possesses four types of substituents which are 
substituted on the hydroxyl groups: methoxy (12%−28%, w/w); hydroxypropyl (4%−23%, w/w); acetate (2% 
−16%, w/w); and succinate (4%−28%, w/w) (225) making it relatively hydrophobic. Due to the succinate 
groups, HPMCAS has a pKa of about 5 (226). Below pH 4, 10% of the polymer ionizes while at least 50% are 
ionized above pH 5. The pH-dependent solubility can be attributed to the ratio of succinate and acetyl 
groups. Hence, different grades of HPMCAS have different pH-dependent solubilities, which are summarized 
in Table 2-2. HPMCAS grades have Tg ranging from 120 °C to 135 °C (227). 
Table 2-2: The succinate and acetyl group ratios in different HPMCAS grades and their soluble pH (225, 228). 
HPMCAS grade Succinoyl (%) Acetyl (%) Dissolved pH 
L-grade 15 8 >5.5 
M-grade 11 9 >6.0 
H-grade 7 12 >6.5 
 
HPMCAS when partially ionized, minimizes the formation of large polymer aggregates which allows 
drug/polymer colloids to form. The hydrophobic regions of HPMCAS can interact with insoluble parts of 
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poorly water-soluble drug molecules, resulting in amorphous drug/polymer complex in solution while the 
hydrophilic regions can allow the structure to be stable in the aqueous solution (225). The negatively 
charged succinate groups keep these nanostructures stable, evading the large hydrophobic aggregates of 
the polymer and drug in solution. HPMCAS used in this work was purchased from Shin-Etsu Chemical Co Ltd. 
(Niigata, Japan) AS-LF grade with an average molecular weight (MW) of 18000g/mol and white fine powder 
appearance. By composition, methoxy is 22.3%, hydroxypropoxy is 6.7%, succinoyl is 18.1%, and acetyl is 
5.7%. The Tg of this grade is 121°C and the range of solubility of this HPMCAS is pH 5.5 to pH 8 (229).  
 
Figure 2-2: HPMCAS structure 
2.2.5 Zein 
Zein is a major storage protein of corn (230). It is a natural protein located in the endosperm of corn 
accounting for almost 50% of the total protein content of whole grain of corn (231). Zein is extracted by wet 
milling from corn gluten meal by solvent extraction using isopropanol (232). Zein is available as a yellow 
powder whose colour is due to the xanthophylls remaining bound with zein by hydrophobic interaction. 
Zein is classified as prolamin protein which has high proportions of one of the three constituents or 
combinations of them; proline and glutamine, all of which are aliphatic amino acid (233). Zein has high 
proportions of hydrophobic amino acids including 20% of leucine, 10% of proline and 10% of alanine (234, 
235). This is the cause of high surface hydrophobicity (236). Zein has been further grouped based on varying 
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molecular weights (237) and solubility in solutions of 0 to 95% isopropyl alcohol (233). The three major 
fractions/groups categorized are α-zein (19 and 22 kDa) accounting for 75–80% of total zein, β-zein (17–18 
kDa) accounting for 10-15% of total zein, and γ-zein (16 and 27 kDa) accounting for 5–10% of the total zein. 
With regards to pharmaceutical applications, zein has been used in tablets and caplets as it is a unique 
matrix former. Zein matrices do not erode (238) but undergo hydration and swelling and can potentially 
increase by more than 200% of the initial mass (14, 160). Such level of hydration can be compared to 
hydrophilic matrices (163) and is significantly greater than that of insoluble matrices (239). In addition to 
this, zein is an excellent candidate due to its natural origin, swelling and self-assembling properties. Purified 
zein used in this work was purchased from Acros (New Jersey, USA) (CAS #: 9010-66-6) with greater than 
91.0% protein content (240). The Tg of pure zein is reported to be approximately 150 °C (241).  
2.2.6 Poly (Ethylene Oxide) (PEO) 
PEO is a hydrophilic, linear polymer available in several molecular weights ranging from 100,000 to 
8,000,000. PEO is a synthetic polymer with the same chemical structure as PEG but higher molecular weight. 
The structure is shown in Figure 2-3. As unbranched linear macromolecules, the grades of PEO differ with 
the length of molecular chains. Polymers with molecular weight less than 100,000 are usually called PEGs 
while higher molecular weight polymers are classified as PEO (242).  
 
PEO can be completely dissolved in both cold and hot water but will precipitate out when the temperature 
of the solution is close to the boiling point of water, called cloud point. This cloud point is affected by the 
concentration, the molecular weight of PEO, the concentration of salts, and the pH (243). The dissolution 
rate of PEO is very slow. The dry powder is easy to be wetted by water, but it tends to form agglomeration 
and gel if it is not dispersed properly when dissolving into water. The Tg of PEO products ranges from -50oC 
to -57oC and molecular weight do not have a significant impact on the Tg (243) within the family of products 
 
Figure 2-3: PEO structure 
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PEO has been used for oral dosages taking advantage of the bioadhesive properties (244, 245) and as an 
osmotic pump tablet (246, 247). The adhesiveness arises due to the long linear chain structure that allows 
them to form a strong interpenetrating network with the mucus (248). Likewise, the osmotic pump 
potential arises due to the aqueous solubility and can be used to create high osmotic pressure (249). It is 
also used as a thickening agent swelling seven times the initial weight (250). PEO used in this work was 
purchased from Colorcon (Kent, UK) Polyox WSR 301 NF with MW of 4,000,000 (251). 
2.2.7 Poly-(Vinyl Alcohol) (PVA) 
PVA is a whitish, tasteless, odourless, non-toxic, biocompatible, thermostable, granular or powdered semi-
crystalline linear synthetic polymer (252, 253). The monomeric structure of PVA is shown in Figure 2-4. The 
physicochemical and mechanical attributes of PVA are governed by the number of hydroxyl groups present 
in the PVA (254). The period length of the saponification reaction determines the degree of hydrolysis of 
PVA. Based on the degree of hydrolysis and MW, different grades of PVA are available on the market having 
different characteristics including melting point, viscosity, pH, refractive index, and band gap (255). The 
effect of variation in vinyl acetate length and degree of hydrolysis under acidic or alkaline conditions results 
in various congeners of PVA having different flexibility, tensile strength, dispersing power, emulsification 
index, adhesiveness, and solubility (256).  
 
Figure 2-4: PVA structure 
PVA has been widely used in the field of 3D printed caplets (46, 257-259). PVA is also well known hydrogel 
materials and having good biocompatibility has many other applications such as used in contact lenses, 
implants, drug delivery systems, medical implants and also wound dressing (260). The PVA used in this work 
was gifted as a sample from Kuraray (Hattersheim, Germany) under the brand name Mowiflex C17 (purity 
>96%) supplied in the form of pellets. The average MW is 50000 g/mol and Tg of this sample is 60 °C. The 
indicated melt flow index is 14-20 g/10min (190 °C, 21.6kg) (261). 
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2.2.8 Poly (ε-caprolactone) (PCL) 
PCL is a polymer composed of hexanoate repeat units in the class of aliphatic polyesters (262). PCL is a 
hydrophobic, semi-crystalline polymer with up to 50% crystallinity (263, 264). The crystallinity and 
molecular weight dictate the physical, thermal, and mechanical properties, and the degradation of PCL 
(264). PCL structure is shown in Figure 2-5.  
 
Figure 2-5: PCL structure  
PCL has a wide range of applications. The good solubility of PCL, its low melting point and exceptional blend-
compatibility has made it a good candidate for research in the biomedical field (265). PCL is used in 
controlled drug delivery systems due to three factors: 1) due to its permeability ensuring uniform API 
distribution in the matrix producing a reliable sustained release of the API (266, 267); 2) due to its slow 
degradation via hydrolysis (268); 3) while undergoing biodegradation, there is a minimal generation of an 
acidic environment as compared to other polyesters such as PLA and polyglycolic acid (264). The PCL used in 
this work was purchased from Perstorp (Malmö, Sweden) brand graded as CAPA 6800 (CAS #: 24980-41-4) 
supplied in granular 3mm pellets. The average MW is 80,000 g/mol, water content of 0.35%, Tg is -61°C, and 
the melting temperature is 62°C (269). The degree of crystallinity of PCL has been reported to be 67% (270). 
2.2.9 Poly (vinylpyrrolidone-co-Vinyl Acetate) (PVPVA) 
PVPVA is a copolymer of vinylpyrrolidone and vinyl acetate in a ratio of 6:4 manufactured by polymerization 
in isopropanol. Since 40% is replaced with lipophilic vinyl acetate functional groups and therefore it is less 
hygroscopic than the homopolymer system (271). It is very soluble (>10%) in hydrophilic liquids and 
hydrophobic solvents (272). Commercial PVPVA is yellowish-white in colour with fine particle size (<100μm) 




Figure 2-6: PVPVA structure.  
PVPVA has a wide range of usages. Usage in oral formulations includes enhancement in solubility and 
bioavailability of the drug poorly water-soluble drugs like indomethacin, tolbutamide, and nifedipine, (274). 
The PVPVA grade used in this work was Kollidon64 from BASF (Ludwigshafen, Germany). This grade of 
PVPVA has a Tg of 111 °C, Tm of 140 °C, pKa of -2.5, and solubility of greater than 300g/L (275, 276).  
2.2.10 Eudragit® RS 100 
Eudragit is the trade name for a common class of polyacrylates and polymethacrylates. Polymethacrylates 
are synthetic cationic and anionic polymers of dimethylaminoethyl methacrylates, methacrylic acid, and 
methacrylic acid esters in varying ratios (277). The commonly used Eudragit for the preparation of 
controlled release solid dispersions is Eudragit L, Eudragit RL, and Eudragit RS, Eudragit RLPO and Eudragit 
RSPO (272).  
 
Eudragit RS and RSPO are copolymers of ethyl acrylate, methyl methacrylate and low content of methacrylic 
acid ester with 5% of functional quaternary ammonium groups (272). The MW of this grade is also 32,000 
g/mol. Different subgrades of RS exist in different forms. RS100 is granules while RSPO is powder. This grade 
of Eudragit is insoluble (278). For all works in this thesis, Eudragit RS100 has been used purchased from 
Evonik (Essen, Germany) supplied as granules, with MW of ≈32000 g/mol and Tg of 64 °C (279). The 




Figure 2-7: Eudragit RS structure. The R groups are from reference (277). 
2.2.11 Soluplus® 
Soluplus is a graft polymer consisting of polyvinyl caprolactam-polyvinyl acetate polyethylene glycol (PCL-
PVAc-PEG). It has been designed for preparing solid solutions of poorly water soluble API by HME due to low 
Tg of 70 °C and thermal stability at high temperatures (280). The average molecular weight of Soluplus 
ranges from 90,000 to 140,000 g/mol (281). Soluplus has an amphiphilic structure shown in Figure 2-8 with 
high aqueous solubility (≈50%). Commercial soluplus is a free flowing white-yellowish granule with a faint 
odour (280). Soluplus used in this work was purchased from BASF (Ludwigshafen, Germany) (CAS #: 402932-
23-4) with MW of ≈118,000 g/mol, Tg of 70 °C, and density of 1.082 g/cm³ (282). 
 
Figure 2-8: Soluplus structure. 
2.2.12 Xanthan Gum (XG) 
Xanthan gum is an extracellular anionic heteropolysaccharide produced by fermentation of carbohydrates 
(283). The primary structure of XG consists of repeating pentasaccharide units (284) shown in Figure 2-9. XG 
has many desirable properties making it of significant industrial interest. One of the characteristics is the 
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manipulation of the rheology of XG in water systems making it a widely used thickener and stabilizer. The 
stability is due to two components; primarily the ordered conformation of XG is believed to be responsible 
for the stability, and secondary is further stabilization by addition of salt. Cations in order Na+<K+<Ca+2, can 
promote intermolecular cross-linking and strengthening the gel network (285, 286). The resultant of this is 
XG exhibits pH independent stability which is unaffected over ranges of pH 1 to pH 13 (283, 287) and 
temperature stability up to 90 °C (288). The XG used in this work was purchased from CPKelco 
(Leatherhead, UK). The brand name is Xantural 180 (CAS #: 11138-66-2) supplied as a white fine powder 
with purity greater than 91% (289). The Tg of xanthan gum has been determined to be between -16.4 and -
23.3 °C (290). 
 
Figure 2-9: XG structure. From reference (291). 
2.2.13 Acrylonitrile butadiene styrene (ABS) 
ABS is a thermoplastic copolymer whose structures of the monomers are shown in Figure 2-10. The 
proportions of the monomers typically range from 15% to 35% acrylonitrile, 5% to 30% butadiene and 40% 
to 60% styrene (292). ABS used is in this work was purchased from MakerBot (Brooklyn, USA) as a 3DP 
filament consisting of ABS resin (CAS #: 9003-56-9) greater than 98% and styrene (CAS #: 100-42-5) less than 
0.1% (293) with Tg of 105°C and filament diameter of 1.75 mm (294). ABS was used in this study as a control 




Figure 2-10: Chemical structures of ABS raw materials. 
2.3 Processing methods 
2.3.1 Hot Melt Extrusion (HME) 
The details of the working principle of HME have been discussed in Chapter 1 and therefore, only 
experimental set up is described here. The raw materials were fed in through the hopper. The hot melt 
extruder used in this work was twin screw that has co-and counter-rotating twin screw option (Thermo 
Scientific HAAKE MiniLab II) with a maximum of 5g of material limit at a given time and volume of 7cm3 
(295). The extrusion temperature was 30 °C above the Tg or melting point. The screw speed was 100 rpm for 
all samples. All extrudates were tested in triplicates. HME technique was used to make pure polymer 
extrudates (studied in Chapter 4) and drug loaded polymeric dispersions (studied in Chapters 3 and 5).  
2.3.2 FDM 3D Printing (FDM 3DP) 
The FDM 3DP was used in this study to prepare solid dispersions in tori shape in Chapter 3 using PVA with 
paracetamol as a formulation (PVA-PCM), and ABS as another. Makerbot Replicator 2X desktop 3DP with 
dual extrusion (MakerBot Industries, LLC) was used with dosages designed in blender software, an open-
source 3D computer graphics software used for creating animation, visual effects, and 3D printed models, 
and finally imported for printing through Makerbot (Brooklyn, USA) ThingiVerse software preinstalled on 
Makerbot (296). The printing temperature for commercial ABS was as per manufacturer recommendation of 
220 °C, while for the PVA-PCM formulation was printed at 170oC, 185oC, 185oC, and 190oC. The platform 
temperature for ABS was 110 °C as per manufacturer recommendation, while 100 °C was used for PVA-PCM 
filaments. Each formulation was printed in triplicates.  
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2.4 Material characterisation methods 
2.4.1 Differential scanning calorimetry (DSC) 
DSC is one of the most common thermoanalysis techniques. DSC is a highly sensitive technique used to 
determine the thermotropic properties of excipients or actives. The primary function of DSC is to determine 
the energetics of phase transitions and conformational changes and subsequently quantifying based on the 
temperature dependence (297). This is achieved by measuring the heat flow difference into the sample and 
a reference as a function of temperature, while both are maintained at an identical temperature for the 
duration (298). Using this flow rate difference, it is possible to detect and characterize the melting 
temperature, the glass transition temperature, the recrystallization temperature, the degradation 
temperature, and the temperatures of polymorphic formations (299) as well as the degree of purity, the 
heat of fusion, heat of reactions, and kinetic determination of chemical reactions, such as curing (300, 301). 
There are two types of commercial DSC; one being powered compensation DSC and the other being heat-
flux DSC. The benefit is that both of these DSC cases require minute quantities of a sample between 0.1-10 
mg will suffice and operating temperatures range from -180 oC to 700 oC (298). In the heat-flux DSC, a single 
furnace contains both the sample and the reference pans as shown in Figure 2-11. The pans are put on a 
heated thermoelectric disk. Attached thermocouples at the bottom of the thermoelectric disk monitor the 
differential heat flow producing a change in thermocouple signal which is directly proportional to a change 
in temperature. The heat flow signal is measured as a function of thermal resistance shown by equation 2-1.  






                                                   Equation 2-1 
Where dQ/dt is the heat flow, ΔT is the temperature difference between the sample and reference, and R is 
the thermal resistance of the heating disk. This heat flow (dQ/dt) can also be expressed in terms of specific 
heat capacity (Cp), which is defined as the energy supplied to increase the temperature of a material by one 
degree Kelvin, as shown by equation 2-2.  






+ 𝑓(𝑇, 𝑡)                                                          Equation 2-2 
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where dQ/dt is the heat flow, Cp is the sample specific heat capacity, dT/dt is the heating rate and f (T,t) is 
the kinetic event that is a function of time at an absolute temperature. The kinetic event can be events such 
as polymer relaxation, melting, and crystallization. With these two equations, it is possible to combine heat 
capacity combined with the kinetics of the sample. A resulting DSC thermogram is shown in Figure 2-13. 
 
Figure 2-11: Schematic of the furnace interior of a heat flux DSC (298). 
In a power compensated DSC, two separate heating elements are used: one for the sample and one for the 
reference. The sample and reference stay at the same temperature and any change in the temperature 
between the sample and the reference acts as a signal to “turn on” one of the heaters. When any chemical 
or physical changes such as reaction, phase change, or glass transition occur in the sample, there is a 
difference in temperature of the sample and reference. This leads to extra power to be directed to the cell 
at the lower temperature to heat it to keep the temperature of the sample and the reference cells as 
constant (ΔT = 0) throughout the experiment. In this way, the power and the temperatures of the sample 
and reference are measured accurately and continuously using Pt resistance sensors (shown in Figure 2-12). 
 
Figure 2-12: Schematics of power compensated DSC (298). 
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The DSC used in this work was A Q-2000 (TA Instruments, Newcastle, DE, USA), which is a heat flux DSC, to 
characterise the polymers powders/pellets, the APIs powder, and the formulation extrudates and 3D 
printed solid dispersions. All samples were weighed up to 3 mg and TA standard aluminium crimped pans 
were used. The standard procedure was to heat at rates of 10 °C/min in the range between -50 to 240 °C 
followed by cooling at 10 °C/min to the starting temperature and reheat at 10 °C/min for all samples. A 
constant nitrogen purge was applied at the 50 mL/min. Samples were tested in triplicate. 
 
Figure 2-13: DSC thermogram showing thermal kinetic events. The area under the curve can be calculated to give the enthalpy of the 
event (298). 
2.4.2 Thermogravimetric Analysis (TGA) 
TGA is a widely used technique for characterising a system by measuring changes in physicochemical 
properties at elevated temperatures either as a function of increasing temperature or time (302). Results 
from such analysis are used to determine the thermal and oxidation stability of materials. It also provides 
information about the components of a material, decomposition kinetics, moisture and volatile content of 
materials (303). Weight loss during analysis is usually an indication of decomposition, evaporation, 
reduction or desorption. On the other hand, weight gain indicates oxidation or absorption. The basic 
operation for TGA is a precision balance is used to weight the sample and placed in a furnace that is 
programmed for a linear rise of temperature with time (302). The resulting graph can have three features; a 
plateau implying constant weight, a curve implying the rate of weight loss, and an inflexion, at which the 
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weight change is minimum but not zero, implying the formation of an intermediate compound (302, 304). 
The TGA used in this study was TGA Q5000 (TA Instruments, Newcastle, USA) for evaluating the thermal 
stability of polymers, APIs, formulation, and physical mixtures. The standard procedure was to heat at rates 
of 10°C/min from 25 °C to 400 °C. All samples were done in triplicates. 
2.4.3 Fourier transform infrared (FTIR) 
FTIR has a wide range of applications from analysis of small molecules or molecular complexes to the 
analysis of cells or tissues (305). In the case of pharmaceutics, it is used for the former two cases. The IR 
region is beyond 700 nm (the ending of visible wavelength) and the classical IR region extends from 200 to 
4000 cm-1. Within this region, subdivisions have been made; Far infrared (400–10 cm−1), mid-infrared 
(4,000–400 cm−1), and near-infrared (13,000–4,000 cm−1) (306). The energies associated in this region are 
low enough to suffice molecules to vibrate but not to cause electron transitions. This leads to the basic 
operating principle of FTIR which is probing molecular vibrations. The IR band absorbed correspond with the 
vibration of certain functional groups (307). The FTIR measurement can be carried out in the modality of 
transmission or reflectance. An IR spectrum is obtained by determining what fraction of the incident IR is 
absorbed or reflected at a particular frequency. Therefore, IR spectroscopy can decipher the molecular 
structure as the spectra contain vibrations uniquely dependant on atomic masses, bond strengths, and 
intra-and intermolecular interactions (306).  
 
The hardware of FTIR consists of an interferometer and the schematic of a two beam Michelson 
interferometer is shown in Figure 2-14 which consists of a fixed and a moveable perpendicular mirror. 
Thereafter Fourier transformation is used to convert the interferogram to a spectrum via a computer 
program. When this is done in the absence of any sample, it results in the base spectrum and when done in 




Figure 2-14: Schematic of a Michelson interferometer (306). 
There are two modalities of FTIR operation which are transmittance and reflection. In transmission, the IR 
source illuminates the sample and the detector is placed behind the sample to acquire the fraction of light 
transmitted through the sample. In such cases, the sample must be at partly transparent. Transmission 
mode has been used to analyze thin samples such as films (308) or tissues (309) but it is not possible with 
thicker tablets. In contrast, for reflection, the detector is placed on the same side of the sample as the 
source to record the signal reflected by the sample. The two types of reflection measurement commonly 
used in the characterisation of pharmaceutical materials are attenuated total reflection (ATR) and diffuse 
reflection (DRIFTS) (306).  
 
In ATR, the sample is placed in optical contact against a special crystal, termed the ATR crystal, which is 
composed of a material with a high index of refraction. The IR beam is focused onto the bevelled edge of 
the ATR element by a set of mirrors which is reflected through the crystal, and then directed to the detector 
by another set of mirrors while in DRIFTS, the IR beam interacts with the sample and is scattered by 
interaction with the particles. A fraction of this beam is reflected by the sample and recorded by the 




Figure 2-15: a) ATR crystal schematic. b) DRIFTS measurement schematic. Adapted from (306, 310) 
In this study, FTIR was used to characterise the samples and to study the interactions between drug and 
polymers in the formulations for chapters 4 and 5. IFS 66/S spectrometer (Bruker Optics Ltd., Coventry, 
U.K.) equipped with a Golden Gate heated top plate attenuated total reflectance accessory (Specac Ltd., 
Orpington, U.K) was used to perform the IR spectroscopic studies. The spectrum reading was taken between 
4000 and 550 cm−1 with 2.0 cm−1 resolution and 32 scans. All samples were examined in triplicate. OPUS 
software version 7.8 was used to analyse ATR-FTIR spectra. 
2.4.4 Ultraviolet Spectrophotometry (UV-vis) 
UV-vis uses ultraviolet light which is ranges from 800 - 200 nm and is based on Beer-Lambert law (Equation 
2-3) which states that the absorbance of a solution is directly proportional to the concentration of the 
absorbing species in the solution and path length. Hence, if the path length is fixed, it can be used to 
determine the concentration from the absorbance in a solution.  
                 A= 𝜀ℓc Equation 2-3 
where A is absorbance,  is molar absorption coefficient, ℓ is the optical path length, and c is the molar 
concentration. The principle of UV-vis is that molecule or ion will exhibit absorption in the visible or 
ultraviolet region when radiation causes an electronic transition within its structure. Thus, the absorption of 
light by a sample in the ultraviolet or visible region is accompanied by a change in the electronic state of the 
molecules in the sample. The energy supplied by the light will promote electrons from their ground state 
orbital to higher energy, excited state orbital or anti-bonding orbital (311). Since each electron in a molecule 
has a unique ground state energy, and because the discrete levels to which it may jump are also unique, any 
absorbed energy will correspond to a specific wavelength. The specific wavelength at which the absorption 
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occurred can be plotted spatially along with any absorption data at wavelengths over the UV region creating 
the UV absorption spectrum (312). The schematic of the UV procedure is shown in Figure 2-16. 
 
Figure 2-16: UV data capture process (313). 
In this study, UV-vis was used to evaluate the drug release concentrations of lidocaine, ibuprofen, and 
paracetamol formulations in chapters 5 and chapter 3 (paracetamol only) as a part of the in vitro studies. 
The UV-vis (PerkinElmer Lambda 35, Llantrisant, UK) was used with ranges from 190–1100 nm and the 
resulting spectrum was analysed on UV Winlab software (version 2.85.04) supplied by PerkinElmer (314).  
2.4.5 Drug Loading Efficiency 
The amount of drug loaded in the HME extrudates which consisted of paracetamol and PVA in Chapter 3, 
lidocaine within zein, HPMCAS, and PEO, ibuprofen within zein, HPMCAS, and PEO, and paracetamol within 
zein, HPMCAS, and PEO matrices in Chapter 5 were measured by dissolving the solid dispersion samples in a 
beaker containing 250 ml of buffer pH 1.2 and ethanol (organic solvent) and measuring the UV absorbance 
of the solution. A similar procedure was followed for measuring drug efficiency in pH 6.8 where the 
extrudates were dissolved in a beaker containing 250 ml of buffer pH 6.8 and ethanol. After complete 
dissolution, 5 ml samples were withdrawn and filtered using 0.45 μm pore size (Minisart NML single use 
syringe, Sartorius, UK). The filtered samples then scanned for their content of the API (lidocaine, ibuprofen, 
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and paracetamol) using a UV–VIS at the max peak wavelength (λmax) 220 nm, 264 nm, and 243 nm for 
lidocaine, ibuprofen, and paracetamol, respectively. The max peak wavelength of each drug was obtained 
by screening across the full spectrum of each sample. The loading efficiency was measured in triplicates. 
2.4.6 In vitro dissolution studies 
In vitro dissolution study is the core of and the final parameter to be measured that allows for the bridging 
of further data analysis and the culminating aspect (drug release) of all the previous steps carried out, which 
included all the preformulation work and formulation work. The dissolution test is carried out in a 
dissolution apparatus according to official pharmacopoeia for reasons of evaluating drug release 
quantitatively in terms of kinetic parameters from formulations (315). This is done for quality control and 
research and development to check if drug content uniformity is within acceptable limits (316). According to 
USP recommendations, there are four official USP apparatus; USP apparatus I (Basket), USP apparatus II 
(Paddle), USP apparatus III (Reciprocating Cylinder), and USP apparatus IV (Flow Through Cell) (317). 
 
In this study, USP apparatus II (Copley CIS 8000, Copley Scientific Ltd., Nottingham, U.K.) was used as shown 
in Figure 2-17. The experiments were performed at 37 °C ± 0.5 °C with a paddle speed rotation of 100 rpm 
in 900 ml of pH 1.2 and pH 6.8, under sink conditions, for all HME polymer placebo extrudates in chapter 4, 
HME formulation extrudates in chapter 5, and FDM 3D printed formulation in chapter 3. The justification of 
performing in sink conditions is that all dissolution models, which were discussed in section 1.2.3, are valid 
in sink conditions. The media was sampled at times of predetermined times and filtered through an 0.45 μm 
filter. The drug concentration was measured by UV-Vis spectroscopy at the sampled time intervals. The in 




Figure 2-17: USP Apparatus II as described by USP standards (318). 
2.5 Advanced Statistical Methods 
In this section, the advanced statistical methods used in analysing the data will be discussed. These include 
classification schemes such as K-means, prediction schemes such as artificial neural network, and dimension 
reduction technique such as principal component analysis which are used in Chapter 6. The first of these 
methods to appear chronologically in Chapter 6 is K-means clustering which is discussed next. All analysis 
was performed on SPSS (statistical software package) from IBM version 25. 
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2.5.1 K-means Clustering 
K-means clustering is a common clustering technique. K-means clustering consists of four steps. The first 
step is termed ‘initialization’ wherein cluster points (k points) are randomly generated in the space, which 
are used as initial centroids. The second step is termed ‘classification’ wherein the distances from all the 
objects (data points) to all the centroids (cluster mean point) are calculated and each object is assigned to 
its closest centroid. The third step is termed ‘centroid calculation’ wherein new centroids are calculated 
using the mean value of the objects that belong to each cluster. This is iterated until the fourth step is 
reached, which is ‘convergence’ wherein no object migrations from one cluster to another is possible due to 
absolute minimization of distance calculation that has been achieved (319). Therefore, the algorithm has 
reached equilibrium and terminates with the output of clusters graphically generated. This process is 
summarized in Figure 2-18. 
 
Figure 2-18: Standard K-means algorithm (319). 
In this study, K-means clustering was performed on the dataset of polymer placebo behaviours and 
formulation drug release parameters in chapter 6 to obtain the centroid value of each cluster. The number 
of clusters was determined to be four clusters in the case of polymers and two or three clusters for 
formulations. The basis for the number of clusters is discussed more in chapter 6. 
2.5.2 Principal Component Analysis (PCA) 
PCA is a multivariate dimension reduction technique that is used to reduce complicated sets of data 
containing possibly correlated variables (320). PCA method of reduction is preferred because the systematic 








collect measurements on several variables simultaneously which are mostly exhibiting some degree of 
correlation. Therefore, it is inherent that PCA must reduce large datasets in an adaptive and insightful way 
and assumes that the phenomena of interest can be explained by the variances and covariances between 
the variables in the original dataset (321).  
 
Mathematically, PCA reduces the dimensionality by taking interrelated variables, x1, x2, …, xp, and finding 
combinations of these based upon variances to produce a transformed set of variables, z1, z2, …, zp, that are 
uncorrelated. The indices zi are called the principal components (PC) (321). The resultant graph is termed 
loading plot and an example of a PCA transformed loading plot is shown in Figure 2-19.  
 
Figure 2-19: Original data in cartesian coordinates on the left and the output on the right after PCA is performed. The transformed 
coordinates are in term of PC1 and PC2, which are the two axes (322). 
The number of PC that most efficiently explains the data is a key step and is achieved by a scree test or 
scree plot which involves eigenanalysis (323, 324). Eigen analysis forms from finding the eigenvectors and 
eigenvalues of the covariance matrix. In a scree plot, the x-axis is the number of eigenvalues determined. 
The eigenvalues are ordered from the strongest to weakest in terms of the effect on the dataset. The y-axis 
gives the magnitude of the eigenvalues from the covariance matrix diagonalization. Based on the scree plot, 
two methods exist in literature to choose the number of PC for analysis. The first is eigenvalue one criterion 
wherein the choice of the number of PC is based on the number of components with eigenvalues higher 
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than the value of 1 while the second is by the amount of variance explained wherein the chosen numbers of 
PC should explain 70 to 80% of data variance (325). An example scree plot is shown in Figure 2-20. 
 
Figure 2-20: Scree plot of 12 components. The red dashed line indicates the threshold for retention. Three of the components have 
eigenvalues greater than 1 and are therefore retained for analysis. This means the creation of loading plots, in this case, will be with 
three axes, PC1, PC2, and PC3. 
In this study, PCA was used to create loading plots of polymer behaviours (swelling, erosion, and hydration) 
and drug release profiles in order to observe trends of the behaviour. The number of principal components 
was chosen based on the number of components that had eigenvalue higher than 1. 
2.5.3 Artificial Neural Network (ANN) 
The research of neural network ANN has attracted great attention in recent years. ANN is a computational 
structure modelled loosely on biological processes (326). The concept of ANN originated from the study of 
mammal’s brain wherein researchers noticed that the brain consists of billions of interconnected neurons 
and can deal with computationally complex demanding tasks such as face recognition, body motion 
planning, and muscles locomotion control (327). From this concept, ANN aims to be able to emulate the 
learning ability of biological systems (328, 329). Therefore, it is important to emphasize that ANN relies on 
learning strategies. Figure 2-21 illustrates the similarities between ANN and the mammalian brain. 
 
The basics of ANN operations consists of three layers which in order of operations are an input layer, hidden 
layer, and an output layer very similar to the neuron of the mammalian brain (330). The input layer accepts 
signals from the outside world and redistributes these signals to all neurons in the hidden layer where the 
weights of the neurons represent the features in the input patterns. As a result, the output pattern of the 
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entire network is established by the output layer (331). The data flowing from input to the output layer 
requires transfer function, also known as activity functions, which determine the relationship between 
inputs and outputs of a node and a network (332). Thereafter, the learning process comes into effect. More 
than a hundred learning algorithms are available. The greatest advantage of ANN is that it consists of many 
nodes operating in parallel and can communicate with each other through connecting synapses yielding to 
the testing of numerous outcomes (333). Meanwhile, the disadvantage is that a large number of sample size 
is required to learn and validate. Only thereafter can prediction for untested data be considered as a correct 
and reliable output (334). 
 
Figure 2-21: a) A mammalian neuron. The black rectangle signifies the input layer while the blue signifies the output. 
The nodes and sheath are the hidden layer. (b) ANN computational structure Zm is the input, Wlm is the weighting of 
features, and fn(z) is the output. Adapted from reference (327) 
ANN has been used in diverse areas including in pharmaceutics (335). In pharmaceutics, ANN has been used 
to predict the effect of formulation and process variables (336), prediction of in vitro dissolution profiles 
(337), prediction of drug permeability (338), optimizing emulsion formulation (339), determination of 
factors controlling the particle size of nanoparticles (340), investigate the effects of process variables on 
derived properties of spray dried solid dispersions (341), and validation of pharmaceutical processes (342). 
In this study, ANN has been used to investigate the importance of factors relating to formulation dissolution 
profile to predict the drug release profile in chapter 6. 
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Chapter 3: Investigation into the origins of errors in drug 
release measurements of polymeric solid dispersions 
prepared by FDM 3D printing 
3.1 Introduction 
A key focus of this project is to first understand, then attempt to predict the drug release behaviour of 
polymeric based solid dispersions prepared by extrusion-based methods including hot melt extrusion (HME) 
and subsequent FDM 3D printing for the potential applications such as personalised medicine. It is 
important to first establish the reliability and reproducibility of the manufacturing process and the 
measurements of in vitro drug release data. In this chapter, the solid dispersions were prepared using a 
two-step coupled process of HME and FDM 3D printing. The experimental research was to account for 
errors that are generated in the due process. All errors from sample preparation to in vitro dissolution tests 
analysis, following the flowchart illustrated in Figure 3-1, were examined to gain insights into the origins of 
the errors that were observed in the final in vitro drug release data. For any scientific experiments, no 
physical quantity can be measured with perfect certainty thereby making errors unavoidable. This implies 
repeated measurements of a quantity will certainly yield varying values and a range within which the true 
value lies with a specified likelihood. The scientific study of measurement is known as metrology (343). Two 
fundamentals, accuracy and precision are explained in the following section. 
 
Figure 3-1: Mapping the error process pathway of drug release and optimization 
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3.1.1 Accuracy vs Precision 
Experimental error, itself, is measured by its accuracy and precision. Accuracy measures how close a 
measured value is to the true value. Since the true value for a physical quantity may be unknown, it is 
sometimes not possible to determine the accuracy of a measurement. Precision measures how closely two 
or more measurements agree with others. Precision is referred to as repeatability or reproducibility. A 
highly reproducible measurement tends to give values which are very close to each other (344). Figure 3-2 
illustrates the difference between precision and accuracy.  
 
Figure 3-2: The four outcomes of varying accuracy and precision 
3.1.2 Types of errors 
The true value is the value that is unique and expected from measurements in the absence of any errors (4). 
Three error types exist in measurement theory. They are systematic, random, and gross errors. Gross errors 
arise due to humans which can be eliminated by a careful recording of the data (343). Examples of gross 
errors include instrument reading before a steady state is reached or parallax error (perceived shift in an 
object's position as it is viewed from different angles) in reading a measurement. Systematic error is hard to 
detect but once detected, is correctable. Systematic error is either constant or proportional to the 
measurement. Systematic errors influence the accuracy of measurement (345). Examples of systematic 
error are imperfect instrument calibration.  
 
Random errors are two-sided errors as the variation in measurement occur unpredictably above or lower 
than the measured mean value or the true value (3). Random errors can be easily detected and can be 
reduced by repeating the measurement or by refining the measurement method. Random errors directly 
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affect the precision of a measurement. The smaller the random error, the more the precision (345, 346). 
Common sources of random errors are problems estimating a quantity that lies between the graduations on 
an instrument and the inability to read an instrument because the reading fluctuates while measuring.  
 
Figure 3-3 shows the Gaussian distribution of probability curves. The systematic and random errors are 
visualizable from this illustration. The systematic error is the difference between the true mean (theoretical 
value) and the experimental (EXP) measured mean. The systematic error can be either positive or negative 
relative to the true value but often cited as an absolute value (modulus). The random error can be 
calculated with many models but most commonly estimated by the standard deviation (347). 
 
In this chapter, the aim is to assess the errors of drug release measurement from the HME-FDM continuous 
process. The systematic and random errors for HME, 3DP, and UV will be investigated, ranked, and 
optimized to achieve more accurate and predictable drug release.  
 
Figure 3-3: Measurement concept of errors from probability curves. Adapted from reference (343). 
3.2 Materials 
PVA was obtained from Kuraray (Germany) under the trade name Mowiflex C17 as pellets. The melt flow 
index (MFI) is (190 oC, 21,6kg) [17g/10min], Tm ≈ 180 – 200 oC, and the Tg is 60 oC (261). The model drug 
chosen was paracetamol (PCM) bought from Sigma Aldrich (CAS Number: 103-90-2) with a purity of ≥ 99% 
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(204). ABS bought from Makerbot, is an amorphous thermoplastic polymer which is used for manufacturing 
multiple household products and is a commonly used in 3D printing has been used as a controlled polymer 
to PVA with (MFI) is (200 oC, 5kg) [5.5g/10min] and Tg of 105 oC (294, 348). Samples were prepared using 
different combination of polymer and drugs or polymer only placebo for the different stages of error study 
and is summarized in Table 3-1. 
Table 3-1: Materials used as per error study aspects summarized. 
Experiment stage Material 
Drug uniformity by HME PCM loaded PVA extrudates 
Printing reproducibility by FDM printing PVA and ABS torus 
Weight uniformity by FDM printing PVA and ABS torus 
In Vitro drug release quantification by UV Spec PCM loaded PVA extrudates 
 
3.3 Methods 
3.3.1 Hot melt extrusion (HME) 
A Thermofisher HAAKE Minilab II with twin co-rotating screws was used for the preparation of the filaments 
for measuring drug content homogeneity. During the preparation of samples, the screw speed was set to a 
standard 100 rpm. The processing temperature was 10–20 oC higher than the melting temperature (Tm) of 
the polymers. The samples were prepared in two separate batches: one with a residence time of five 
minutes and another with ten minutes. Four different extrusion temperatures for preparation of filament 
were used.  
3.3.1.1 Drug content uniformity of the HME extrudates  
Mowiflex (PVA) mixed with 10% PCM were fed into the extruder. Four filaments were made by HME at 
temperatures of 170oC, 180oC, 185oC, 190oC. Six pieces with a length of 1.5 cm were cut at 5 cm interval 
from each filament to produce six random samples per filament. The cut samples were weighed, and their 
dimensions measured via a digital caliper. All filaments per temperature were done in triplicates. The 




Figure 3-4: Schematic of filament sampling. Red dots indicate 1cm (not shown in triplicates) samples taken at 5cm interval indicated 
by the red rectangle across the filaments.  
The weight uniformity is presented as drug weight per polymer weight. Due to the filament flattening under 
gravity when exiting the die from HME, the geometry of the solidified filament is an elliptical cylinder shown 
in Figure 3-5. The volume of an elliptical cylinder is given by 𝑉 = 𝜋 × 𝑎 × 𝑏 × 𝐿, where a is the major radius, 
b is the minor radius, and L is the length, all in centimetres. 
 
Figure 3-5: Elliptical cylinder where a is the semi-major axis; b is the semi-minor axis, and L is the length 
3.3.2 FDM 3D Printing 
The FDM 3DP is the subsequent step after filament production through HME and was used to print oral 
dosage to investigate printing accuracy and precision of the printing process. MakerBot Replicator 2X 
consisting of dual extrusion print nozzles was used. It has a maximum print volume of 15 X 16 X 24.9 cm3, 
nozzle diameter of 1.75mm, and an exit tip diameter of 400 microns (349). The printer has three print 
settings from low to medium to high quality printing whereby the extrusion speed decreases with each 
higher print quality. The printed oral dosage was in the shape of a torus (plural: tori). A torus geometry has 
a mathematical advantage over other geometries in drug release studies. Other geometries as pyramid, 
cube, sphere, and slabs, all of which were considered in the preliminary phase as a validation of the work 
performed by Goyanes et al (350). First, the surface area (SA) to volume (V) ratio can be increased or 
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decreased in a manner that allows either surface area or volume to be constant while altering the other 
parameter. The surface area to volume ratio (calculated: SA/V) is an important indicator of the drug release 
with the torus exhibiting the faster dissolution rate of all (350, 351). Second, the drug release flux can be 
assumed in one direction outward (radially) in polar or spherical coordinates (352). Third, the torus is a 
cylinder wherein the boundaries are adjoined together, effectively postulating it as an infinite cylinder 
illustrated in Figure 3-6. Thus, the equations of a cylinder can be applied in a simpler form where any API 
diffusion at the ends can be neglected, in turn making computations less intensive and less time consuming. 
 
Figure 3-6: a) In polar coordinates, the diffusion occurs in one dimension in the radial direction (r) indicated by the blue arrows while 
is θ the angle at which the radial diffusion takes place. b) The starting cylinder if curved and joined end to end forms a torus which is 
effectively an infinite cylinder. 
3.3.2.1 Reproducibility of 3DP torus  
The reproducibility of the FDM 3DP was investigated by observing any difference in physical dimensions 
between the designed and printed specifications of the torus. The dimensions refer to the diameter and the 
annulus, which were measured using a digital caliper. Figure 3-7 shows these two parameters of the torus 
that was measured. The radius was obtained by halving the diameter values. Twenty tori were printed from 
two filaments of two polymers. Ten tori were prepared in each batch. One batch was using the commercial 
filament ABS while the other was using PVA via HME process. The PVA with PCM filament was prepared at 
HME processing temperature of 190 oC and residence time of five minutes. The printing temperatures for 
PVA formulation were 200 oC and 230 oC for ABS. The selected design specification was a torus diameter of 
14mm and an annulus of 2mm. For a torus, the annulus is equal to the width which is also equal to the 
height. For calculations of the volume of the torus and surface area, equations 3-1 and 3-2 can be used, 
respectively. The null hypothesis (H0) is that no volume difference will be observed.   
V (r,R) = 
1
4
𝜋2(𝑟 + 𝑅)(𝑅 − 𝑟)2 Equation 3-1 
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SA = 𝜋2(𝑅2 − 𝑟2) Equation 3-2 
 
Figure 3-7: Inner radius (r) and outer radius (R) for torus V and SA calculation. A is the annulus (the diameter of the ring) and is equal 
to the height (h). D is the diameter of the torus. 
3.3.2.2 Weight uniformity 
The FDM 3DP tori were weighed using analytical mass balance. It is expected samples of each batch are 
identical and as such, should, therefore, exhibit no weight difference, which is the H0. 
3.3.2.3 In vitro drug release studies 
In vitro drug release studies were carried out in dissolution testing apparatus (Caleva, Germany) using 
British Pharmacopeia (BP) apparatus 2 paddle method.  A paddle rotation speed of 100 rpm and 900 ml of 
Milli-Q deionized water were used with a temperature of 37°C±0.5°C. During dissolution, at predetermined 
time intervals, 5 mL samples were taken and replaced by 5 ml fresh water. The samples were collected 
through filtration membrane of 0.45μm pore size (minisart NML disposable syringes, UK) before UV 
measurements. The sampling times were every three minutes up till fifteen minutes, every thirty minutes 
thereafter, and every hour beyond three hours (3min, 6, 9, 12, 15, 30, 60, ..., 180, 240, …, End). All samples 
were tested using the above in vitro method three times. 
3.3.2.4 Calculation of cumulative error in drug release data 
For the cumulative error in drug release, three tori were prepared using PCM and PVA by using HME-FDM. 
The mean weights and volume of these tori were 0.130±0.041 g and a volume of 117.1±3.4 mm3. The aim 
for investigating cumulative errors in drug release is to be able to predict the variations that will result from 
using drug release models. The drug release model used is the Korsmeyer-Peppas equation which is used to 
analyze both Fickian and non-Fickian drug release from swelling and non-swelling polymeric delivery 















 is the drug fraction, K is the release rate constant, and n is the aspect ratio. The term anomalous 
refers to non Fickian diffusion which is driven by micro-instabilities obstructing a laminar flow or laminar 
diffusion. The above equation has only one variable: time (t). The other two are constants that can be found 
from curve fitting. Since this equation parametrises the drug release profile, using partial differentials, the 
absolute error for the drug release profile can be estimated. The generic error of a function of n variables 
f(x,y..., i) using partial differentials is given by equation 3-4 (353). 






δy + ⋯ +
∂f
∂i
δi    Equation 3-4 
Where 𝛿𝑓 is absolute error in f, 
𝜕𝑓
𝜕𝑖
 = partial derivative of f with respect to i, and δi is error in i. This drug 
release absolute error is given by equation 3-5. The error in sampled drug mass (δMt) value is obtained 
experimentally from UV, thus UV errors (EUV) can substitute the right side expression of equation 3-5. This is 
discussed on the next page where the Beer-Lambert law is introduced. 
                         δMt = (M0knt
n−1)δt = 𝐸𝑈𝑉  Equation 3-5 
In the above equation, δt (the time in error sampling) is negligible, especially for automatic dissolution 
machine. In equation 3-5, M0 is taken as a constant and thus error-free but in reality, is an averaged value. 
There are two approaches to obtaining the error in Mo. The first approach is to measure it directly using a 
UV-Vis spec. The second approach is to estimate it from the process steps involved. An error in initial drug 
mass (δM0) exists which arise from the processing steps involved (from HME to 3DP, then to UV). Therefore, 
predicting δMo requires an estimation of the error in each step. In section 3.3.1.1, the drug content 
uniformity is investigated. From this, the initial drug mass error in HME (δMHME) arises. For 3DP, there are 
two approaches to deducing δM0. Both of these approaches are investigated. The errors in 3DP arise in 
volume and weights. The error in volume (δV3DP) is estimated by equation 3-6 and drug mass error in 3DP 
(δM3DP) is directly from weighing after printing. This δM3DP is a direct approach to get δM0. In the case the 
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oral dosage is not weighed, the other approach involves δV3DP. Knowing the δV3DP and the density of the 
drug, δM3DP can be found using 𝑚 = 𝐷𝑉. For example, -20% δV3DP indicates δM3DP is also less by 20% since 
density is constant.  
 
The UV spectrometer relies on the Beer-Lambert law (equation 3-7) containing one variable concentration 
(c). The UV spectrometer error can be subdivided into three types: calibration curve errors, instrumental 
errors, and sampling errors. To deduce calibration curve errors, three calibration curves were prepared for 
PCM in deionized water. The resulting variation will quantify the errors due to calibration curves. To deduce 
instrumental error, the absorbance of one diluted sample was repeatedly obtained. Ten repeat readings 
were done. The sample concentration was 15μg/ml. To deduce sampling error, the absorbance of PCM 
released from ten tori samples were measured at using the mean calibration curve found in the 
investigation of calibration errors. Since the cumulative averaged concentration of the tori can fluctuate 
based on the number of samples, any variations in absorbance is due to sampling error. The cumulative 
averaged concentration converges to a number as the sample size grows larger. This convergence occurs 
because of the sensitivity of random difference in the concentration among each sample diminishes with a 
larger size. The time point chosen for sampling was 3 mins. The three errors combined will give the total 
error in absorbance (δA). The δA is given by equation 3-8. Rearranging equation 3-8, δc can be gathered. 
The error in drug mass from UV (δMUV) is deduced from the c using 𝛿m=δCV, with a volume of 900mL. As 









𝜋2(3𝑟2 − 2𝑟𝑅 − 𝑅2)
4
𝛿𝑟 +
𝜋2(3𝑅2 − 2𝑟𝑅 − 𝑟2)
4
𝛿𝑅 Equation 3-6 
          A = εℓc Equation 3-7 
          δA = εℓδc Equation 3-8 
Where 𝛿𝑟 is the error in inner radius, 𝛿𝑅 is the error in outer radius measurements, ε is the molar 
absorption coefficient, ℓ is the path length, c is the concentration of the solution, 𝛿A is the absorbance 
absolute error and δc is the concentration error. Expressions of cumulative error can be formulated for drug 
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release which includes both Mt (error in sampled mass) as well as Mo (error in initial mass). Mt is indicative 
of UV error while M0 is indicative of HME-FDM production steps. The δMt, in terms of UV, is by combining 
equation 3-5 and equation 3-8 with 𝛿m=δCV, is given by equation 3-9. δM0 from 3DP is given by equation 3-
10. In case the oral dosage is not weighed after 3DP, δM0 is given by equation 3-11, where δM3DP is in terms 
of density and volume (DδV3DP). Lastly, combining equations 3-9 and 3-11, with non-constant M0, gives the 
drug release error in terms of the manufacturing processes, which given by equation 3-12, where the left 
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𝜋2(3𝑟2 − 2𝑟𝑅 − 𝑅2)
4
𝛿𝑟 +
𝜋2(3𝑅2 − 2𝑟𝑅 − 𝑟2)
4
𝛿𝑅] 𝐷 Equation 3-12 
where V is the volume which in this case is 900mL, A1 is the dissolution sampled absorbance, A2 is the initial 
sample absorbance, and D is the density. 
3.4 Results and discussion 
3.4.1 Characterization of samples 
The characterization of the formulations has been presented in the appendix. The DSC thermograms shown 
in Appendix Figure 1. The 10% drug loading showed a plasticizing effect of the PVA and in amorphous form.  
3.4.2 In vitro drug release studies 
In this section, the error in UV measurement was deduced. Three sources of error arise in measurement by 
using the UV spectrometer (δAUV) which consist of calibration error (δAc), equipment error (δAe), and 
sampling error (δAs). the first of these presented is the δAc. The average of three calibration curves for PCM 
are shown in Table 3-2. The total error was calculated using the following equation: 𝐸𝑇 = (𝐸𝑠
2 + 𝐸𝑟
2)1∕2 
where ET, ES, and Er are total error, systematic error, and random error respectively (354, 355). The 
standard deviation was used to represent the random error. The ES depends on comparing the 
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difference in measurement between the averaged experimental value and the true expected value. 
The true value cannot be determined as the 𝛆 (the molar absorption coefficient) in equation 3-7 is a 
value that is derived from the absorbance, concentration, and length (𝛆=A/ℓc) of which, concentration and 
absorbance, vary simultaneously. However, since the ES is constant and present in every process step, 
the source of error that affects in practice is the Er. Therefore, for δAc, the Er is 1.1x10-3, and thus the ET 
is 1.1x10-3. 
Table 3-2: The variations of calibration and the goodness of fit (R2) measuring the three curves in deionized water. y is the 
absorbance and x is the corresponding concentration obtained from best fits. 
Trials Equation R2 
Calibration Curve 1 y = 0.0617x 0.999 
Calibration Curve 2 y = 0.0596x 0.992 
Calibration Curve 3 y = 0.0604x 0.997 
Average y = 0.0606x 0.996 
Standard Deviation ± 0.0011 - 
 
The equipment error (δAe) was quantified by repeated measurement of absorbance of one of the diluted 
samples. The sample concentration was 15μg/ml and the mean measured absorbance was 0.95520 AU. 
Based on the ten repeated absorbance measurements, the Er of δAe was 1.37x10-4 absorbance units (AU), 
and ET of 1.37x10-4 AU. Figure 3-8 shows the absorbance frequency distribution for repeated measurement. 
 
Figure 3-8: UV absorbance distribution for 15μg/ml sample over ten repeated measurements. The dotted line is the measured mean. 
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The δAS (from sampling) was deduced from the UV absorbance of ten 3DP tori, which is shown in Figure 3-9. 
The δAS exhibited an Er was 0.12 AU equating to an ET of 0.12 AU.  
 
Figure 3-9: UV absorbance distribution of ten samples. The dotted line is the measured mean. 
The δAUV is a linear combination of calibration error (δAc), equipment error (δAe), and sampling error (δAs) 
(𝛿𝐴𝑈𝑉 = 𝛿𝐴𝐶 + 𝛿𝐴𝐼 + 𝛿𝐴𝑠). Figure 3-10 illustrates the contribution, percentwise. The total 𝛿𝐴𝑈𝑉 is 0.121 AU. 
Percentwise ranking shows 𝛿𝐴𝑆>𝛿𝐴𝑐>𝛿𝐴𝑒. Lowest contribution from 𝛿𝐴𝑒  is as expected due to 
instruments undergoing quality control testing for many aspects including accuracy and precision before 
being commercialized (356). The highest δAUV error from sampling was also expected. Two explanations can 
be proposed. First, sampling in UV is the last step in the pipeline of HME-FDM continuous process of oral 
dosage manufacture. This implies, that each of the ten samples has varying errors present; that have 
propagated from earlier manufacture steps. Second, the average sampling error of all the samples and 
sample size have an inversely correlated relationship (357). As the sample size increases, the sampling error 
is lower. A sample size of ten is still low with a high margin of error. Statistical approaches such as Monte 
Carlo simulations have been applied to reduce the sampling error (358, 359). Anderson demonstrated the 
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importance of small sample size affecting sampling error in MC simulations. Due to the small sample size, 
the goodness of fit (R2) was highly sensitive of any outliers compared to larger sample sizes with outliers. 
Smaller sample sizes led to sampling distributions of the likelihood ratio test statistic that were different 
from the corresponding theoretical chi-square distribution (360).  
 
Figure 3-10: A percentwise in terms of the that affects the UV spectrometer. Ae is equipment error replaced 
Furthermore, the convergence of random error with increasing sample size can be deduced from the central 
limit theorem (CLT) (358, 361). Figure 3-11 shows the convergence of δAs for the ten replicates. The 
variance in δAs, found from standard deviation (random error in δAs), for ten samples was scaled to 100,000 
samples. Beyond 100,000, the effect of sample size diminishes. According to CLT, the central value (mean) 
that will be attained when the sample size is large enough is 0.94 AU. The sample size at which this occurs 
was found out to be 99,995. On 99,995th sample, the random error in δAs is zero. 
 
Figure 3-11: Convergence of δAs. The solid curve represents the maximum and minimum absorbance (A±δA) at various sample sizes. 
The dotted-dashed line represents the mean absorbance that is reached at large sample sizes. The double line is the UV absorbance 










































3.4.3 HME Studies 
3.4.3.1 Measuring drug content uniformity of HME 
With a drug loading of 10%, the weight of the drug per weight of the polymer (mg/g) of the six filament 
samples for the four temperatures is shown in Table 3-3. At residence time of five minutes, the average 
drug homogeneity (column) does show a difference for inter-filament at different processing temperature 
but not significantly different in the case between 170oC and 180oC. The processing temperature of 190oC is 
significantly more homogenous than 170oC or 180oC. It was expected that the standard deviation of weight 
homogeneity for intra-filament would decrease with increasing processing temperature as the melt 
viscosity decreases above the melting of the drug. The Tm of PCM form I is 169oC (203). A decrease in melt 
viscosity allows a smoother flow of the material in the HME barrel. The variance decreased for identical 
processing temperatures of ten minutes of residence. The residence time characterizes the heat energy 
produced over a specific period during the material shear (362). Due to the increased holdup time in time in 
the HME barrel, more homogenous mixing of the API can occur. Li et al reported that the short residence 
time of materials in the extruder is not sufficient to achieve complete API dissolution in the matrix (363). 
However, numerous literature cites prolonged residence times as the cause of drug degradation, which 
suggests the effect of residence time may be parabolic on drug content (362-364). 
Table 3-3: Drug w/w of filament cut samples at the two residence times and various temperatures. 
 5 minutes of residence 10 minutes of residence 
 Temperature (oC) 
 170 180 185 190 170 180 185 190 
Intervals (cm) Drug weight per polymer weight (mg/g) 
5 90.88 59.90 73.44 92.12 73.81 96.14 105.64 96.90 
10 90.13 82.76 78.67 98.65 77.99 93.51 94.43 104.36 
15 116.29 117.20 106.55 103.07 77.46 105.19 85.65 92.24 
20 91.91 141.98 74.48 99.56 74.20 119.98 87.54 98.65 
25 86.18 118.26 53.75 104.86 96.19 122.92 117.49 77.65 
30 161.77 120.31 97.88 100.68 96.16 127.82 119.32 104.34 


















Censi et al have reviewed the factors that can be optimized for HME process (365). The focus here is to 
assess the errors in weight uniformity of the HME process. Therefore, it is important to discern the two 
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types of errors quantitatively in the HME. Since each processing temperature is a different population, the 
errors will also be different for each temperature. As an example, the measurement concept of weight 
uniformity for HME processing temperature at 170oC is shown in Figure 3-12. 
 
Figure 3-12: Measurement concept for HME weight uniformity at 170oC. Blue dashed line marks the true (target) value that is 
theoretically expected. The red dashed line is the EXP mean. The black dashed curve is the probability distribution curve. 
The two errors types for each temperature are presented in Figure 3-13. A trend in ET exists of improved 
drug concentration uniformity with increasing HME processing temperature and residence times. 
Extrapolating to where the ET = 0 by fitted to a quadratic equation, yields HME processing temperatures of 
161 oC or 191 oC for 5min residence time and no solution for 10 min residence time. The former 
temperature 161oC is below the Tm of PCM and therefore excluded. The latter temperature is suitable for 
HME. This processing temperature was performed but the error was not eliminated. Additionally, the onset 
of PCM degradation is 240 oC from TGA (366). The FDM printing temperature ranges about 20 to 50oC above 
the HME processing temperature (25). Mackay et al reported the minimum printing temperature required 
for amorphous polymers is Tg+78oC (367, 368). Therefore, an HME processing temperature of 191oC implies 




Figure 3-13: Error subtypes for HME processing temperature. The 5 or 10 in brackets beside temperature indicate the residence time. 
The trendline fitted to 5 minutes is shown on the bottom left while the trendline for 10 minutes is on the bottom right. 
3.4.4 FDM 3DP studies 
3.4.4.1 Reproducibility of FDM 3DP object dimension 
The comparison of twenty tori dimension is shown in Table 3-4. It was observed that a significant deviation 
for diameter exists from the theoretical (THRY) specification. The expected lower bound for diameter from 
THRY due to printer reproducibility error is 13.89mm (14.00-0.11 from column 1 and row 1 or table 3-3) but 
instead was lower for both polymers. Upper bound diameter from experimental (EXP) measurements also 
fails to attain the lower bound diameter of the THRY specification. This can signify issues for the printer in 
controlling the nozzle over the x-y plane. However, the annulus measurement (also x-y plane) was within 
the THRY specification.  
Table 3-4: Tori dimension comparison. THRY denotes design specification while EXP denotes experimental measurement. 
 
PVA ABS 
Diameter Annulus Height Diameter Annulus Height 
THRY (mm) 14.00 ± 0.11 2.00 ± 0.11 2.000 ± 0.003 14.00 ± 0.11 2.00 ± 0.11 2.000 ± 0.003 
EXP (mm) 13.65 ± 0.07 2.02 ± 0.04 1.99 ± 0.09 13.78 ± 0.09 2.02 ± 0.03 1.98 ± 0.04 
 
One possible explanation for this is shrinking of the sides of the printed layers. During solidification, cooling 
takes place due to the temperature gradient between the oral dosage and the surrounding. As stated in 






































































































TEMPERATURE (0C)    (RESIDENCE TIMES) 
Systematic Error Random Error Total Error
y = 0.009x2 - 3.74x + 402.3
R² = 0.9566
y = -0.16x2 + 54.96x - 4806.1 




and object. Ceteris paribus, convection of heat is faster than conduction (369). Due to the position of 3DP 
design, the air at the bottom near the platform and air at the top near the nozzle tip is hotter than the 
region between the two parts. Therefore, the lateral sides of the oral dosage are in contact with cooler air. 
The fastest rate of cooling happens in this direction and hence the fastest rate of solidification and 
accounting for fastest shrinkage. The bottom plate would be the subsequent slower rate of cooling due to 
the slightly lower temperature gradient. The surface layer is in closest proximity to the heated nozzle and is 
always subjected to the most recent deposited layer which is always hotter the layers beneath. Therefore, 
the solidification rate is the slowest in this direction. This phenomenon is shown in Figure 3-14. A 
temperature reading at any point in time during 3DP would show a ranking of Ta < Tb < Tn . 
 
Figure 3-14: Cooling gradient from the object (black torus shape) while successive layers are being deposited. The arrows represent 
outgoing convection. A greater thickness of the arrow represents higher heat flux. The lateral side will always shrink the fastest and 
prone to have the highest deviation. Red region shows the most heated area while the yellow region shows the cooler moderate 
region and the green region shows the lowest heated area. 
In the case of height, which operates in the z plane, the EXP error range (±0.09mm for PVA and ±0.04mm for 
ABS) was greater than the theoretical error range of ±0.01mm. This is most likely due to a ‘double printing 
effect’ that is observed on all the tori. This seems an unavoidable issue for the printing of torus geometry. 
For such geometries where the initial deposition conjoins with final deposition, the strands (printed 
filament) overlap after deposition on the same point of the platform causing an abrupt increase in height, 
which is usually reflected as a variance/error in the z plane. Figure 3-15 illustrates this issue for one of the 
ABS torus printed of the ten tori samples.  
Slowest heat loss 
Nozzle temperature (Tn) 
Air temperature (Ta) 
 
Fastest heat loss 




Figure 3-15: a) Ten ABS tori. b) A closeup of torus # 10 showing the double printing effect upon solidification. 
Overall, experimental results showed that the range of error was lower for the commercial filament ABS 
than PVA (expect for diameter). In chapter 1, the phases of FDM 3DP was divided into three aspects: 
feeding, deposition, and solidification. Any error due to the feeding phase can be eliminated as the oral 
dosage has successfully printed. Solidification accounted for the shrinkage. Therefore, since both polymer 
oral dosage exhibits constantly lower error ranges (indicating a systematic error), a contributing factor can 
be rheological properties during deposition. Wang et al states Melt Flow Index (MFI), crystallinity, and 
plasticization are important for successful 3DP (370). The MFI of PVA is 17g/10min at 190 oC and the MFI of 
ABS is 5.5 g/10min at 200 oC (261, 348). The PVA flows better at lower temperatures. Accounting for the 
external printer factor, Alhijjaj et al concluded the printing speed will have a greater contribution than 
printing temperature (48). However, the printing speed was identical for both polymers. Therefore, the 
printing temperature may be an issue. The printing temperatures of 200 oC for PVA and 230 oC for ABS 
indicate that PVA will flow better due to the MFI difference. This may be the cause of higher error range for 
PVA as the better flow can lead to uncontrolled smearing on the platform before the solidification occurs. 
However, this does not explain the higher error range for ABS (±0.09) than PVA (±0.07). This most likely is a 
random error as this is not constantly reproducible in other dimensions and relative minuscule compared to 
each other (±0.02).  
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The systematic and random error in terms of resolution (in x, y, and z plane) for ABS and PVA geometries by 
FDM 3DP are presented in Figure 3-17. As an example, the distribution curve for PVA torus diameter is 
shown in Figure 3-16. The diameter indicates the error in the x-y direction resolution of the 3DP. The 
systemic error for the diameter is 0.35mm (14.00mm –13.65mm). The random error is estimated by using 
the standard deviation found to be 0.072mm.  
 
Figure 3-16: Measurement concept for the diameter of PVA. The blue dashed line marks the true value expected from THRY 
specification. The red dashed line is the EXP mean. The black dashed curve is the probability distribution curve.  
It was observed in both cases, the ABS showed higher errors, which was unexpected. ABS is a commercial 
filament with uniform filament thickness and hence consistent feeding into the 3DP. Additionally, the 
rheological and thermal properties required for smoother deposition and solidification respectively for ABS 
is likely optimized. Moreover, it was surprising to observe that the random error in the height of printed 
ABS torus was reasonably similar to the systematic error of ABS height. Although this can make the 
reproducibility of the height a serious technical problem, it should be noted that this random error 
(0.09mm) is identical to the random error in printed PVA torus (0.09mm) and therefore consistent. Yet, the 
systematic error varied by six times (0.12mm/0.02mm) for the height of the two polymers. This is most 




Figure 3-17: Error types categorized for 3DP resolution in x, y, and z directions. 
Using equation 3-1, the volume of tori can be calculated. The error in the radius for volume is given by 
equation 3-6. The total error found for the diameter of PVA and ABS, after dividing by 2 (𝑅 = 𝐷/2), is taken 
to be the error in major radius (δR). The minor radius (δr) is found by subtracting the annulus from the 
diameter and halving the value. The errors in the volume are discussed in section 3.4.5.1 Case I: δM0 from 
3DP tori volume measurements). 
3.4.4.2 Weight uniformity 
Figure 3-18 depicts the weight per volume distribution. The theoretical weight for the formulation was 
deduced by accounting 90% polymer weight and 10% PCM. The ABS theoretical weight was deduced by 
using theoretical volume with density. The density of ABS is 1.07g/cm3 (371), PVA is 1.25g/cm3 (261), and 
PCM is 1.31g/cm3 (203). It can be observed that weight uniformity is more precise and accurate for ABS. In 
contrast, PVA weight uniformity was relatively less accurate and highly imprecise, as expected. ABS being a 
commercial filament should have more homogenous distribution in the filament. Knowing the systematic 
error of printing resolution to be less than the true value, a lower volume than true volume was expected 
for both ABS and PVA, which was observed. As mentioned earlier, if the weight of the object is measured 
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true M3DP of the torus is 0.015g (0.15g/10). The total experimental δM3DP of the ten tori is 0.0081g with a 
random error of 0.0078mg and a systematic error of 0.0025g.  
 
Figure 3-18: Weight vs volume distribution of the printed tori from the two polymers. 
Skewness is a measure of how much the data is nonsymmetric. For the application of any parametric tests 
to the data group, the skewness has to be within ±3; else the results are invalid (372). The PVA with PCM 
loaded filament was prepared at 190 oC via HME. The skewness for the drug weight uniformity (μg/mm3) at 
190 oC is 0.715 (from analyzing Table 3-3 190 oC in SPSS). The printing temperature was 200oC and the 
skewness of the PCM concentration at 200 oC for 3DP is 1.531. As the skewness for both was within ±3, any 
parametric test is valid. For successful printing, the weight of PCM should not significantly differ between 
HME and FDM. Statistically significant lower drug weight indicates drug degradation. Paired sample T-test (a 
parametric test) was used to compare the means of two dependent groups before and after an event was 
employed for the PCM weights (373). The event, in this case, is the printing. The PCM mean drug weight 
from HME process is 131.36 μg/mm3 and the PCM mean drug weight from 3DP process is 123.58 μg/mm3. 
The significance level of the paired T-test was 0.105 for the 95% confidence interval. This is greater than the 
significance level of 0.050 and hence Ho of no difference between the sample is statistically significant. In 
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3.4.5 Cumulative error in drug release 
The left side of equation 3-11 is a measure of the drug mass release during dissolution obtained from the 
UV spectrometer. The δAUV is affected by δAc, δAI, and δAs. In the case of the cumulative error in drug 
release, two scenarios exist. First, the δM0 is derived from volume calculation in the 3DP process step. 
Second, the δM0 is calculated directly from the weight of the printed oral dosage.  
3.4.5.1 Case I: δM0 from 3DP tori volume measurements 
Equation 3-12 outlines the possible error from volume measurements. The drug release is expressed as a 
percentage. The % relative error for a function (f) is given by 
𝛿𝑓
𝑓
× 100 (353). The % relative error for drug 
release is given by rearranging in the form of equation 3-13. δA is the total δAUV excluding the systematic 
error which is 0.121 AU. The reason for excluding the systematic error is that the drug release profile does 
not include any systematic error. The systematic error that exists in the oral dosage, appear in both Mt and 
Mo. For example, an oral dosage can have systematically 50% of the mass compared to theoretical 
specification. This 50% is reflected equally in δMt. Thus, the % relative error is more accurate if the 
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2(𝑟 + 𝑅)(𝑅 − 𝑟)2(𝐷)
 
 𝑋 100 Equation 3-13 
Where A1 is the sample absorbance. Since these parameters are constant for any absorbance and radius 
values of triplicate sample size, error bound for the oral dosage profile can be found. With the appropriate 
δr and δR of 0.36mm, and δA of 0.12 AU, the % relative error according to equation 3-13 is ±56%. This has 
been illustrated in Figure 3-19 for a drug release profile. The red curve shows the absolute error bounds. It 
is observed that random error from the experiment is within the absolute error bound. When the upper 
bound of the curve goes above fractional drug release of 100%, the increasing portion of the curve 
thereafter can be taken as a constant valued at 100%. This is because the fractional drug release more than 
100% does not have any physical interpretation.  
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3.4.5.2 Case II: δM0 from 3DP tori mass measurements 
If the oral dosage weight is measured, the δM3DP is directly from the weight measurements. The resulting 
left side of equation 3-10 is simply the δM3DP. Equation 3-14 shows the resulting relative percentage error 















 𝑋 100 
Equation 3-14 
 
The δM3DP for the ten tori was 7.8mg. This δM3DP is equated to be the δM0. δAUV is 0.12AU which equates to 
a δMt of 1.69mg. This produces a % relative error of ±22% shown in Figure 3-19. It is observed that many of 
the random error at sample time points are not within the error bound derived by this method. This 
indicates that the total error estimation from the mass measurement may underrepresent the experimental 
errors. This can be because of the number of variables used in calculating the relative error in the two cases. 
The estimation of absolute error from volume calculation (Equation 3-13) is less precise due to more error-
prone variable present in the calculation (3 in total: δA, δr, and δR) vs two in total (δA and δM3DP) for direct 
weight measurements. The less precision allows more variance of drug release, allowing for more 
experimental error and in this case encompasses the experimental random error. 
 
Figure 3-19: The absolute error in drug release attainable at each sample time point. The red solid curve represents absolute error 
from the volume calculations of 3DP oral dosage while the red dashed line represents absolute error from the mass calculations from 























3.4.6 Process Optimization 
Knowing the error from each of the processes, it is possible to minimize the cumulative error in drug 
release. For HME, the optimization of HME weight homogeneity is attainable through longer residence 
times. For 3DP, the printing temperature can have an effect which for the formulation was 200oC. For the 
UV spectrometer, creation of more calibration curves can reduce the random error. Bigger sample sizes also 
improve the error. Lower error in drug release leads to a better approximation of the parameters (k and n) 
on the right side in the Peppas equation (equation 3-3). Therefore, in vitro dissolution studies of a torus 
processed optimally with 10% PCM has been used to validate minimization of errors. In the previous 
section, drug release for the torus undergoing 5min residence time in the HME process was shown. From 
Figure 3-13, it was observed that higher HME processing temperature had more homogeneous drug 
distribution. A higher printing temperature of 210oC was used. Five calibration curves were utilized, and the 
experiment was replicated in quintuplicates. The cumulative error in drug release was found using equation 
3-12. δA was 0.11AU. δr and δR are both 0.31mm. Figure 3-20 shows the resultant drug release profile with 
a relative error of ±17%. As expected, the EXP error decreased and possible error bounds were narrower.  
 
Figure 3-20: drug release of PCM under optimized manufacture process condition. The red curve is the possible error bound for this 























The parameters of Peppas equation can be estimated from the two bounds. It can be seen that the aspect 
ratio which indicates the underlying transport mechanism does not alter significantly that can indicate a 
different mechanism. An aspect ratio of 0.45 to 0.89 is anomalous transport. This is shown in Table 3-5. 







Lower estimate (Experimental) 9.39 0.56 
Averaged estimate (Experimental) 10.13 0.51 
Upper estimate (Experimental) 10.88 0.47 
 
3.5 Limitations 
Limitations exist that can hinder the use of such error cumulations to be generic for all drugs. The error in 
the drug release profile is essentially cumulative random error exhibited from all the manufacturing 
process. The random error will vary for different equipment and alterable process parameter. For example, 
a different hot melt extruder will have different δAe and varying the process parameter like screw speed will 
affect the weight homogeneity. The same reasoning holds for the 3DP and UV spectrometer. The systematic 
error will also be minimized by using newer improved equipment.  
 
The limitations to generalizing the drug release from the dosage also stem from the materials itself. A 
different drug or polymer will have a different melt viscosity. The drug loading will influence the drug 
release. A higher drug loading or a hydrophilic drug will likely exhibit faster dissolution rates. The choice of 
drug or polymer will alter the rheological and thermal properties of the formulation which will cause 
changes to the printing resolution and thereby the associated 3DP error (δM3DP and δV3DP). This in practice 
will be demonstrated by shrinking during solidification and in the deposition phase.  
 
Lastly, gross error and analytical errors are not emphasized in this chapter. This is because gross errors can 
be eliminated, and analytical errors cannot be quantified for every step of the process. Due to the fact, that 
all possible errors cannot be always quantified for an experiment, the concept of triplicate repeats exists as 




In this chapter, the error for the manufacture of oral dosage via HME-FDM continuous process method was 
investigated. The systematic, random, and total error for each of the process was deduced. Based, on the 
random error from each manufacturing process, the cumulative error in the drug release profile was 
produced. This helps in ascertaining the highest margins of error possible for the given formulation in the 
current manufacture process pipeline. Thereafter, based on the findings, five tori under optimum 
processing condition were prepared. The drug release profile for these tori was compared wherein the 
random error of the quintuplicate was found to be lower compared to sub-optimum processing conditions. 
Unfortunately, although the error propagation concept can be generalized for any formulation, the error 
values obtained here cannot be applied to any generic formulation. Furthermore, the error values 




Chapter 4: Characterisation of the polymers and polymer 
blends behaviour in aqueous media 
4.1 Introduction 
Polymers are often used as the carriers in the solid dispersions based dosage forms manufactured using 
FDM 3D printing (368, 375). A limited number of pharmaceutical grade polymers can be directly printed 
using FDM and in most cases, additional excipients such as plasticizers or blending with other polymers are 
needed to achieve the thermoplasticity required for FDM printing (368, 376). Examples of such polymers 
include HPC (377), Eudragit EPO (378), PEO/PEG (47), PVA (379), PLA (380), and PCL (381).  In general, 
polymers used in pharmaceutical solid dispersions can be differentiated into hydrophobic and hydrophilic 
matrix formers. Examples of hydrophobic polymers include ethylcellulose (382), Eudragit (383), PLA (384), 
and PCL (268) while hydrophilic ones such as PEO (385), PEG (386), and PVA (387). Depending on the 
solubility of one polymer in the other, blends of polymers can be classified as miscible, semi-miscible and 
immiscible. Therefore, the resultant blend can be a single phase or a phase-separated system. This aspect is 
important in formulations as phase phenomenon governs the behaviour of the blend and their performance 
(such as physical stability and drug release pattern) when used as a drug delivery vehicle. 
 
In order to understand and subsequently predict the drug release behaviour of a polymeric based solid 
dispersion system, it is important to have a thorough understanding of the behaviour of the polymeric 
matrix in aqueous media in the first instance (388, 389). In this chapter, a systematic study of a group of 
commonly used pharmaceutical polymers for hot melt extrusion (HME) and FDM 3D printing was performed 
in order to parametrise the hydration, swelling and erosion behaviour of the polymers and polymer blends 
in aqueous environments. The kinetics of these three processes of each polymer in the aqueous media were 
measured. In addition, the behaviour of miscible and semi-miscible polymeric blends was studied. All 
experiments were carried out in pH 1.2 (gastric pH) and pH 6.8 PBS (intestine pH). These kinetics 
parameters along with other intrinsic characteristics of the polymer were used to form a dataset that was 
used by later chapters to categorise the polymers based on their behaviour in the aqueous media. 
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4.2 Materials and Methods 
The materials used in this chapter are HPMCAS LF, PCL CAPA 6800, PEO WSR N10 LEO, purified zein, 
Eudragit RS100, Xanthan Xantural 180, Soluplus, PVPVA Kollidion, Moweiflex PVA. The product details and 
their physicochemical properties are described in chapter 2. 
4.2.1 Preparation of Filaments 
Filaments were prepared using HME method. The standard procedure mentioned in section 1.1.2.1 and 
2.3.1 of preparing filaments was used. The feeding batch size was 7g in all cases. The extrusion 
temperatures for the polymers and their behaviors are listed in Figure 4-1. Xanthan gum extrudate was 
prepared by adding 10% MilliQ water and gently stirring the mixture for 10 to 15 mins. The addition of 
water is necessary to facilitate extrusion at a temperature of 70 oC. Zein extrudates were prepared by 
adding 10% MilliQ water to powdered zein and mixing in a ceramic mortar and pestle to facilitate HME with 
an extrusion temperature of 80 oC. The screw speed in all cases was 100 rpm. For the polymer blends, the 
default polymer mix ratio was 50/50% as per the weight of two polymers. The miscible blend was composed 
of HPMCAS/Soluplus while the semi-miscible blend was composed of HPMCAS/PEO. The filament extruded 
was cut into an equal length of 2cms.  
Table 4-1: Polymer extrudates at their temperatures with behaviors observed 
Polymer Extrusion temperature (oC) Polymer characteristics 
HPMCAS 160 Swell, hydrate, and erode in pH 6.8 
PCL 100 Insoluble/very low solubility 
PEO 120 Swell, hydrate, and erode in both pH 
Eudragit 160 Insoluble/ very low solubility 
Soluplus 110 Hydrate and erode in both pH 
PVPVA 160 Erode in both pH 
PVA 190 Hydrate and erode in both pH 
Xanthan gum 70 Swell, hydrate, and erode in both pH 
Zein 80 Hydrate and swell but non-eroding 
HPMCAS/Soluplus 
(miscible blend) 
150 Hydrate and erode in pH 6.8 
HPMCAS/PEO 
(Semi-miscible blend) 
150 Swell, hydrate, and erode in both pH 
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4.2.2 Measurement of Polymer behaviour 
Three polymer behaviours were studied in this chapter. They were hydration, erosion, and swelling in 
aqueous media which were parametrised. The parametrisation allowed comparison of the polymers in 
terms of the three behaviours. For polymer blends, these parametrised values of the individual polymer 
were used to emulate the behaviour of the blend, accounting for the 50% mass of individual polymers. 
During each sampling point, these three measurements were done.  
 
The hydration was measured by recording the wet weight of the polymer at the sampling time points by 
using an analytical balance. The increased wet weight measured compared to the initial dry weight which 
signifies the additional weight due to hydration (water intake) The normalised hydration is given by the left 
side of Equation 4-1. The right side of the equation is the Vangernaud model used for fitting to hydration 
curve (390). KH is the hydration constant. The hydration index (nH) is an indicator of the diffusion mechanism 
for the material. For cylindrical shapes, n<0.55 and corresponds to Fickian diffusion whereas 0.50<n<1.0 
indicates that diffusion is non-Fickian diffusion (391). 
                𝐻% =  
𝑤(𝑤𝑒𝑡)𝑡−𝑤(𝑑𝑟𝑦)0
𝑤(𝑑𝑟𝑦)0
 × 100 = 𝐾𝐻𝑡
𝑛𝐻  Equation 4-1 
where Wt is weight at time t, W0 is weight at time 0 min, KH is hydration constant, and nH is hydration index.  
The swelling was measured by using a digital caliper. The volume was measured at the sampling times. The 
radius (from the diameter) and length of the filament were used to calculate the volume of the cylindrical 
filament shown in Figure 4-1. Equation 4-2 shows the volume calculation of cylindrical geometry. The left 
side of Equation 4-3 shows the swell ratio calculation while the right side is an empirical equation, used for 
parametrising the swelling curve. All readings were done in triplicates. 
                     𝑉 = 𝜋 × 𝑟2 × 𝑙  where  𝑟2 =
𝑑
2
 Equation 4-2 
                   𝑆% =
𝑉𝑡−𝑉0
𝑉0
× 100 = 𝐾𝑆𝑡
𝑛𝑆  Equation 4-3 
 
where l is length, d is diameter, r is the radius, S% is the swell percentage, Vt is the volume at time t, V0 is the 




Figure 4-1: The filament cross-section in 3D perspective. Length is denoted by (l) while the diameter is denoted by (d) 
The erosion was calculated by measuring the dry weight change of the polymers at every sampling time and 
comparing to the initial weight. This procedure is as follows. First, an equal number of filament samples 
were made to the number of sampling times. For example, sampling times of 5 mins, 10 mins, 15 mins and 
30 mins would mean four sampling times. As such, four filament samples can be made. Next, all four 
filament samples are put in one dissolution vessel. Thereafter, at a sampling point, one of the samples 
would be taken and dried before the weight was measured. This sample would then not be put back in the 
vessel. This meant there are only three samples left in this with three more sampling times. Eventually, all 
samples were measured by the end of the dissolution sampling times and all the dry weights were referring 
to the weight of the samples after complete drying at each time point. This differential weight is calculated 
using the left side of the Equation 4-4. There are reports that polymer erosion has been fitted to linear 
regression models (zero order) as well as exponential decay (first order) (392, 393). Gaillard et al 
investigated polymer erosion and concluded that first order fitting provided higher accuracy (394). 
Therefore, the first order model was used for fitting. This is illustrated by the right side of Equation 4-4. 
These measurements were done for samples in pH 1.2 and pH 6.8 in triplicates. 
                        𝐸% =
𝑤(𝑑𝑟𝑦)𝑡−𝑤(𝑑𝑟𝑦)0
𝑤(𝑑𝑟𝑦)0
×  100 = 𝑊(𝑑𝑟𝑦)0𝑒
−𝐸𝐾𝑡 Equation 4-4 
where W(dry)t is the dry weight at sample time, W(dry)0 is the initial dry weight and EK is erosion constant. 
4.2.3 Characterization of polymer blends 
The pure polymers chosen were HPMCAS, PCL, PEO, Eudragit, Xanthan, Soluplus, PVA, PVPVA, and Zein. The 
blends were chosen to represent miscible and semi-miscible blends. HPMCAS/Soluplus was the miscible 
blend and HPMCAS/PEO was the semi-miscible blend. The miscibility of polymer blends was determined by 
the glass transition temperature (Tg) of the resulting mixture compared to the single polymers. The Tg was 
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gathered by using differential scanning calorimetry (DSC). The Tg of a miscible blend should exhibit a single 
Tg between the Tg’s of the component. The miscible blend in this work is HPMCAS/Soluplus. The Tg can be 
calculated by using the Flory-Fox equation, shown in equation 4-5 (125). A semi-miscible blend will show 
two separate Tg between the range of the individual components (122). The semi-miscible blend in this 
work is HPMCAS/PEO. Both miscible and semi-miscible polymer blends had a 50/50 weight ratio of the 
individual polymers. For semi-crystalline PEO, the recrystallization enthalpy was used to estimate the 









 Equation 4-5 
 
4.3 Results and Discussion 
4.3.1 Overview of polymer behaviour in aqueous media 
The summary of the kinetics of the behaviour of the polymers is given in Figure 4-2 for pH 1.2 and in Figure 
4-3 for pH 6.8 excluding the insoluble polymers that do not any physical changes in the media. It is observed 
that for all polymers plotted, there is a simultaneous activity of the three aspects except for zein which does 
not exhibit any erosion. Since the polymers, excluding zein and insoluble polymers, are eroding and 
hydrating simultaneously, it is not possible to identify the effect of hydration alone. However, it is possible 
to distinguish the mechanism of transport from the shape of the curve and the effect of erosion individually. 
Since some polymers swell and some erode without swelling from the beginning of the experiment, it is 
possible to categorize them as swellable or erodible polymers. The swellable polymers consist of PEO, 
Xanthan gum, zein, and soluplus for pH 1.2 and pH 6.8. Meanwhile, the erodible polymers consist of PVPVA, 
PVA in pH 1.2 and HPMCAS, PVPVA, and PVA in pH 6.8. PCL (not shown in Figure 4-2) is also an eroding 
polymer in both pH but the progression of erosion is longer than the experiment duration. PCL erosion time 
has been reported to be two to four years (395). Such polymers that erode without swelling have a negative 
ratio in terms of volume on the plots as the volume decreases compared to initial volume. As an example, 






Figure 4-2: Mass and volume changes with the time of polymers in pH 1.2. The polymers that do not show any changes are omitted (PCL, Eudragit, and HPMCAS). The axis for all graphs has been 
replaced with a generic (X-Xo)/Xo. For hydration, the generic (X-Xo)/Xo is (Mt-Mo)/Mo where the M has been stated in equation 4-1. For volume, the generic (X-Xo)/Xo is (Vt-Vo)/Vo where the V 
parameters have been stated equation 4-3. For erosion, the generic (X-Xo)/Xo is (Mt-Mo)/Mo where the M has been stated in equation 4-4. Erosion is plotted in reverse from a ratio of 1 eroding 



































































































































Figure 4-3: Mass and volume with time of polymers in pH 6.8. The polymers that do not show any changes are omitted 
(PCL and Eudragit). The axis for all graphs have been replaced with a generic (X-Xo)/Xo. For hydration, the generic (X-
Xo)/Xo is (Mt-Mo)/Mo where the M have been stated in equation 4-1. For volume, the generic (X-Xo)/Xo is (Vt-Vo)/Vo 
where the V parameters have been stated  equation 4-3. For erosion, the generic (X-Xo)/Xo is (Mt-Mo)/Mo where the M 




















































































































































4.3.2 Hydration behaviour  
The first parameter measured was the differential wet weight signifying the hydration. The hydration ratio 
for all the polymers in pH 1.2 and pH 6.8 is presented in Figure 4-4. At both pH, there are two groups of 
polymers. The first group are hydratable polymers which exhibit net positive hydration. Net positive 
hydration is when there is an increase in the wet mass during the experiment. All hydratable polymers have 
been plotted up to the maximum hydration timepoint. After this point, erosion is more dominant in polymer 
behaviour. The second group are non-hydratable or minimally hydratable polymers. Polymers that maintain 
95% of the initial mass for the duration of the experiment are considered in the second group of non-
hydratable polymers. The first group of polymers include Xanthan gum, PEO, zein, and PVA (only pH 1.2). 
Two of the four polymers are superabsorbent polymers (SAPs). SAPs have three factors contributing to 
water absorption. They are the density of cross-linking, the affinity between polymer and solvent, osmotic 
pressure caused by polyelectrolyte counter ions. Xanthan gum, a hydrophilic polymer, has a high affinity to 
water (396). It is also stable over ranges of pH 1 to pH 11 (283). This indicates the properties it shares for 
water as super absorbent are also unchanged over the range of pH wherein it is stable. As such, it expands 
in water and other solvents. This generates a wider surface area upon which the polymeric chain molecules 
can interact with the solvent attracting more solvent molecules in close proximity. Furthermore, the 
conformation of xanthan gum is responsible for the stability which is due to the presence of salt. The cation 
(Na+, K+, or Ca2+) promote the intermolecular cross-linking strengthening the gel network (397, 398).  
 
PEO, a hydrophilic polymer, is a linear polymer but upon contact with water, rapidly hydrates due to its high 
solubility and forms a hydrogel which is seen in both pH. When PEO come into contact with water, forces of 
attraction (chiefly hydrogen bonding) start acting between polymer and water. Due to the high water-
affinity of the polymer, these forces are likely to be preferred over polymer-polymer interactions (190). The 
structure of PEO (-O-CH2 -CH2-) n OH is likely to hydrogen bond. It has also been reported that such gels have 
high osmotic activity (193). This, for a hydrophilic polymer, causes the crosslinked network to expand 
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outward as polymeric material tends to flow outward due to the high affinity for the solvent and solvent to 
penetrate to balance the pressure leading to greater hydration which is a property of SAPs. 
 
PVA is a water-soluble synthetic polymer but the physicochemical and mechanical attributes of PVA are 
dictated by the number of hydroxyl groups. PVA comes in varying hydrolysis percentages. With higher 
hydrolysis, there is an abundance of vinyl alcohol units, which are distributed within PVA, disrupting the 
crystalline phase of the PVA. This makes the polymer very hydrophilic and water-soluble with a high 
capacity for hydrogen bonding (399). In this case, with the 98-99% hydrolysis (261), the PVA chains disperse 
in a short time and tend to form hydrogen bonds with the solvent.  
 
For zein, it was reported that the hydration can be contributed to the charge. Bouman et al mention 
osmotic pressure is increased at pH 1.2 as there are more counter ions present due to positively charged 
zein coming from the predominant α helix zein with an isoelectric point of pI 6.8 (14). In addition, the 
expansion of the network structure was stated likely due to the de-amidation of the glutamine and 
asparagine amino acids of the zein (14). Although swelling was the result of this, for the volume to expand, 





Figure 4-4: Top) The hydration ratio all the nine polymers in pH 1.2. Bottom) The hydration ratio all the nine polymers in pH 6.8. The 
timescale for non-hydratable polymers have been shortened. 
The second group of polymers in Figure 4-4 include Eudragit, PCL, PVPVA, and HPMCAS which are non-
hydratable polymers or exhibit minimal hydration. Eudragit RS100 is a copolymer of ethyl acrylate, methyl 
methacrylate and low content of methacrylic acid ester with quaternary ammonium side groups. The 
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Eudragit RS consists of groups of R1:H, CH3, R2: CH3, C2H3, R3: CH3, R4: CH2CH2N(CH3)+ Cl- (277, 278) of which 
non-polar CH3 in major proportion are hydrophobic and impart low solubility even though Cl- is hydrophilic 
(400). The hydration observed for PCL can be due to the fact it is a hydrophobic semi-crystalline polymer. 
The degree of crystallinity hinders diffusion of solvent molecules. It is also noted that with the increase of 
molecular weight, the crystallinity decreases. HPMCAS lack of hydration could be due to the unionised state 
in the buffer. HPMCAS has four types of substituents on the hydroxyls. The first is methoxy with a mass 
content of 12−28%, second is hydroxypropyl with a mass content of 4−23%, third is acetate with a mass 
content of 2−16%, and fourth is succinate, with a mass content of 4−28% (225). This succinate group has a 
pKa of 5. This means HPMCAS is 10% ionised at most at pH ranges less than pH 4 and at least 50% ionised at 
pH values of about 5 and higher. Therefore, HPMCAS is insoluble and not significantly ionised at pH 1.2 with 
the presence of hydrophobic methoxy and acetate substituents. At pH 6.8, there is more solubility due to 
the higher ionisation, making HPMCAS a pH responsive polymer. 
 
Table 4-2 shows the fitting to Vangernaud model which is a semi-empirical model similar to the Korsmeyer-
Peppas model. For Xanthan gum and PEO, the hydration constant is higher than all the other polymers in 
both pH indicating a higher rate of solvent ingress. The explanation for this can be gathered from the 
hydration index. The hydration index indicates the mechanism of transport is Fickian diffusion, which is 
commonly referred to as Fickian or case I diffusion in literature. According to Singh, the shape of the 
hydration curve can yield about the mechanism of transport (401). However, an issue exists that the shape 
of the curve is not an unambiguous criterion for distinguishing Fickian II from Fickian I transport. In such 
cases, it is important to know whether the boundary moves. If the boundary moves (i.e. volume changes) 
and the gel remains rubbery throughout swelling or collapse after, the transport is called Fickian I. Since the 
boundary moves for zein, PEO, and Xanthan gum, they exhibit Fickian I transport. Additionally, the 
molecular relaxation may be either much faster than diffusion (T>Tg) or extremely slow (T<Tg) (401). The Tg 
of PEO (-57 oC) and Xanthan gum (-23 oC) are both below the dissolution temperature of 37oC which 
indicates faster molecular relaxation compared to diffusion. Hence the higher solvent ingress and the higher 
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hydration ratio. The Tg of zein (150 oC) is higher than dissolution temperature indicating very slow 
molecular relaxation. Hence the lower solvent penetration and the lower hydration ratio. 
Table 4-2: Vangernaud model fitted to hydratable polymers. 
pH 1.2 6.8 
Polymer kH nH R2 kH nH R2 
PVA 0.04 ± 0.01 0.61 ± 0.03 0.99 - - - 
Xanthan gum 1.31 ± 0.70 0.52 ± 0.01 0.98 2.51 ± 0.83 0.27 ± 0.04 0.99 
PEO 0.73 ± 0.12 0.18 ± 0.02 0.99 0.66 ± 0.12 0.23 ± 0.05 0.99 
Zein 0.03 ± 0.01 0.37 ± 0.09 0.95 0.02 ± 0.01 0.37 ± 0.02 0.97 
 
4.3.3 Swelling behaviour 
The anatomy of a swelling tablet is shown in the top left of Figure 4-5. The swelling front is the boundary 
between the glassy region (circle A) and the rubbery gel region (circle B) of the polymer marked as rA (179). 
The diffusion front indicates the boundary between the undissolved and dissolved polymer in the gel layer 
marked as rB. The erosion front is the most outer fringe of the tablet or polymer extrudate identifying the 
boundary between the matrix (circle C) and the dissolution medium marked as rC. This was observed for 
some polymers such as PEO while not observed for others such as Xanthan gum (shown at the bottom of 
Figure 4-5). In both cases, the erosion front was the limit of measurement for matrix edge. 
 
Figure 4-5: a) Schematic representation of diffusion, erosion and swelling fronts and different layers of swelling dosage (179). (b) PEO 
exhibiting swelling front and erosion front. (c) Xanthan gum without a clear swelling front. 
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The swelling ratios of the polymers are shown in Figure 4-6. It can be seen that the two highest swelling 
polymers are SAP. Zein also does swell but a lower ratio. There are distinctly two groups of polymers where 
swelling is observed and where swelling does not occur. The non-swelling polymers (PCL, HPMCAS, Eudragit, 
PVPVA, Soluplus and PVA) have a combination of insoluble and soluble polymers. For insoluble polymers, 
there is no hydration and hence no causation for swelling. For soluble polymers, if the hydration ratio of the 
solvent was faster then the molecular relaxation rate of the polymer, swelling was observed. Conversely, 
swelling was not observed if diffusion was slower than molecular relaxation.  
 
Furthermore, it is seen that the swelling ratios are not proportional to the hydration ratios for the same 
swellable polymer. In pH 1.2, Xanthan gum had a maximum hydrated ratio of ≈10X while the swelling ratio 
was ≈20X. PEO in pH 1.2 had a maximum hydrated ratio of ≈1.8X and swell ratio of ≈3.6X. The similar case 
for both polymers in pH 6.8. This behaviour is not seen with zein. In pH 1.2, zein at 30 minutes exhibited a 
hydrated ratio of 0.12X (12%) and a swollen ratio of 1.11X (11%); at 300 minutes (5 hours) exhibited a 
hydrated ratio of 1.36X (36%) and a swollen ratio of 1.34X (34%); at 1440 minutes (24 hours) exhibited a 





Figure 4-6: The swelling ratios of swellable polymers in pH 1.2 on top and pH 6.8 at the bottom. 
Using equation 4-3, the swelling constant and swelling index is shown in Table 4-3. The high KS values of 
PEO, Xanthan gum, and soluplus compared to zein indicate burst swelling kinetics. Zein shows no burst 
swelling consistent with the much lower value of 0.04. Higher KS gives a steeper gradient which gives faster 
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Table 4-3: The swollen polymers fitted to the generalized model and their goodness of fit (R2). Ks is the swelling constant and n is the 
swelling index. 
 pH 1.2 pH 6.8 
Polymer Ks ns R2 Ks ns R2 
Xanthan gum 1.54 ± 0.13 0.74 ± 0.03 0.99 1.15 ± 0.27 0.68 ± 0.08 0.99 
PEO 0.46 ± 0.11 0.42 ± 0.10 0.99 0.43 ± 0.18 0.49 ± 0.07 0.99 
Zein 0.04 ± 0.01 0.37 ± 0.08 0.98 0.09 ± 0.01 0.18 ± 0.03 0.95 
Soluplus 0.51 ± 0.08 0.05 ± 0.01 0.98 0.31 ± 0.01 0.05 ± 0.01 0.91 
 
4.3.4 Erosion behaviour 
The erosion ratios of erodible polymers are presented below in Figure 4-7. It can be seen that other than 
PVPVA, the SAP have high erosion rates. However, very high erosion rates of PVPVA might be contributed to 
the unit composition of PVPVA. The unit composition is 6:4 of PVP:VA in PVPVA chain with the aim was of 
increased solubility (192). Without swelling, erosion is the only dominant process for PVPVA, which occurs 
rapidly. Furthermore, it can be argued that the zero order model might be a better fit for PVPVA. From 
chapter 1, zero order polymer mass loss is expected for surface erosion polymers.  
 
 The erosion rate found from equation 4-4 is presented in Table 4-4 suggests that the first order model is in 
good agreement with the data denoted by R2. Ranking the erosion ratios show a similar trend for both pH 
medium (PVPVA < Xanthan gum < PEO < Soluplus < PVA). The exception is with pH 6.8, where HPMCAS 
erodes and the descending erosion ratios are PVPVA < Xanthan gum < PEO < HPMCAS < Soluplus < PVA. 
Table 4-4: The erosion rates of erodible polymers in both pH fitted to exponential decay. 
Polymer 
pH 1.2 pH 6.8 
EK  R2 EK  R2 
PVPVA 19.15±0.10 0.99 17.34±0.12 0.97 
Xanthan Gum 2.77±0.03 0.99 3.07±0.09 0.94 
PEO 1.91±0.02 0.99 1.90±0.03 0.99 
PVA 0.66±0.02 0.98 0.83±0.02 0.98 
Soluplus 1.21±0.04 0.95 1.30±0.10 0.91 
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4.3.5 Characterization of blends 
The DSC thermogram of the miscible HPMCAS-Soluplus is shown in Figure 4-8. A single Tg is observed for the 
HPMCAS-Soluplus between the pure HPMCAS and pure soluplus at 95.81 oC, which agrees with a Tg of 96.75 
oC obtained from the Flory-Fox equation (equation 4-5) for a 50/50 blend, indicating a miscible blend (125). 
 
Figure 4-8: DSC thermogram of the HPMCAS (red), Soluplus (black), and HPMCAS-Soluplus 50/50 blend (blue). The Tg is shown on the 
thermogram, and with the corresponding polymer colours. 
In the case of HPMCAS-PEO, the PEO Tg has been reported to be -62 oC to -67 oC (402-405). This well-
established value of -62 oC will be taken as the Tg of PEO. Rather, the recrystallization and melting 
enthalpies are taken into account. The thermogram is shown in Figure 4-9. It can be seen that for pure PEO, 
the recrystallization enthalpy is 189.4 J/g. After accounting for the quantity of PEO in the blend, the 
enthalpy calculated is 88.83 J/g. The recrystallization enthalpy of the blend is 38.53 J/g which is about 2.3 





Figure 4-9: DSC of HPMCAS (green dash), PEO (red line), and HPMCAS-PEO 50/50 blend (black line). The melting and recrystallization 
temperatures and the corresponding enthalpies are given (J/g) while the Tg for HPMCAS is given. 
4.3.6 Miscible and semi-miscible blend behaviour 
The hydration ratios of the miscible blend are shown in the top left of Figure 4-10. In pH 6.8, there is not 
positive hydration but rather, negative hydration (erosion) and as such, has been omitted. The blend 
appears to exhibit characteristics of both polymers. While HPMCAS is insoluble at pH 1.2 and soluplus 
hydrates to a maximum of 1.31X (31%) at 60 minutes, the blend hydrates to the same ratio of soluplus but 
at a delayed time of 420 minutes (7 hours). The duration of hydration is 7 folds slower compared to 
soluplus. It can be seen that if one is an insoluble polymer and the other is hydratable, the net effect is 
slower hydration. The hydration ratio of the semi-miscible blend has been shown in the top right of Figure 
4-10. In the case of the semi-miscible blend, the hydration time is faster than the pure PEO but a point to 
note is that that behaviour kinetics of the blends are different than the constituents when compared to 
miscible blend. For the fully miscible blend, the hydration profile is in between the two polymer profiles 
while for the semi-miscible blend, the hydration profile is outside the region of the two constituting polymer 
profiles. One reason for this could be due to the fact this is not a single phase system. Since the HPMCAS is 
10% ionised at this pH, this can increase the osmotic activity in the matrix thereby increasing the affinity of 
the solvent. The hydration parameters are presented in Table 4-5. Work done Mudassir et al on hydrogels 
shows that the mechanism changes with pH and polymer blend composition degree (406). The penetrant 
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transport from the matrix system is governed by diffusion, so determining the diffusion coefficient of the 
hydrogel is essential.  
 
The swelling ratio shown in the bottom left of Figure 4-10 shows the miscible blend swelling does occur at 
pH 1.2. The swelling profile of the miscible blend is also between the constituting polymers as opposed to 
the semi-miscible blend. The swelling constants for the miscible blend (Table 4-6) indicate that at pH 1.2, 
there is a significant decrease in the swelling ratio due to the addition of HPMCAS. The swelling mechanism 
is still hydration dominated but shows this faded about two-folds, explainable by the insoluble HPMCAS 
slowing hydration; not necessarily increasing diffusion. At pH 6.8, as soluplus swelling constant is lower with 
HPMCAS eroding, no swelling is observed compared to pH 1.2. In contrast, the semi-miscible blend swelling 
constant showed a smaller decrease from KS 0.46 to 0.31 at pH 1.2 due to retaining of more individual blend 
properties and some conversion of PEO to amorphous form. The value of index change is greater for the 
HPMCAS/PEO is 1.5X greater than PEO. This can account of some portion of two-fold slowdown by the 
addition of HPMCAS. However, the increased rate in hydration is due to some of the PEO becoming 
amorphous which is in agreement with roughly the amount of amorphous PEO. The erosion ratios for the 
miscible are shown in Figure 4-11. The erosion ratios exhibit first order mass loss in the cases of all blends in 
all medium. As before, the erosion ratios for the miscible blend is between the two constituent polymers. 
This is expected as both polymers aggregately contribute to faster erosion than either of the one polymer. 
An exception emerges for the semi-miscible blend eroding in pH 1.2. HPMCAS/PEO erosion is between the 
two constituent polymers while it was expected to be outside of the region of two polymers erosion profile. 
This can be intuitive as PEO is soluble while HPMCAS is not. It is expected that HPMCAS will slow down the 
erosion causing the profile to be between the two constituting polymers. This is due to the insoluble 
HPMCAS polymer slowing down erosion. However even in the blend, only the PEO composition erodes and 




Figure 4-10: Top left) Hydration ratios of HPMCAS/Soluplus compared to pure polymers in pH 1.2. Top right) Hydration ratios of HPMCAS/PEO and pure polymer in pH 1.2. Bottom left) Swelling 
ratios of HPMCAS/Soluplus and pure polymer in pH 1.2. Bottom right) Swelling ratios of HPMCAS/PEO and pure polymer in pH 1.2. pH 6.8 exhibits negative hydration (erosion) for the blends and 
have been omitted here. The grey last data point for some polymers indicates the beginning of erosion. HPMCAS, being insoluble has data over longer duration but this has been omitted as it is 























Hydration Ratio of HPMCAS/Soluplus in pH 1.2





















Hydration Ratio of HPMCAS/PEO in pH 1.2
























Swelling Ratio of HPMCAS/Soluplus in pH 1.2






















Swelling Ratio of HPMCAS/PEO in pH 1.2





Table 4-5: Hydration parameters fitted to the Vangernaud model in pH 1.2. (*) indicates the error here is omitted as it is too small. 
Polymer blend KH nH R2 
HPMCAS/Soluplus 50/50 0.01* 0.55 ± 0.07 0.99 
HPMCAS/PEO 50/50 0.39 ± 0.09 0.48 ± 0.04 0.98 
 
 
Table 4-6: swelling constant (Sk) and swelling mechanism for the blends in both pH. Cases of no swelling are denoted by -. 
 pH 1.2 pH 6.8 
Polymer KS nS R2 KS nS R2 
HPMCAS - - - - - - 
PEO 0.46 ± 0.11 0.42 ± 0.10 0.996 0.43 ± 0.18 0.49 ± 0.07 0.999 
Soluplus 0.51 ± 0.08 0.05 ± 0.01 0.983 0.31 ± 0.01 0.05 ± 0.01 0.812 
HPMCAS/Soluplus 0.09 ± 0.02 0.12 ± 0.03 0.947 - - - 
HPMCAS/PEO 0.31 ± 0.16 0.61 ± 0.08 0.956 - - - 
 
 
Table 4-7: The erosion constant of the polymers and blends in both pH and the goodness of fit 
Polymer EK  R2 
 pH 1.2 pH 6.8 pH 1.2 pH 6.8 
HPMCAS - 1.56 ± 0.34 0.97 0.99 
PEO 1.91 ± 0.92 1.90 ± 0.23 0.99 0.99 
Soluplus 1.21 ± 0.04 1.30 ± 0.10 0.95 0.91 
HPMCAS/Soluplus 0.44 ± 0.08 3.51 ± 1.91 0.95 0.99 


























Miscible blend erosion ratio
HPMCAS pH 1.2 Soluplus pH 1.2 HPMCAS:Soluplus 50%-50% Ph 1.2





















Semi-miscible blend erosion ratio
HPMCAS pH 1.2 PEO pH 1.2 HPMCAS/PEO 50/50 pH 1.2
HPMCAS pH 6.8 PEO pH 6.8 HPMCAS/PEO 50/50 pH 6.8
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4.3.7 Towards predicting polymer blend behaviour in aqueous media 
One initial approach is to inspect if the prediction of polymer blend as an ideal solution yields accurate 
prediction. Prediction refers to applying the information deduced about the polymer to another blend in a 
pre-tested stage. Since the blends are 50/50% weight, the predicting profile would result from summing 
50% of the weight data at each time point. The resultant for hydration and swelling of HPMCAS/Soluplus is 
presented in Figure 4-12. It can be seen that hydration and swelling ratios in pH 1.2 has been overpredicted 
by the calculated profile. This is due to the fact pure soluplus hydrates and swells more than the blend. The 
effect of an insoluble blend has affected this behaviour by more than half for the 50% of the blend. It is 
interesting to note that curve fitting of the calculated profile yielded the transport mechanism to be 
borderline Fickian and anomalous with a nH of 0.55±0.03 while experimental data curve fitting yielded nH of 
0.55±0.07, indicating the transport mechanism was not mis-deduced. The calculated profile is based on a 
prediction case while the experimental curve fitting is based on the actual data. Meanwhile, the hydration 
constant was lower for the experimental data. In pH 6.8, the model was able to better predict the blend 
behaviour kinetics but still produced inaccurate results. In the case of semi-miscible HPMCAS/PEO blend 
(Figure 4-13), both ratios were underpredicted by the calculated profile. This is because of pure PEO, which 
hydrates and swells less than the blend. Moreover, the prediction was erroneous. The fitting of calculated 
profile yielded anomalous transport mechanism (nH=0.70±0.07) which is significantly different from the 
experimental profile which yielded Fickian transport (nH=0.48±0.04). In pH 6.8, the calculated profile over 
predicted the blend behaviour for hydration and swelling. This is because pure PEO hydrates while pure 
HPMCAS erodes slowly. Comparing identical sampling times, the hydration ratio of PEO is higher than the 
negative hydration ratio (effectively erosion ratio) of HPMCAS. For example, a sampling time point of 15 
minutes at pH 1.2, the PEO hydration ratio is 1.26 times while the HPMCAS hydration ratio is 0.86 times 
(Figure 4-4). The difference in PEO is 26% increase while the difference in HPMCAS is 14% decrease. The 
faster ratio increase due to PEO causes the cumulative ratio of calculated blend hydration ratio to be higher 























































































































































































Comparing the erosion ratios of both blends in pH 1.2 yields similarly inaccurate blend profile prediction as 
shown in Figure 4-14. The insolubility of HPMCAS in pH 1.2 slows erosion of the blend causing lower than 
observed values. However, the prediction was more accurate for pH 6.8 but still significantly different for 
many of the sampled time points. A trend seems to emerge when investigating the constituting polymers 
and their respective blends. The ideal polymer mixture seems to hold in certain circumstances. If the 
polymers both exhibit the same properties (i.e.: both swell or both erode), then the ideal polymer mixture 
scenario appears to be able to predict with better accuracy compared to when the properties of the 
polymers differ, shown in Table 4-8. When they differ, the application of ideal polymer mixture calculation is 
most likely to be invalid. For example, in pH 1.2, HPMCAS does not erode () while PEO erodes (✓) causing 
the resultant blend calculation to be invalid (). The calculations hold valid in pH 6.8; when HPMCAS erodes 
(✓) as well as PEO (✓) erode resulting in the blend to be accurately predicted (✓). Ideal solutions form from 
the random mixing of molecules with the same size and shape wherein the intermolecular forces between 
pairs of like segments and unlike segments are all equivalent (407). The molar volume of HPMCAS is 14,008 
cm3/mol (229, 408) while PEO is 3,571,429 cm3/mol (409), and soluplus is 109,225 cm3/mol (409). Since the 
molecule sizes are not the same, the agreement to ideal solution laws is surprising. 
Table 4-8: Blend and polymer kinetics. The () indicates no while the (✓) indicates yes for the category of the row. 
pH 1.2 Soluplus HPMCAS PEO HPMCAS/Soluplus HPMCAS/PEO 
Hydration (positive ratio) ✓  ✓   
Swell ✓  ✓   
Erosion (negative ratio) ✓  ✓   
pH 6.8 Soluplus HPMCAS PEO HPMCAS/Soluplus HPMCAS/PEO 
Hydration (positive ratio) ✓  ✓   
Swell ✓  ✓   




































































































For more accurate prediction than the ideal polymer mixture, other approaches can be applied. The critical 
aspect of blends is the miscibility of the constituents leading to the stability of the system. The stability 
of polymer mixtures can be predicted from knowledge of the solubility parameters and hydrogen-bonding 
tendencies of the components. However, these predictions are not always very accurate as the model is 
oversimplified. More sophisticated solution theories do not perform any better prediction (410). They 
contain parameters that can only be determined by analysis of particular mixtures, and it is not possible to 
characterize individual components a priori. Numerous attempts have been made to improve the predictive 
ability of the solubility parameter method. These generally proceed on the recognition that intermolecular 
forces can involve dispersion, dipole-dipole, dipole-induced dipole, or acid-base interactions. The most 
promising has been proposed by Hansen and often known as the Hansen solubility parameters which relies 
on contributions due to dispersion forces, polar forces, and hydrogen-bonding (410). 
 
Other approaches have dealt with determining the miscibility of polymer blends wherein the analysis is 
depended on the Random Phase Approximation (RPA) theory and the classical Flory–Huggins (F-H) theory 
(411). In the framework of the F-H theory, the interaction parameter (χ) is dependent on temperature, 
pressure, composition. The polymer kinetics will differ with different composition. The χ can give the energy 
difference of the molecules of the polymer and the solvent (412). The smaller the value of χ, the greater the 
rate at which the free energy of the solution decreases with the addition of solvent. Consequently, liquids 
with the smallest χ’s are usually the best solvents for a polymer. Negative values of χ often indicate strong 
polar attractions between polymer and solvent, thus increasing miscibility (413).  
4.3.8 Categorization summary 
In this section, a table was constructed enlisting the parameters measured for the polymer and blends. The 
table has been split into three tables. The first, Table 4-9 represents the solubility and swellability of the 
polymers. The second, Table 4-10, represents the time points at which the maximum hydration ratios (t 
Hmax) and maximum hydration ratios (t Smax) were attained. The third , Table 4-11, shows the hydration, 




Table 4-9: Polymer swelling and solubility in pH 1.2 and pH 6.8 given by yes (Y) or no (N). 
Polymer Soluble (Y/N) Swell (Y/N) 
 
pH 1.2 pH 6.8 pH 1.2 pH 6.8 
HPMCAS N N N N 
PEO Y Y Y Y 
Zein N Y Y Y 
Xanthan Gum Y Y Y Y 
PCL Y N N N 
Eudragit N N N N 
PVPVA Y N N N 
PVA Y N N N 
Soluplus Y Y Y Y 
HPMCAS/PEO (50/50) Y Y Y N 
HPMCAS/Soluplus (50/50) Y Y Y N 
 
Table 4-10: The peak hydration and swelling times of the polymer and blend in pH 1.2 and pH 6.8. 
Polymer t Hmax t Smax 
 
pH 1.2 pH 6.8 pH 1.2 pH 6.8 
HPMCAS - - - - 
PEO 60 60 60 60 
Zein 2880 2880 2880 2880 
Xanthan Gum 30 30 30 30 
PCL - - - - 
Eudragit - - - - 
PVPVA - - - - 
PVA 10 10 - - 
Soluplus 30 30 30 30 
HPMCAS/PEO (50/50) 45 - 45 - 







Table 4-11: Polymer kinetics dataset of hydration, swelling, and erosion in pH 1.2 and pH 6.8 
Polymer Hydration constant Transport mechanism Swell constant Swelling Index Erosion constant 
 pH 1.2 pH 6.8 pH 1.2 pH 6.8 pH 1.2 pH 6.8 pH 1.2 pH 6.8 pH 1.2 pH 6.8 






























































PCL - - - - - - - - - - 
Eudragit - - - - - - - - - - 
PVPVA - - - - 
19.15 




























































4.4 Limitations of the study 
In this chapter, only a fixed polymer ratio was investigated. Earlier studies confirm that polymer behaviour 
kinetics differ with differing polymer blend ratios. Since a generic set of rules could not be gathered by 
adding the individual constituting polymer behaviours, except where the polymer behaviour kinetics are 
identical, a database would need to include a certain number of ratios that may be used widely (thus saving 
from investigating every varying degree of composition) such as HPMCAS/soluplus 10/90, 20/80, 30/70, 
70/30, 50/50, 25,75, 75/25, 10/90, and other polymer combinations.  
 
Further, molecular level interactions are not investigated in this work but proposed such as the Hansen 
solubility parameter and Flory Huggins theory. Based on these theories, more differences observed among 
the blends may be more accurately described such as the hydrated or swelling ratios observed which differ 
from the calculated profile of the blends. It may also describe the inter-pH differences observed between 
pure polymers such as hydration ratio of 9 times for Xanthan gum in pH 1.2 vs a ratio of 6.5 times in pH 6.8.  
4.5 Conclusion 
In this chapter, the factors affecting the kinetics of the polymer behaviour were studied by investigating the 
hydration, swelling and erosion ratios in the two buffers of pH 1.2 and pH 6.8. The use of Vangernaud model 
was used to fit the hydration ratios while a power law empirical model was used for fitting the swelling 
ratios. Both were chosen over simple fits as they encompass the initial to plateau better shown by R2 values. 
The erosion ratios exhibited inverse first order and were fitted to first order decaying models.  
 
In addition, an identical approach was used for the blend. The blends in some cases exhibited complex 
multiphase profiles which were time dependant of the composite’s polymer properties such as maximum 
hydration time and/or maximum swell. At these maximum points, the dominant mechanism would change 
for the blend. The application of ideal polymer mixtures accounting for 50% weight of the constituting 
polymer to create the blend profiles yielded only reasonably good agreement when both effects were 
common in the constituting polymers such as both eroding. This has rendered the deduction of a generic 
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equation unattainable for blends which do not exhibit commonly shared behaviour in the media such as one 
constituent being a swelling polymer and the other a non-swelling polymer or likewise one hydrating 
polymer and the other a non-hydrating polymer. 
 
Lastly, a dataset, with the gathered data of polymers, was constructed to help in modelling the behaviour of 
the drug loaded formulation using the polymer/blend bringing one step closer to being able to achieve a 





Chapter 5: Categorizing the effect of drug types on 
polymer behaviour 
5.1 Introduction 
In the previous chapter, the factors affecting the kinetics of the behaviour of pharmaceutical polymers 
(hydration, swelling and erosion) used in 3D printing were investigated. The cornerstone of polymer choice 
in oral dosages is to attain drug release in a desired pattern in order to achieve the optimal absorption and 
therapeutic outcome (414, 415). There have been several drugs reported being made solid dispersions using 
FDM 3D printing such as acetaminophen (49), indomethacin (368), warfarin (378), carvedilol (375), 
theophylline (47), puerarin (416), gentamicin sulfate (25), felodipine (52), haloperidol (417), ciprofloxacin 
hydrochloride (418), domperidone (377), prednisolone (419), dipyridamole (53). As reported widely in the 
solid dispersions research, the physicochemical properties of the drug and the polymer-drug interactions 
can have profound impacts on the properties of the formed solid dispersions (420, 421). Therefore, it is 
important to investigate systematically how different types of drugs can interact with polymers to influence 
the polymer behaviour and drug release. 
 
In this chapter, the drug release behaviour of the solid dispersions formed by three model polymers and 
three model drugs were carried out. The model drugs were chosen to present positively charged, negatively 
charged or neutral in pH 1.2 or 6.8. The data generated were used to build a dataset that was later used in 
building the classification approach to facilitate the choosing the appropriate polymer or combination of 
polymers for a given drug. 
5.2 Materials and methods 
The polymers used in this chapter were purified zein, Hypromellose acetate succinate (HPMCAS) AS-LF, and 
Poly-(Ethylene Oxide) (PEO) WSR N10 LEO and their physicochemical properties are described in section 
2.2.4 to 2.2.6 of chapter 2. The three drugs used were lidocaine, ibuprofen, and paracetamol and their 
physicochemical properties are described in section 2.2.1 to 2.2.3 of chapter 2.  
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5.2.1 Preparation of filaments 
The procedure mentioned in section 4.2.1 of preparing filament using HME technique was used. However, 
in this case, the addition of drug loadings of 10% and 30% by weight in two different batches were 
prepared. The extruded filament was then cut into 2cm pieces for in vitro studies.   
5.2.2 Measurement of factors 
The measured factors of the formulation were hydration, swelling, and erosion in pH 1.2 and pH 6.8. The 
methods of measurement were as per the outlined procedure of hydration, swelling, and erosion in section 
4.2.2 of chapter 4. An additional procedure was to measure the drug release of the formulations. The drug 
release was measured by UV spectroscopy at wavelengths of 220nm, 264nm, and 243nm for lidocaine, 
ibuprofen, and paracetamol respectively using the procedures described in section 2.4.4 of chapter 2. 
5.2.3 Choice of polymers and drugs 
The choice of polymers here was to investigate the difference between a polysaccharide (HPMCAS), a 
protein (zein) and superabsorbent polymer (PEO), in the presence of a positively charged, a negatively 
charged, and a neutral drug. Most molecules contain some specific functional groups likely to lose or gain 
proton(s) under specific circumstances. Each equilibrium between the protonated and deprotonated forms 
of the molecule can be described with a constant value called Ka. The log of this value is known as pKa The 
charge of the drug can be deduced from the species distribution diagram of the drug in the buffer (422). The 
species distribution diagram was calculated using Marvinsketch software (423). The pKa plugin calculates 
the pKa values of the molecule based on its partial charged species distribution. The reported pKa values for 
lidocaine, ibuprofen, and paracetamol is 7.8, 4.5, and 9.5 respectively (207, 210, 424). The percentages of 
charged species are shown in Table 5-1. The charged form (column 2) indicates the charge that is possessed 
by the percentage fraction in pH 1.2 (column 4) and pH 6.8 (column 6). For example, in pH 6.8, lidocaine is 
90.01% positively charged while ibuprofen is 98.89% negatively charged. It is hypothesized that lidocaine, 
which is ionic in both pH, is soluble and has a higher osmolarity than neutral drug and will cause higher 
hydration, swelling, and erosion in the formulation compared to placebo. Two sets of drug loading with 
each polymer were chosen for the studies: 10% and 30% drug loading. It is hypothesized that higher ionic 
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drug loading should cause higher and faster hydration, swelling, and erosion due to the fact higher quantity 
should amplify the osmolarity compared to the 10% drug loaded formulations. 
Table 5-1: The % of charged species of the drugs in the buffers. The charged form of the drug in the buffer is given by column 3. 
 pKa Charged form Neutral (%) Charged (%) Neutral (%) Charged (%) 
Drug   pH 1.2 pH 6.8 
Lidocaine 7.9 + 0 100 9.99 90.01 
Ibuprofen 4.4 - 99.98 0.02 1.11 98.89 
Paracetamol 9.5 - 100 0 99.78 1.22 
 
5.3 Results and Discussion 
The characterisation of the formulations are presented in the appendix. The presentation of results is 
divided into eight sections. Prior to all the sections, the results of polymer behaviours and drug release is 
presented for all the formulations. HPMCAS formulations results are presented in Figure 5-1 for 
HPMCAS/lidocaine, in Figure 5-2 for HPMCAS/ibuprofen, and in Figure 5-3 for HPMCAS/ paracetamol. Zein 
formulation results are presented in Figure 5-4 for zein/lidocaine, in Figure 5-5 for zein/ibuprofen, and in 
Figure 5-6 for zein/paracetamol. PEO formulations results are presented in Figure 5-7 for PEO/lidocaine, in 
Figure 5-8 for PEO/ibuprofen, and in Figure 5-9 for PEO/paracetamol. In each section, the effect on the 
individual polymer with regards to hydration, swelling, and erosion with the different drugs is presented. 
The first section (section 5.3.1) presents drug release cases. The first case, in no particular order, is drug 
release driven only by diffusion. In this case, the diffusion is due to hydration. The second case is the 
diffusion is accompanied by simultaneous swelling or erosion. In this case, there are two polymer behaviour 
exhibited. The third case is when all three of the behaviour occur. Thereafter, the individual polymer 
behaviour will be investigated to understand the different cases of drug release from formulation. Three 
cases of polymer behaviour arise for drug release. The second section (section 5.3.2) report effect of charge 
state on polymer hydration. The third section (section 5.3.3) presents the effect of drug loading on 
hydration. The fourth section (section 5.3.4) presents the effect of charge state on polymer swelling, while 
the fifth section (section 5.3.5) presents the effect of drug loading on swelling. The sixth section (section 
5.3.6) presents the effect of charge state on polymer erosion and the last section (section 5.3.7) summarizes 





Figure 5-1: Drug release and HPMCAS behaviour for lidocaine formulations. The generic ratio ((X-Xo)/Xo) has been presented, which can be substituted by wet mass in the case of hydration, 








































HPMCAS+lidocaine 10% pH 1.2










































HPMCAS+lidocaine 30% pH 1.2



































HPMCAS+lidocaine 10% pH 6.8



































HPMCAS+lidocaine 30% pH 6.8




Figure 5-2: Drug release and HPMCAS behaviour for ibuprofen formulations. The generic ratio ((X-Xo)/Xo) has been presented, which can be substituted by wet mass in the case of hydration, 





































HPMCAS+ibuprofen 10% pH 1.2







































HPMCAS+ibuprofen 30% pH 1.2



































HPMCAS+ibuprofen 10% pH 6.8




































HPMCAS+ibuprofen 30% pH 6.8




Figure 5-3: Drug release and HPMCAS behaviour for paracetamol formulations. The generic ratio ((X-Xo)/Xo) has been presented, which can be substituted by wet mass in the case of hydration, 








































HPMCAS+Paracetamol 10% pH 1.2






































HPMCAS+Paracetamol 30% pH 1.2



































HPMCAS+Paracetamol 10% pH 6.8
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Figure 5-4: Drug release and zein behaviour for lidocaine formulations. The generic ratio ((X-Xo)/Xo) has been presented, which can be substituted by wet mass in the case of hydration, volume in 




































Zein+lidocaine 10% pH 1.2



































Zein+lidocaine 30% pH 1.2





































Zein+lidocaine 10% pH 6.8







































Zein+lidocaine 30% pH 6.8




Figure 5-5: Drug release and zein behaviour for ibuprofen formulations. The generic ratio ((X-Xo)/Xo) has been presented, which can be substituted by wet mass in the case of hydration, volume 




































Zein+Ibuprofen 10% pH 1.2






































Zein+Ibuprofen 30% pH 1.2





































Zein+Ibuprofen 10% pH 6.8
































Zein+Ibuprofen 30% pH 6.8





Figure 5-6: Drug release and zein behaviour for paracetamol formulations. The generic ratio ((X-Xo)/Xo) has been presented, which can be substituted by wet mass in the case of hydration, 









































Zein+paracetamol 10% pH 1.2













































Zein+paracetamol 30% pH 1.2





































Zein+paracetamol 10% pH 6.8








































Zein+paracetamol 30% pH 6.8




Figure 5-7: Drug release and PEO behaviour for lidocaine formulations. The generic ratio ((X-Xo)/Xo) has been presented, which can be substituted by wet mass in the case of hydration, volume in 






































PEO+lidocaine 10% pH 1.2



































PEO+lidocaine 30% pH 1.2






































PEO+lidocaine 10% pH 6.8






































PEO+lidocaine 30% pH 6.8




Figure 5-8: Drug release and PEO behaviour for ibuprofen formulations. The generic ratio ((X-Xo)/Xo) has been presented, which can be substituted by wet mass in the case of hydration, volume 







































PEO+ibuprofen 10% pH 1.2






































PEO+ibuprofen 30% pH 1.2









































PEO+ibuprofen 10% pH 6.8
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Figure 5-9: Drug release and PEO behaviour for paracetamol formulations. The generic ratio ((X-Xo)/Xo) has been presented, which can be substituted by wet mass in the case of hydration, 
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5.3.1 Effect of Ionisation state of the model drug on drug release of solid 
dispersions 
In this section, the drug release profile and polymer behaviour will be presented. As mentioned previously, 
three cases of polymer behaviour arise for drug release. The first case is drug release driven only by 
diffusion which is due to hydration. The second case is the diffusion is accompanied by simultaneous 
swelling or erosion and the third case is when all three of the behaviour occur. Additionally, the drug release 
constant (KD), release mechanism (n), and the t50 (drug release half-life) will be useful in comparing the 
formulations.  
5.3.1.1 Case I  
In case I, the drug release is driven only by diffusion which is due to hydration. The first case is seen with 
HPMCAS formulations in pH 1.2. HPMCAS, in pH 1.2, is insoluble. The addition of a hydrophilic drug 
increases the osmotic gradient. This drives the diffusion of the solvent into the matrix which becomes 
entrapped causing a density reduction in the matrix while allowing the hydrophilic drugs to dissolve into the 
solvent. At 30% lidocaine loading for HPMCAS, the quantity of lidocaine is sufficient to exhibit a disintegrant 
effect in the matrix. The duration of complete drug release was much shorter than 10% lidocaine loaded 
HPMCAS. Hydrophobic ibuprofen slowed the diffusion significantly. Additionally, HPMCAS, in pH 1.2, 
showed a low KD and a long (t50) duration compared to other formulations, shown in Table 5-2. Lidocaine t50 
was lower than paracetamol t50 as expected while Ibuprofen had a higher t50 which is expected for a 
hydrophobic drug. For both paracetamol and ibuprofen at lower drug loadings, the mechanism or release 
was Fickian diffusion (n<0.45) and becomes anomalous transport (<0.45n<0.89) at higher drug loading. As 
mentioned in chapter 1, Fickian diffusion occurs when the polymer relaxation time is much greater than the 
solvent diffusion time. At 10% drug loading, diffusion becomes the only mechanism and thus the t50 is slow, 
but at 30% loading, majority of the formulation composition is more hydrophilic, the diffusion rate becomes 
equal to the polymer relaxation and hence the increase of n values for all lidocaine and paracetamol 
formulations in pH 1.2. By comparing the drug release of lidocaine, which is charged, to ibuprofen, it can be 
noted that solubility is a more dominant factor of determining drug release than ionisation. 
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5.3.1.2 Case II 
In this case, the diffusion is accompanied by either swelling or erosion. In such cases, the density of the 
polymer at the matrix interface is quite low so that the polymer chains along with drug molecules dissolve 
into the solvent. In such cases, the higher the ratio of swelling or erosion, the lower the density of the 
matrix will become at the interface. This will drive the drug release to be greater compared to a less 
swelling or eroding polymer. This behaviour can be seen with all zein formulations, shown in Figure 5-4, 
Figure 5-5, and Figure 5-6. The parametrized values of fitting of zein formulations are shown in Table 5-2. 
Zein does not erode in either pH. Zein is positively charged in pH 1.2. Paracetamol and lidocaine release did 
not show any significant difference for t50, KD, or n. Zein exhibited an intermediate t50 between HPMCAS and 
PEO. Zein with 30% ibuprofen loading had release mechanism value of 0.99 indicates case II transport 
whereby the movement of molecules in the matrix is influenced by polymer relaxation and associated with 
state transition (glass-to-gel transition). As such the gelling layer of zein gradually becomes thicker and 
therefore the drug concentration gradient along the diffusional pathlength is decreased. The gradually 
decreased drug concentration gradient results in progressively slower drug release rates as evidenced by 
very low KD (0.04) for this formulation. Ibuprofen is neutral like paracetamol but showed significant 
difference reasoning that solubility is a factor, not ionisation. In pH 6.8, Zein is neutrally charged and 
exhibits longer t50 for lidocaine and paracetamol formulations. Bouman et al observed that charge 
difference between zein and indomethacin retarded the drug release and like charges accelerated the drug 
release (14). The charges for zein, lidocaine, and ibuprofen are shown in Figure 5-10. This still does not 
explain the reason for zein (neutral) and ibuprofen (negative) fast drug release times. One possible 
explanation for this might be that the hydrophobic drug diffuses through the hydrophobic zein matrix faster 
than the hydrophilic drug (425). This may indicate that intermolecular forces have a more dominant role 
compared to ionisation.  However, if ibuprofen is charged it is behaving as weak acid. This may lead to 
certain local regions where the pH is reduced. Once water is absorbed, the system becomes more 




Figure 5-10: Schematic overview of the charge of zein, lidocaine, and ibuprofen. The pH scale has only been shown until pH 8. Beyond 
this, any charge attainted was not part of the experimental pH. Paracetamol was omitted as it is neutral in all pH. The dashed line 
shows the two pH at which studies were performed. 
5.3.1.3 Case III 
The third case is wherein diffusion, swelling, and erosion occur simultaneously. This is observed for PEO 
formulations shown in Figure 5-7, Figure 5-8, and Figure 5-9. PEO exhibited the shortest t50 and high KD 
values as a superabsorbent polymer. However, in both pH, there was no significant difference among the 
drug release parameters. In the case of 30% ibuprofen loading in pH 1.2, case II transport was seen with a 
significantly prolonged t50 of 88 minutes (5.5X slower than other PEO formulation which is slowed 1.3X). In 
general, ibuprofen loadings retarded t50 due to the hydrophobic nature of the drug. This reaffirms the 








Table 5-2: Drug release constant (KD) ± SD and the mechanism of release of the formulations in pH 1.2 and pH 6.8. t50 is 
the half release time that allows for comparison. 
 
pH 1.2 pH 6.8 
Formulation KD ± SD nd R2 t50 (min) KD ± SD nd R2 t50 (min) 
HPMCAS+Lidocaine 10% 5.93 ± 1.98 0.29 0.91 325 16.79 ± 6.91 0.39 0.95 26 
HPMCAS+Lidocaine 30% 1.46 ± 0.88 0.59 0.98 50 13.60 ± 0.38 0.23 0.98 20 
HPMCAS+Ibuprofen 10% - - - - 3.58 ± 1.41 0.75 0.99 36 
HPMCAS+Ibuprofen 30% 15.69 ± 14.43 0.46 0.84 14 2.93 ± 1.76 0.80 0.99 28 
HPMCAS+Paracetamol 10% 4.87 ± 1.54 0.37 0.93 539 11.28 ± 3.49 0.43 0.94 48 
HPMCAS+Paracetamol 30% 2.12 ± 1.15 0.64 0.92 88 14.83 ± 2.38 0.32 0.98 36 
Zein+lidocaine 10% 8.84 ± 2.04 0.33 0.97 220 2.91 ± 1.59 0.44 0.99 680 
Zein+lidocaine 30% 7.22 ± 3.31 0.35 0.96 120 4.26 ± 1.25 0.41 0.98 340 
Zein+Ibuprofen 10% 1.62 ± 0.47 0.51 0.98 120 1.98 ± 0.34 0.61 0.87 12 
Zein+Ibuprofen 30% 0.04 ± 0.29 0.99 0.98 120 1.99 ± 0.98 0.25 0.91 15 
Zein+Paracetamol 10% 6.78 ± 1.69 0.38 0.96 190 2.18 ± 1.93 0.39 0.98 760 
Zein+Paracetamol 30% 7.45 ± 1.56 0.34 0.95 120 4.12 ± 1.34 0.52 0.97 634 
PEO+lidocaine 10% 13.22 ± 8.38 0.46 0.93 10 4.22 ± 2.47 0.64 0.99 10 
PEO+lidocaine 30% 8.85 ± 4.43 0.58 0.91 13 2.56 ± 0.41 0.72 0.99 14 
PEO+Ibuprofen 10% 2.95 ± 1.21 0.24 0.94 16 3.51 ± 2.25 0.68 0.98 33 
PEO+Ibuprofen 30% 0.74 ± 0.45 0.99 0.91 84 3.44 ± 1.38 0.77 0.95 21 
PEO+Paracetamol 10% 9.48 ± 4.34 0.53 0.94 14 3.98 ± 2.08 0.68 0.98 18 
PEO+Paracetamol 30% 12.38 ± 3.23 0.58 0.97 14 3.49 ± 1.87 0.68 0.98 24 
 
5.3.2 Effect of ionisation state of the model drug on polymer hydration 
(positive weight change) 
A note about the word hydration used in this work needs to be mentioned. When measuring the wet weight 
of the extrudate, there is a simultaneous activity of water ingress and erosion is taking place. The hydration 
ratio of pure HPMCAS and HPMCAS formulation is presented in Figure 5-11. Hydration ratio is taken as a 
positive ratio. As such, hydration of HPMCAS formulation occurs only in pH 1.2. The hydration ratio was 
higher for lidocaine than the other two drugs. Lidocaine is a hydrophilic drug which is fully positively 
charged in pH 1.2. As the formulation is immersed in the solvent, the charged drug molecule in the matrix 
modifies the wettability of the formulation interface (426). In this case, the wettability is increased resulting 
in an increased solvent uptake. Ibuprofen and paracetamol, meanwhile, are neutral in this pH and does not 




Figure 5-11: HMPCAS hydration ratio and HPMCAS formulation hydration ratios in pH 1.2.  
However, although paracetamol is also neutral, there is a difference in the hydration ratio between 
ibuprofen and paracetamol loaded formulations. This greater solubility of paracetamol (21 mg/mL in pH 1.2) 
than ibuprofen (0.06 mg/mL in pH 1.2) results in higher hydration in pH 1.2 (427). Hence, in the case of an 
insoluble polymer (HPMCAS) which acts as a non-interacting carrier, the true effect of the drug can be 
investigated. The driving force for hydration is likely the solubility of the drug.  
 
The PEO loaded formulation hydration is shown in Figure 5-12. In the case of PEO, the effect of the ionised 
state of the drug is less obvious due to PEO being a super-absorbent polymer (SAP). Such SAP can retain a 
large percentage of solvent, relative to its weight, within their structure (143). Lidocaine loaded PEO had an 
initial high hydration ratio but plateaued earlier than the two other formulations. This may be because 
lidocaine was released earlier within the first ten minutes when the hydration ratio was higher. The drug 
release to hydration will be compared later on. At pH 6.8, the two hydrophilic drugs, of which lidocaine is 
90.01% positively charged and paracetamol is 99.78% neutral, did not show any significant variation of 

























Hydration ratio of HPMCAS formulaiton in pH 1.2
HPMCAS+Lidocaine 10% HPMCAS+Ibuprofen 10% HPMCAS+paracetamol 10% HPMCAS
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slowdown. Ionisation will increase the osmolarity and therefore the driving force for water ingress. This can 
explain the decrease the wettability of the surface of ibuprofen loaded formulations leading to less amount 
of solvent ingress.  
 
The zein formulation hydration ratios are shown in Figure 5-13. Lidocaine loaded zein formulations were 
observed to show a higher hydration ratio in both pH. A factor for this could be the electrostatic interaction 
between the drugs and the zein matrix. Bouman et al observed the drug release was faster when the carrier 
and drug were identically charged and release was slower when they were oppositely charged (14). The 
same reasoning could hold in the case of hydration. In pH 1.2, zein and lidocaine are positively charged 
while ibuprofen and paracetamol are neutral. This can explain the higher hydration ratio observed for zein 
and lidocaine. Lidocaine is positively charged and ibuprofen is negatively charged while paracetamol is 
neutral. This can explain the higher hydration ratio observed for zein and lidocaine (both +) and lower 
hydration ratio for zein and ibuprofen (+ and -). Figure 5-10 illustrated this, however, it is more likely that 








Figure 5-12: Top) PEO hydration ratio and PEO formulation ratios in pH 1.2. Bottom) PEO hydration ratio and PEO formulation 


























Hydration ratio of PEO formulaiton in pH 1.2






























Hydration ratio of PEO formulation in pH 6.8




Figure 5-13: Top) zein hydration ratio and zein formulation ratios in pH 1.2. Bottom) Zein hydration ratio and zein formulation 




























Hydration ratio of zein and its formulation in pH 1.2






























Hydration ratio of zein and its formulation in pH 6.8
Zein+lidocaine 10% Zein+ibuprofen 10% Zein+paracetamol 10% Zein
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5.3.3 Effect of drug loading on polymer hydration 
An interesting case arose with 30% lidocaine loaded HPMCAS. The tendency of lidocaine to dissolve is much 
greater than at 10% lidocaine loading that it causes erosion (negative hydration) for the insoluble HPMCAS 
polymeric matrix. Hydration ratio is taken when the wet formulation to dry formulation ratio is positive but 
this formulation was included in the hydration ratio as this is an exception. As the surface of the matrix 
erodes, this causes the solvent to percolate to the inner layers causing more wetting and erosion. In pH 1.2, 
the solvent limits ionisation of HPMCAS chain to 10% at most. Due to this, the dissolved chain remains in a 
compact folded state. As the chains are hydrophobic when unionised in a poor solvent, HPMCAS/lidocaine 
30% formulation collapses into globules. The addition of lidocaine in high quantities has made the drug act 
as a super disintegrant and although paracetamol loading of 30% with HPMCAS did not exhibit this 
behaviour, it is believed that higher loading of paracetamol will cause the same eroding behaviour of 
HPMCAS formulation to occur in pH 1.2 (428). The hydration ratios of HPMCAS formulation in pH 1.2 is 
shown in Figure 5-14.  
 
Figure 5-14: HPMCAS formulation hydration ratio in pH 1.2. Hydration ratios are not shown for pH 6.8 as no hydration but erosion 





























HPMCAS formulation hydration ratios in pH 1.2
HPMCAS+Lidocaine 10% HPMCAS+Ibuprofen 10% HPMCAS+paracetamol 10%




The compared ratio of hydration at different drug loadings is shown in Figure 5-15. The hydrated ratio 
(plotted on the primary axis) was derived by dividing the maximum hydrated ratio at 30% by the maximum 
hydrated ratio at 10% (i.e. Formulation30%/Formulation10%). A value, greater than one would indicate higher 
hydration for the 30% formulation as the numerator is increasing faster than the denominator. A value 
between zero and one would indicate slower hydration for the 30% drug loaded formulation relative to the 
10% drug loaded formulation. A negative ratio indicates erosion. Erosion is not included in this plot. The 
only exception was the case of HPMCAS loaded with 30% lidocaine at pH 1.2. This was included for 
comparison as the 10% lidocaine loaded did not show any erosion but 30% lidocaine loaded HMCAS 
formulation did.  
 
The time ratio (secondary axis) indicates how fast the higher drug loading caused the formulation to reach 
the maximum hydrated ratio where the hydration ratio was compared on the primary axis. A value of one 
indicates the time taken was the same for both formulations while a value lower than one indicate a shorter 
time. Therefore, it can be seen that for the HPMCAS lidocaine formulation, the addition of higher drug 
loading caused erosion and the time taken to was faster at a ratio of 0.1 (a tenth of the time). For most 
formulations, the higher drug loading caused slower hydration. Zein loaded with ibuprofen had value just 
above one (1.08) but this can not be taken to be significant due to the variation overserved on the 
triplicates. The time ratio for most of them is the same which allows for a comparison of the hydration 
ratios at identical times ratio. Some formulations such as PEO with lidocaine and PEO with paracetamol in 
pH 1.2 and PEO with ibuprofen at pH 6.8 showed lower hydration but at a much shorter time. This seems to 
be an observation with PEO which is prone to absorbing high quantities of solvent but also undergoing 
erosion. Since the hydration ratio is lower but the time is shorter, it could be the rate of solvent ingress is 
faster due to the increased affinity of the matrix from higher drug loading causing most of the drug to be 




Figure 5-15: Formulation hydration ratio and time to reach hydration ratio comparison. A weight ratio above 1 indicates faster 
hydration while between 0 and 1 indicates slower hydration. Negative ratio is indicating erosion. The time ratio (secondary axis) 
indicates how fast the higher drug loading caused the formulation to reach the maximum hydrated ratio. The time ratio 
(H30%/H10%) is the time of maximum hydration ratio at 30% drug loading divided over maximum hydration ratio at 10% drug 
loading. A value of less than 1 indicates faster swelling for the 30% formulation. 
5.3.4 Effect of ionisation on polymer swelling 
The swelling ratios of zein formulations are shown in Figure 5-16. The addition of hydrophilic charged drug 
increased the swelling ratio in both pH. This is to be expected based on the hydration ratio that was 
observed. As more of the solvent ingresses, more of the polymer free volume is occupied causing the 
polymer to undergo relaxation. Ibuprofen caused less swelling due to the drug hydrophobicity. The addition 
of hydrophobic drugs to the zein matrix makes the combined system more hydrophobic. It has been known 
that upon contact with the solvent, five steps occur in sequence (165). First, the solvent diffuses into the 
matrix. Then, the solvent acts as a plasticizer, lowering the polymer glass transition temperature, Tg, causing 
the glass-rubber transition, the gel formation, and polymer swelling. At this point, the soluble drug dissolves 
and diffuses through the gel layer. If the drug is hydrophilic, it will accelerate the diffusion as the 
molecularly dispersed hydrophilic drug particles in the matrix enhance affinity for the solvent particles. If 
the drug is hydrophobic, the particles will decelerate the diffusion of solvent by acting as a repulsive the 














































Hydration ratio comparision 




Figure 5-16: Top) Zein and zein formulation swelling ratios in pH 1.2. Bottom) Zein and zein formulation swelling ratios in pH 6.8 
In the case of PEO formulations, lidocaine loaded formulation did show higher swelling than ibuprofen. 
While, in pH 6.8, the swelling ratio for both drugs is lower than the pure PEO. Rowell and Banks describe 
that moisture control can be subcategorized as water repellents and dimensional stabilizers. While water 
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chemical modifications (429). The reason ibuprofen loading could lower the swelling ratio is that ibuprofen 
is negatively charged while the hydroxyl in PEO is also negatively charged leading repelling which cause less 
solvent uptake and in turn less swelling. Lidocaine is positively charged in this pH and the increase in 
positive charge while the reduction in OH- could lead to less solvent uptake and therefore less swelling too. 
The PEO formulation swelling ratio is shown in Figure 5-17. 
 
 
























Swelling ratio of PEO formulation at pH 1.2


























Swelling ratio of PEO formulation in pH 6.8
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5.3.5 Effect of drug loading on polymer swelling 
It appears the swelling was reduced in pH 1.2 but not significantly as the ratio is close to one but in the 
range of 0.9 to 1 except for 30% lidocaine loaded PEO formulation. The swelling rate increased for this 
formulation as the value is close to 0.2 (value on the secondary axis for the dashed line), indicating swelling 
was five times faster with three times the drug load. The swelling rate increased for all PEO formulations in 
pH 1.2 with the highest increase being for lidocaine followed by ibuprofen and then paracetamol. The 
compared ratio of swelling at different drug loadings are shown in Figure 5-18. In pH 6.8, the swelling 
increased for both zein and PEO by the addition of higher quantities of hydrophobic ibuprofen. The swelling 
rate decreased for all formulations with the addition of higher drug loading as all values are less than 1. 
Moreover, it can be observed that the swelling rates exhibited the fastest increase for lidocaine 
formulations and slowest increase for paracetamol for both formulations. According to obstruction theories 
(430-432), which focus on sieve effect in the polymeric network, the addition of more hydrophobic drug 
particles should make the network more impenetrable elongating the path length for solvent molecules to 
defuse in and drug molecules to diffuse out. Conversely, the addition of more hydrophilic lidocaine should 
make the network more impenetrable but to a lesser degree than hydrophobic ibuprofen. The swelling 
profile fitted to the semiempirical power model is presented in Table 5-3.  
 
Figure 5-18: Swelling ratio comparison for swellable formulations. The time ratio (secondary axis) indicates how fast the higher drug 
loading caused the formulation to reach the maximum swelling ratio. A volume ratio above 1 indicates faster swelling while between 
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Table 5-3: The swelling constant (KS), the swell index(n), and their goodness of fit (R2) for polymers and drug loadings in pH 1.2 and 
pH 6.8.  
 
pH 1.2 pH 6.8 
Formulation Ks ns R2 Ks ns R2 
Zein* 0.04 ± 0.01 0.37 ± 0.08 0.99 0.09 ± 0.01  0.18 ± 0.03 0.99 
PEO* 0.46 ± 0.11 0.42 ± 0.10 0.99 0.43 ± 0.18 0.49 ± 0.07 0.99 
Zein+lidocaine 10% 0.04 ± .001 0.48 ± 0.06 0.96 0.02 ± 0.01 0.52 ± 0.16 0.95 
Zein+lidocaine 30% 0.21 ± 0.04 0.38 ± 0.12 0.91 0.01 ± .008 0.68 ± 0.24 0.98 
PEO+lidocaine 10% 0.59 ± 0.08 0.37 ± 0.09 0.94 0.45 ± 0.14 0.55 ± 0.17 0.99 
PEO+lidocaine 30% 0.24 ± 0.06 0.31 ± 0.12 0.94 0.29 ± 0.16 0.52 ± 0.18 0.92 
Zein+Ibuprofen 10% 0.08 ± 0.01 0.34 ± 0.08 0.97 0.07 ± .006 0.23 ± 0.08 0.96 
Zein+Ibuprofen 30% 0.02 ± 0.01 0.26 ± 0.05 0.96 0.01 ± .008 0.49 ± 0.14 0.93 
PEO+Ibuprofen 10% 0.38 ± 0.08 0.23 ± 0.04 0.98 0.16 ± 0.08 0.35 ± 0.10 0.70 
PEO+Ibuprofen 30% 0.25 ± 0.04 0.37 ± 0.13 0.98 0.09 ± 0.02 0.53 ± 0.09 0.99 
Zein+Paracetamol 10% 0.06 ± 0.01 0.42 ± 0.08 0.97 0.05 ± .008 0.56 ± 0.16 0.99 
Zein+Paracetamol 30% 0.17 ± 0.02 0.54 ± 0.07 0.98 0.03 ± .009 0.61 ± 0.21 0.99 
PEO+Paracetamol 10% 0.43 ± 0.24 0.26 ± 0.03 0.96 0.13 ± 0.08 0.49 ± 0.14 0.95 
PEO+Paracetamol 30% 0.37 ± 0.16 0.28 ± 0.11 0.97 0.23 ± 0.10 0.54 ± 0.19 0.94 
 
5.3.6 Effect of ionisation state of the model drug on polymer erosion 
The erosion rates of the formulations fitted to exponential decay are presented in Table 5-4. There is a 
significant increase in erosion rates with the addition of drugs for all formulations except zein. Zein is a non-
eroding polymer. HPMCAS is insoluble in pH 1.2 while 30% lidocaine HPMCAS loading exhibited a 
disintegrating effect. The likely explanation for this is the quantity of the hydrophilic drug. Lidocaine is 
hydrophilic and upon contact with the solvent, the hydrostatic pressure in the formulation is increased 
(433). The pressure is increased either by water/solvent wicking into the plug or swelling phenomena. The 
latter effect is not observed. This wicking promotes de-aggregation of the plug particles (434). Since the 
majority of the constituent is the insoluble polymer, the plugs particles are all drug particles. As these 
particles are dissolved, microscopic channels are created through which percolation of the solvent occurs. 
The surface layer breaks at some point when a critical osmotic pressure builds up inside the matrix due to 
the accumulation of solvent (161). Such effect is not seen with paracetamol 30% HPMCAS loading but it is 
suspected that with higher paracetamol loading, this phenomenon will be observed.  
 
The type of bond within the polymer backbone mainly that determines the rate of hydrolysis, degradation, 
and subsequent erosion. In the case of PEO, the C-O-C backbone of PEO gives unmatched hydrophilicity 
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compared to carbon based backbone (435). The increase in erosion of PEO formulation relative to pure PEO 
is due to the addition of the lidocaine and the decrease is due to the addition of ibuprofen. Generally 
increasing net solubility gives rise to hydrophilicity and erosion. By the same token, PEO/ibuprofen loadings 
were observed to have lower erosion ratio than lidocaine as ibuprofen has two atoms available for 
hydrogen bonding. However, this does not fully explain for differences in solubilities between lidocaine and 
ibuprofen. Based on solubility theory, factors such as temperature, pressure, density and concentration of 
the solvent, intramolecular attractive forces, and polarity affect the solubility of the solute (drug) (436, 437). 
Furthermore, hydrate theory, and theories of dissociation and molecular association advance the study of 
the solubility of solvents. Since the dissolution of a particle of a solute in a liquid is due to (i) the attraction 
exercised by the molecules of the solvent (ii) the attraction exercised by the molecules of solute already in 
solution, the variance in erosion ratios between lidocaine and ibuprofen can reducibly be explained by this 
variance of attraction due to all the solubility factors mentioned above.  
 
In pH 6.8, the erosion ratio for PEO was lower than pH 1.2 but all PEO formulations exhibited a higher 
erosion rate. Kavangh et al showed that an increase in ionic strength of polymer to a decrease in matrix 
erosion rate (438) implying reverse is also true. The decrease in erosion rates as the ionic strength increased 
was attributed to the “salting out” of the polymer by the organic ions present in the dissolution media. 
However, PEO is a non-ionizable polymer and pH insensitive polymer (243). Additionally, Kofi also showed 
the model drugs used showed that despite HPMC being a non-ionic polymer, the medium ionic composition 
can influence its behaviour (438, 439). Similarly, HPMCAS (pH responsive) formulations exhibited erosion 
(higher erosion rate for HPMCAS-lidocaine 30%) in this pH. In the previous chapter, the pH responsiveness 
of HPMCAS has been discussed. HPMCAS polymer chains, which are ionised in pH 6.8, expands due to the 
repulsion between charges on the polymer chain allowing for the dissolution of the chain and subsequently 
undergoes erosion. In contrast, in pH 1.2, the solvent prevents ionisation of HPMCAS chain, the dissolved 
chain remains in a compact, folded state. Since the chains are hydrophobic when unionised in a poor 
solvent, they collapse into globules which were precisely observed for HPMCAS-lidocaine 30% in pH 1.2. 
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With regards to the ionisation of drugs, there was not a significant difference between HPMCAS-lidocaine 
(+) and HPMCAS-paracetamol (neutral). This reflects a similar result trend obtained by Rania et al where the 
dissolution behaviour of carvedilol was investigated. They found that although carvedilol was 100% ionised 
from pH 1.2 to 90% ionised at pH 6.8, the dissolution behaviour and erosion was unaffected and only 
changed when the ionic strength of the medium was altered by adding salts which varied the solubility from 
2398.6 μg/ml in pH 1.2 to 31.3 μg/ml in pH 6.8 (440). Thus, the erosion variance between ibuprofen and 
lidocaine/paracetamol can be explained by the difference in their solubilities in the medium; not by the 
ionisation which if true, would exhibit a difference in pH 1.2.  
Table 5-4: Erosion rates (EK ±SD) of polymers and formulations in pH 1.2 and pH 6.8. 
 pH 1.2 pH 6.8 
Formulation EK R2 EK R2 
HPMCAS  -  - 0.64 ± 0.23 0.98 
Zein  -   -   -   -  
PEO 0.79 ± 1.32 0.94  0.58 ± 0.12 0.98 
HPMCAS+Lidocaine 10%  -   -  2.24 ± 0.12 0.98 
HPMCAS+Lidocaine 30% 1.19 ± 0.23 0.91 4.91± 0.63 0.98 
Zein+lidocaine 10%  -   -   -   -  
Zein+lidocaine 30%  -   -   -   -  
PEO+lidocaine 10% 7.91 ± 1.09 0.95 8.11 ± 1.43 0.95 
PEO+lidocaine 30% 3.11 ± 0.87 0.85 5.05 ± 1.56 0.96 
HPMCAS+Ibuprofen 10%  -   -  1.63 ± 0.42 0.96 
HPMCAS+Ibuprofen 30%  -   -  0.86 ± 0.52 0.97 
Zein+Ibuprofen 10%  -   -   -   -  
Zein+Ibuprofen 30%  -   -   -   -  
PEO+Ibuprofen 10% 3.87 ± 1.34 0.94 5.89 ± 1.18 0.96 
PEO+Ibuprofen 30% 2.54 ± 1.23  0.93 4.72 ± 0.92 0.98 
HPMCAS+Paracetamol 10%  -   -  1.81 ± 0.83 0.97 
HPMCAS+Paracetamol 30%  -   -  3.82 ± 1.19 0.98 
Zein+Paracetamol 10%  -   -   -   -  
Zein+Paracetamol 30%  -   -   -   -  
PEO+Paracetamol 10% 5.33 ± 1.67 0.96 8.08 ± 1.07 0.98 
PEO+Paracetamol 30% 4.72 ± 0.84 0.98 7.03 ± 1.15 0.99 
 
5.3.7 Effect of ionisation on overall polymer behaviour 
In the preceding sections, the overall effects of the ionisation of the drugs on polymer behaviours were 
investigated. The dynamics of polymer behaviour and drug release is complex. The ionisation of the drug 
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affects the drug release of the matrix system compared to the placebo polymer. However, it is more likely 
that solubility plays a more dominant role than ionisation. The effect of ionisation on polymer behaviour 
compared to the placebo is summarized in Table 5-5. 
5.4 Conclusion 
In this chapter, four major parameters were investigated relating to the dissolution behaviour of the 
formulation in pH 1.2 and pH 6.8. They were hydration, swelling, erosion, and drug release. Three different 
carrier classes were investigated with three different drugs. The aim was to investigate whether the 
ionisation of drugs contributed to a difference in the four parameters. It was found that formulations 
showed differences in hydration ratio and a clear trend based on ionisation was not shown. Higher drug 
loading increased hydration ratios in some cases. However, the solubility of the drug had a more dominant 
role. For swelling, the SAPs have the highest swell as well as their formulations. The difference in this 
swelling behaviour can define a distinguishing criterion for different classes of carriers which is discussed 
more in detail in the next chapter. The swelling increased for ibuprofen as expected compared to lidocaine. 
The mechanism of swelling also changed with the drugs (indirectly loss of polymer). Higher loading of 
hydrophilic drugs caused more anomalous transport. With regards to erosion, solubility seems to be the 
driving factor for erosion rates with the pH be one of the factors that can alter solubilities of the 
formulation. It was also observed that very high quantities of hydrophilic drugs can act as a disintegrant.  
 
Variations in drug loadings cause a change of release mechanisms. Addition of higher hydrophobic drug 
quantities equates to more diffusion controlled release while the addition of hydrophilic drugs leads to 
more anomalous controlled release. The addition of some hydrophobic drugs to a formulation can give rise 
to case II transport. In terms of duration of release, SAPs are the fastest and proteins are the slowest. pH 
responsive formulations are very versatile in this regard. It was also confirmed that if the polymer and drug 
have identical charges, this accelerates drug release while if they have non-identical charges, this 





Table 5-5: Polymer behaviour compared for ionised drug loadings. The arrows indicate if the factor is increasing or decreasing as a 
result. The = sign denotes change of the same magnitude. N/A is noted when the specific factor does not apply to the polymer. 
 pH 1.2 pH 6.8 
HPMCAS 
 Hydration Swelling Erosion Hydration Swelling Erosion 
Charge Ratio Time Ratio Time Ratio Time Ratio Time Ratio Time Ratio Time 
+   N/A N/A   N/A N/A N/A N/A   
-  = N/A N/A N/A N/A N/A N/A N/A N/A   
0  = N/A N/A N/A N/A N/A N/A N/A N/A   
Zein 
 Hydration Swelling Erosion Hydration Swelling Erosion 
Charge Ratio Time Ratio Time Ratio Time Ratio Time Ratio Time Ratio Time 
+ = = = = N/A N/A  = =  N/A N/A 
- = = = = N/A N/A  =   N/A N/A 
0 = = = = N/A N/A  =   N/A N/A 
PEO 
 Hydration Swelling Erosion Hydration Swelling Erosion 
Charge Ratio Time Ratio Time Ratio Time Ratio Time Ratio Time Ratio Time 
+   =     = =   = 
-  = =    =     = 





Chapter 6: Classification of drug release profiles 
6.1 Introduction 
In this chapter, the aim is to utilize statistical approaches to analyse the correlations between polymer 
behaviour and drug release kinetics with an attempt to use such knowledge to develop a prediction tool to 
aid the development of solid dispersion formulations. The polymer behaviours data gathered in chapter 4 
are classified using K-mean clustering while the drug release profiles gathered in chapter 5 are first reduced 
using principal component analysis (PCA) to create a reduced model of drug release profiles followed by K-
means clustering. This allows the creation of a classified library (shown in the top panel of Figure 6-1). 
Thereafter, the scenario of achieving a desired drug release profile is investigated where the drug and the 
drug release duration is known (shown in the bottom panel of Figure 6-1).  
 
Figure 6-1: Top) The integration of chapter 4 and chapter 5 data to classify the data. The dashed line indicates separation. Bottom) 
The logical pathway of investigation when the drug and drug release duration is provided for achieving a desired drug release profile. 
Create a library of correlated polymer behaviours and drug release profiles  
Chapter 4 data of polymer behaviours 
(hydration, swelling, and erosion) 
Chapter 5 data of formulation drug 
release profiles 
Does the 
drug exist in 
the library? 
Yes No 








Add the drug and/or polymer to the dataset 
No No Use the drug and 
polymer 
Yes Yes 
Clinical scenario where the drug and 
the expected drug release is given 
 
Classify polymer behaviour 
using K-means clustering 
Use PCA to create a reduced model 





K-means clustering, being linear, is faster computational clustering method but and only reduces in speed 
for a much larger dataset and hence not a problem for the dataset being analysed here (441). Background 
to K-means clustering technique has been discussed in chapter 2. K-mean clustering was used on the 
polymer dataset for all the factors that were measured. The cluster distinguishing criteria was chosen based 
on the data. The cluster centres gave the value of the factor that is common characteristics of the cluster, 
which was also obtained from K-means clustering. Clustering was performed on SPSS software. 
6.2.2 Principal component analysis (PCA) 
PCA is a dimension reduction technique that was performed on all the drug release profiles (known as the 
full model) to create a reduced model. This type of PCA is known as functional PCA (442). Details of the PCA 
technique has been discussed in chapter 2. The creation of the reduced model is mathematically complex 
but in a simplified step is given below: 
1. All drug release profiles are passed as a data matrix 
2. The mean and variance of all the profiles are computed in the matrix 
3. Eigenvalue decomposition of the matrix is computed which gives eigenvalues and eigenvectors 
• The eigenvectors are the principal components (PC) 
4. The significance of the PC is observed (variation as a probability that is accounted by each PC) 
5. The PCs are plotted as profiles. These plotted PC profiles are termed as ‘reduced curves’ 
These reduced curves are important as it gives the underlying most distinct curves that account for most of 
the variation of all drug release profiles in the full model. Separate PCA was performed for drug release 
profiles for pH 1.2 and pH 6.8. The number of components for PCA was chosen based on eigenvalues that 
have a value greater than the value of 1.  
 
A different type of PCA, known as simplified PCA, was used to deduce any difference of any underlying 
behaviour that distinguishes all the drug release profiles (442). Simplified PCA gives the best possible 
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representation of a p-dimensional dataset in q dimensions (q<p) while being able to account for maximizing 
variance in q dimensions. Rotations of axis are used to find the best suited axis for q dimensions that 
minimize the distance to all data points thereby accounting for maximum variance among all the data 
points. In this case, Varimax rotation was used on the drug release profiles. Loading plots (mentioned in 
chapter 2 Figure 2-20) created from this PCA, on which further K-means clustering was performed to classify 
any groups of observations. 
6.2.3 Artificial neural network (ANN) 
ANN was used on the polymer and formulation dataset. Chapter 2 outlines the details of ANN in general. 
The input for ANN were all the factors measured and the output was chosen to be t50 (half drug release 
time) in the first scenario and t100 (complete drug release time) in the second scenario. ANN procedure 
resulted in the ranking of the importance of individual factors. This ranking is useful in understanding the 
effect of each factor in achieving the output (t50 and t100). This means that given this ranked list, the most 
important factor can be varied to have the highest variation of the output. Likewise, the second most 
important factor has the second most variation on the output. ANN was performed on SPSS software V25. 
6.3 Result and discussion 
6.3.1 Polymers classification 
Polymers behaviours were classified using K-means clustering for hydration, swelling, and erosion. As a 
reminder, the term hydration is used to describe weight gain and only positive weight gain of the polymer. 
The aspect on which these behaviours were classified was with respect to the half-life (t50) of the behaviour. 
Four cluster categories were chosen with each of them representing a different t50 interval. Cluster #1 
represents no t50 of hydration for polymers. Cluster #2 represents short t50 (low value) of hydration for 
polymers. Cluster #3 represents intermediate t50 of hydration for polymers and cluster #4 represents long 
t50 (high value) of hydration for polymers. The intervals of clusters are relative to the data available. Since 
the cluster intervals (high or low or intermediate) are relative to the data, the cluster boundary does not 
imply an absolute physical interpretation and subject to users’ choice of the number of subdivisions such as 
very low, low, high, and very high t50 etc. For example, the boundary between no t50 and low t50 for 
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hydration is a value of five minutes. Values greater than five minutes lie within the cluster#2 (no t50) 
whereas values less than five minutes lie within cluster#1 (low t50). The clusters are shown in Table 6-1 
through to Table 6-3 below. 
Table 6-1: Hydration t50 of polymers 
Case 
Clusters 
(pH 1.2)      
Clusters 
(pH 6.8)      
1:HPMCAS 1 1 
2:PEO 2 3 
3:Zein 4 4 
4:XG 2 2 
5:PCL 1 1 
6:Eudragit 1 1 
7:PVPVA 1 1 
8:PVA 2 2 
9:Soluplus 2 2 
10:HP/PEO 2 1 
11:HP/Sol 3 1 
 






1:HPMCAS 1 1 
2:PEO 3 3 
3:Zein 4 4 
4:XG 2 2 
5:PCL 1 1 
6:Eudragit 1 1 
7:PVPVA 1 1 
8:PVA 1 1 
9:Soluplus 2 2 
10:HP/PEO 2 1 
11:HP/Sol 2 1 
 






1:HPMCAS 1 2 
2:PEO 3 3 
3:Zein 1 1 
4:XG 3 3 
5:PCL 1 1 
6:Eudragit 1 1 
7:PVPVA 4 4 
8:PVA 2 2 
9:Soluplus 2 2 
10:HP/PEO 2 2 
11:HP/Sol 1 2 
The cumulative classified clusters of all polymer behaviours are presented in Table 6-4 for pH 1.2 and in 
Table 6-5 for pH 6.8. In both tables, the column denotes the clusters, and the cluster category denotes the 
characteristics of the cluster. The two tables represent the library of polymer behaviours in the two pH. 
Table 6-4: Clusters of all factors for pH 1.2. Polymers of the factors clustered are displayed in the cell unit. The cluster category row 
indicates the interpretation of each cluster for the preceding factor in the row. 
pH 1.2 Clusters 
Factor 1 2 3 4 
Hydration HPMCAS, PCL, Eudragit,  
PVA, Xanthan gum, Soluplus 
PEO, HP/PEO 
HP/Sol Zein 
Cluster category No hydration Low t50 Intermediate t50 high t50 
Swelling 
HPMCAS, PCL, Eudragit,  
PVPVA, PVA 
Soluplus, HP/Sol, HP/PEO  
Xanthan gum 
PEO Zein 
Cluster category No swelling Low t50 Intermediate t50 high t50 
Erosion 
HPMCAS, Zein, PCL, Eudragit, 
HP/Sol 




Cluster category No erosion High t50 Intermediate t50 Low t50 
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Table 6-5: Clusters of all factors for pH 6.8. Polymers of the factors clustered are displayed in the cell unit. The cluster category row 
indicates the interpretation of each cluster for the preceding factor. 
pH 6.8 Clusters 
Factor 1 2 3 4 
Hydration 
HPMCAS, PCL, Eudragit,  
PVPVA, PVA, HP/Sol, HP/PEO 
Xanthan gum, soluplus, 
PEO 
PVA Zein 
Cluster category No hydration Low t50 Intermediate t50 high t50 
Swelling 
HPMCAS, Zein, PCL, Eudragit, PVPVA,  
PVA, HP/PEO, HP/PEO 
Xanthan gum, Soluplus PEO Zein  
Cluster category No swelling Low t50 Intermediate t50 high t50 
Erosion Zein, PCL, Eudragit 
PVA, HPMCAS 




Cluster category No erosion High t50 Intermediate t50 Low t50 
 
6.3.2 Drug release curves classification 
The drug release curves of all the formulations are shown in the top left and top right of Figure 6-2 for the 
two pH. Functional PCA performed on the full model in each pH yielded the most underlying curves that 
explain most of the variation. The number of components in PCA was chosen to be three as they explained 
most of the variance in observance. The bottom left of Figure 6-2 shows the reduced curves in pH 1.2. In pH 
1.2, Component #1 explained 88.1% of the variance, while component #2 explained 8.8% of the variance, 
and component #3 explained 1.8% of the variance for a cumulative of 98.7% of the total variation explained. 
The similarity of the rotated curves to a formulation is given by the coefficient of the rotated component 
matrix. Only the highest similarity of the generated curve to a formulation is stated here. The curve 
generated by component #1 is 93.5% similar to HPMCAS loaded with 10% lidocaine. The curve generated by 
component #2 is 93.7% similar to PEO loaded with 10% ibuprofen. The curve generated by component #3 is 
57.7% similar to HPMCAS loaded with 30% ibuprofen. The bottom right of Figure 6-2 shows the reduced 
curves for pH 6.8. In pH 6.8, Component #1 explained 55.7% of the variance, while component #2 explained 
39.4% of the variance, and component #3 explained 3.3% of the variance for a cumulative of 98.4% of the 
total variation explained. The curve generated by component #1 is 92.9% similar to PEO loaded with 10% 
lidocaine. The curve generated by component #2 is 95.2% similar to zein loaded with 10% lidocaine. The 
curve generated by component #3 is 26.7% similar to PEO loaded with 30% ibuprofen. It is observed that 
even with the number of PCA components chosen to be three, two components explain most of the 
variance sufficiently reasonably. The drugs which appear in both pH are lidocaine and ibuprofen. Looking at 
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the coefficient of the rotated component matrix shown in Table 6-6 for pH 1.2 and in Table 6-7 for pH 6.8, 
the coefficient (values) of paracetamol formulations are close to the lidocaine curves indicating most of the 
characteristics of the paracetamol formulation can be explained by the lidocaine formulations. Therefore, all 
the drug release profiles can be explained as a linear combination of ibuprofen and lidocaine, which also 
explains paracetamol, accounting for 98.7% and 98.4% of the variance in pH 1.2 and pH 6.8, respectively. 
 
Next, the polymers in terms of drug release can be classified by combining PCA and K-means clustering. The 
number of components was determined using the eigenvalue cut-off approach (eigenvalue >1) which led to 
two PCA components. In the loading plot that is constructed from the PCA, the components appear as 
component #1 and component #2, not what the components are. The interpretation of the component is 
subject to the user’s perception of the commonalities that might be shared by the data that lie highly 
correlated on that specific component axis. From loading plot, component #1 (x-axis) can be interpreted to 
be the drug release times and component #2 (y-axis) can be taken to be release amount. The loading plot 
(also known as component plot) of the formulations in pH 1.2 is shown in Figure 6-3. 
Table 6-6: Component matrix in pH 1.2 





1 2 1 2 
HPLido10 0.902 -0.417 HPPara10 0.913 -0.383 
HPLido30 0.981 0.134 HPPara30 0.964 -0.254 
ZeinLido10 0.963 -0.217 ZeinPara10 0.999 -0.004 
ZeinLido30 0.986 -0.155 ZeinPara30 0.986 -0.156 
PEOLido10 0.900 0.406 PEOPara10 0.888 0.433 
PEOLido30 0.918 0.385 PEOPara30 0.928 0.357 
HPIbu10 0.977 -0.130 
   
HPIbu30 0.979 -0.131 
   
ZeinIbu10 0.960 -0.261 
   
ZeinIbu30 0.994 0.081 
   
PEOIbu10 0.943 0.066 
   
PEOIbu30 0.924 0.313 




Table 6-7: Component matrix in pH 6.8 
Component Matrix in pH 6.8 
 
Component  Component 
1 2  1 2 
HPLido10 0.953 -0.291 HPPara10 0.953 -0.291 
HPLido30 0.956 -0.283 HPPara30 0.890 -0.352 
ZeinLido10 0.798 0.569 ZeinPara10 0.806 0.568 
ZeinLido30 0.875 0.482 ZeinPara30 0.875 0.482 
PEOLido10 0.955 -0.248 PEOPara10 0.955 -0.248 
PEOLido30 0.966 0.004 PEOPara30 0.961 0.088 
HPIbu10 0.974 -0.168 
   
HPIbu30 0.988 0.044 
   
ZeinIbu10 0.955 0.263 
   
ZeinIbu30 0.969 0.205 
   
PEOIbu10 0.940 -0.304 
   
PEOIbu30 0.912 -0.303 
























































































































Figure 6-3: PCA rotated loading plot of formulations in pH 1.2. Greater values of PC 1 possibly represent longer release times of formulations and greater PC 2 values possibly represent higher 





It can be observed that all the data in Figure 6-3 lie within the first quadrant of the graph where both x and y 
are positive. Neither release time nor release amount can be negative excluding the possibility of any data in 
any other quadrants. It can be observed that PEO based formulations have shorter drug release times and 
achieve a higher drug release in that time frame relative to other formulations. Therefore, PEO polymer can 
be clustered in terms of drug release in that region of the plot. HPMCAS and zein form the other cluster as 
zein is very slow in drug release times and release less amount in that time relative to PEO formulations. 
HPMCAS is insoluble and for all practical purposes, attain the same effect as zein for drug release. Two 
clusters represent were formed based on the distance to the nearest neighbour. Cluster #1 seem to contain 
PEO while cluster #2 contains zein and HPMCAS. 10% ibuprofen loaded with PEO seems to be an outlier and 
is within the region bounded by cluster #2, which in this case is miscategorized.  
 
In pH 6.8, a clear distinct clustering is harder for the polymers. One polymer to note is HPMCAS which is 
erodible in pH 6.8 has shifted towards PEO in the loading plot of pH 6.8, shown in Figure 6-4. Moreover, 
three clusters formed can be seen. HPMCAS can be grouped with PEO mostly. Cluster #2 contains both zein, 
HPMCAS, and PEO. Therefore, a general categorization of polymers may not be possible based on clusters 
directly. However, one modification that could be done is to calculate the number of polymer formulations 
that fall within each cluster. If the majority of polymer lies in a cluster, cluster #2 data can be attributed to 
that cluster. So, for zein formulations, four samples fall in cluster #1 and two samples fall in cluster #2. Based 
on this, cluster #1 contains 66% (4/6) of the zein samples. Therefore, the two zein formulations from cluster 
#2 can be taken to be part of cluster #1. Likewise, calculations for PEO and HPMCAS lead to all formulations 
of cluster #2 to be allocated to cluster #3. The clustered polymers in terms of PCA component interpretation 
from Figure 6-3 and Figure 6-4 is sorted in Table 6-8. 
Table 6-8: Polymer categorization from PCA components for drug release 
 Drug Release times Drug Release amount 
 Short Long Low High 
pH 1.2 PEO Zein, HPMCAS Zein, HPMCAS PEO 




Figure 6-4: PCA rotated loading plot of formulations in pH 6.8. Greater values of PC 1 possibly represent higher amounts of drug released of the formulations and greater PC 2 values possibly 






6.3.3 Relating polymer behaviour clusters to drug release clusters 
In sections 6.3.1, the classification of polymer behaviour kinetics which was based on hydration, swelling, 
and erosion was performed. These classification schemes have not been related to drug release. This is 
crucial as the aim is to be able to extrapolate a drug release profile based on the polymer behaviour 
kinetics. The pathway to relating is shown in Figure 6-5.  
 
Figure 6-5: Concept of associating polymer behaviour with drug release 
So far, the cluster centre information for hydration, swelling, and erosion was omitted but is now enlisted in 
Table 6-9 for this part of the analysis, which was obtained from K-mean clustering. These cluster centres 
give a single quantified value of the appropriate constants being measured (hydration, swelling, and 
erosion), which is an approximated value and a common characteristic of all the polymers in that cluster. 
The cluster centre of the drug release is based on the drug release time and drug release amount.  
Table 6-9: K-means cluster centres for factors from K-means clustering in pH 1.2 and pH 6.8.  
 Cluster #1 Cluster #2 Cluster #3 Cluster #4 
 No effect Low t50 Intermediate t50 High t50 
pH 1.2 
(Low               High) in minutes 
Hydration 0 24 210 728 
Swelling 0 17 25 728 
Erosion 0 30 45 86 
pH 6.8 
  (Low               High) in minutes 
Hydration 0 20 190 728 
Swelling 0 26 38 728 
Erosion 0 40 52 80 
Gather the cluster centers of polymer 
hydration, swelling, and erosion which was 
presented in Table 6-4 for pH 1.2 and in 
Table 6-5 for pH 6.8 
Link the hydration, swelling, and erosion 
cluster center with the corresponding 
polymer for drug release cluster center. 
Get cluster centers of 
drug release clusters 




Cross relating Table 6-8 and Table 6-9 in terms of cluster centre yields the main dataset library, shown in 
Table 6-10, which links the cluster centre of drug release and polymer behaviour. 
Table 6-10: Clusters relating polymer behaviour and drug release summarized. The basis of effect interpretation (low, high, etc.) is 
based on the cluster distinction as noted in Table 6-4 and Table 6-5. The effect interpretation of release time and amount from the 
clustering of the loading plot is introduced here. 
pH 1.2 
  Hydration t50 Swelling t50 Erosion t50 Release time (min) Release amount (%) 
Zein 728 728 0 2304 40 
Effect High High None Slow Low 
HPMCAS 0 0 0 2304 40 
Effect None None None Slow Low 
PEO 24 25 50 146 96 
Effect Low Intermediate Intermediate Fast High 
pH 6.8 
Zein 728 728 0 2649 39 
Effect High High None Slow Low 
HPMCAS 0 0 160 72 95 
Effect None None Intermediate Fast High 
PEO 20 38 52 72 95 
Effect Low Intermediate Intermediate Fast High 
 
With Table 6-10, it is possible to proceed to the different scenarios of achieving a desired drug release 
profile. Three possible scenarios can arise. In all the scenarios, it is first important to be able to find the 
closest resembling ‘reduced curve’ which is similar in the time scale and quantity. The ‘reduced curves’ are 
found in the bottom of Figure 6-2 for the two pH. Scenarios I is where the drug and the desired drug release 
profile (which is dictated by the polymer) exists in the library. Scenarios II is where the given drug does not 
exist but a drug from a similar class exist in the library the desired drug release profile does exist in the 
library. Scenarios III is where neither the drug nor desired drug release profile exists in the library.  
6.3.4 Scenario I  
In this scenario, the drug, and the drug release profile both exists in the library. As an example, the choice of 
drug is lidocaine and the chosen pH is pH 1.2. The chosen drug release profile is a fast drug release profile 
similar to the reduced curve by component #2 in the bottom left of Figure 6-2. The polymer this ‘reduced 
curve’ has is PEO. Therefore, the choice of polymer, in this case, would likely be PEO. Moreover, additional 
reconfirmation is obtained from Table 6-10, where the fast drug release is associated with PEO polymer for 
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pH 1.2. It could have been any other polymer that shares the commonality of fast release (if the data library 
of Table 6-10 had more polymers). Thus, for comparison, the experimental lidocaine loaded PEO 
formulation drug release profiles in pH 1.2 are given along with the predictor curve, which are shown in 
Figure 6-6. The predictor curve is a ‘reduced curve’ but the naming switches as it is used for prediction here. 
 
Figure 6-6: PEO-lidocaine experimental and predictor curve compared in pH 1.2 
6.3.5 Scenario II 
Scenarios II is where the drug does not exist in the library but the desired drug release profile does exist in 
the library. In this scenario, logic would be to predict with another drug release profile which would achieve 
the identical desired release profile. For this, the first step would be to locate if a substitute drug exists in 
the library. A well established classification system for drugs is the Biopharmaceutics Classification System 
(BCS) which consists of four classifications based on solubility and permeability (443, 444). In BCS, the drugs 
are grouped in four classes with class I being drugs possessing high solubility and high permeability, class II 
consisting of drugs possessing low solubility and high permeability, while class III consisting of drugs 
possessing high solubility and low permeability, and class IV consisting of drugs possessing low solubility and 
low permeability (445). The solubility and permeability in BCS refer to aqueous solubility and intestinal 




















PEO lidocaine formulation in pH 1.2
Predictor drug release profile PEO+lidocaine10% PEO+lidocaine30%
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(448, 449), and lidocaine(450)) and other drugs gathered from secondary sources (445) in the BCS are 
shown in Figure 6-7. 
 
Figure 6-7: Some drugs in the BCS system 
An example of scenario II, the chosen drug will be ranitidine, which does not exist in the dataset library in 
Table 6-10. However, a similar BCS class III drug, paracetamol, does exist in the dataset. The chosen 
duration of drug release is chosen to be a long duration and the chosen pH is pH 6.8. From Figure 6-2, the 
only ‘reduced curve’ which resembles the desired characteristics is that of component #2. That particular 
curve most resembles is that of zein loaded with 10% lidocaine with a resemblance is 95.2%. Even though 
from this, it can be deduced that the most likely polymer which should be used is zein, confirmation from 
Table 6-10 is desired. This indeed is zein from Table 6-10. Therefore, zein formulations with paracetamol 
can be used to predict the drug release of zein with ranitidine in pH 6.8. Bouman et al investigated zein 
loaded with 22.2% ranitidine in pH 6.8 (14). The drug release profile obtained from that work will be used 
for comparing the ‘reduced curve’, which is used as the predictor curve (term changed based on the 
perspective of usage criteria), for this work. This is shown in Figure 6-8. Interestingly, zein with 22.2% 
paracetamol loading in pH 6.8 was also obtained by Bouman et al (14). This is added for comparison of the 




















release profile does not exist in the dataset. In this case, the drug with a polymer that would exhibit similar 
drug release duration would need to be experimentally performed and added to the dataset. 
 
Figure 6-8: Paracetamol loaded zein formulation and predictor curve compared in pH 1.2 
6.3.6 ANN as a predictor refinement technique 
ANN can be used to rank order the importance of all the inputs in relation to the output. The ranking of the 
inputs will aid in understanding which factor(s) can be altered to achieve the most variation of this 
outcome, and thus achieving a refined more accurate desired outcome. ANN was used with the outcome 
being ‘drug release time’, shown in Figure 6-9. In this case, there was one hidden layer for performing 
internal neural network process but however cases of two or three hidden layers have also been performed 
(451). The outcome, in this case, is also a single factor but cases of two or more factors have been 
performed (452). Four inputs were provided but the ANN process always automatically adds a bias input. 
The variable ranking of this particular ANN process is shown in Figure 6-10. However, due to the number of 
data points, an issue of reproducible consistent results exist. It can be seen that as the ANN process is run, 
the ranking of the variables differs. Therefore, deducing which variable has the highest effect based on 
these few runs would be a false deduction. Nevertheless, this approach will produce accurate consistent 




















Zein formulation release in pH 6.8






































































Several limitations exist in the approach used. First, as mentioned, the usage of clustering causes loss of 
individual attributes and only a cluster-wide common property exists for the cluster such as cluster common 
hydration constant, or cluster common drug release amount, etc. However, the hope of using clusters is 
that on large scale varying datasets, common properties can be found to categorize subsets of data. There 
were cases where cluster miscategorized dataset from PCA component reduction. Numerous classification 
techniques are being developed to improve categorization (453). Using clusters was the dominant 
technique in this chapter. This caused the introduction of errors in the form of miscategorization. The 
proposed method of reducing miscategorization is adding more dataset of with varying nature. This causes 
more clusters to be created, which can not only reduce errors but give emergence to explain the data more 
refined. Another limitation was the correlating polymer hydration, erosion, and swelling to the drug release 
based on clusters. It was not possible to directly relate these factors to drug release constant or drug 
release index as was shown in chapter 5. A sense of how the drug ionization affects polymer hydration, 
swelling, or erosion kinetics was summarized in comparison to the pure polymer kinetics. The degree of 
correlating aspects is less objective to deducing an analytical equation, which has a high degree of 
objectivity and strict restrictive underlying postulations. The limitation observed with the use of ANN is with 
the number of data points available and usually preferred by ANN. ANN is capable of learning and predicting 
indicators to a specific outcome but with a sufficiently large number of data points. 
6.5 Conclusion 
In this chapter, the method of K-mean clustering was used to classify the polymers in terms of polymer 
behaviour, which included hydration, swelling, and erosion. The interpretation of the classification arose 
from the data extremes, with one extreme being labelled high and other no observed effect.  
 
Functional PCA was applied to create a reduced model of the full model consisting of all the drug release 
profiles. This resulted in three curves that explained about 98% of the variances in both pH. Additionally, 
simplified PCA was performed on all drug release profiles to deduce any distinguishing characteristics of the 
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polymers and the drugs. Two principal components were chosen based on eigenvalues that had values 
higher than one, from which loading plots were created. The interpretation of the two principal 
components was taken to be drug release time and drug release amount. Further K-means clustering on the 
loading plots deduced clusters and their centres which yielded quantitative information about the polymer 
behaviour, such as common hydration or common swelling ratio, and drug release parameters, such as drug 
release times and drug release amount, in that cluster, which was correlated. Thereafter, the drug release 
profile was generated using the PCA ‘reduced curve’ acting as ‘predictor curve’. Several limitations were 
discussed which affect the possibility of error in the created drug release profile. In the next chapter, further 




Chapter 7: Conclusion remarks and future outlook 
Controlled drug release systems (CDRS) deliver the drug locally or systemically at a predetermined rate for a 
specified duration (454, 455). 3D printing has shown promising potentials of being used to manufacture 
CDRS. Drug release from CDRS is often dependent on polymer properties. Therefore, a thorough 
understanding of the drug and polymer's properties and their interactions will facilitate the production of 
highly reproducible CDRS with the desirable drug release kinetics (456). This indicates two areas of research 
for improvement: reproducibility and predictability. This was the overarching theme of this work. The issue 
of reproducibility is related to the minimization of errors that arise during the manufacture and the 
measurement of the performance CDRS. The issue of predictability is related to polymer, drug and the 
formed solid dispersion properties and any pharmacokinetic models used to attain the drug release. The 
reproducibility of CDRS was investigated in chapter 3, and the predictability was investigated in chapters 4 
through to chapter 6. 
7.1 Reproducibility 
Error in the measurement of the drug release profile is unavoidable. In some publications, the error is 
reported to be as large as ±30% (31). Commercial software such as GastroPlus reports errors based on 
user’s chosen confidence intervals (CI) (200, 202). In this case, a range is defined such that the 
measurement is within the range (interval) with the specified probability (confidence). For example, a 95% 
CI indicates that 95% of the measurement from the true mean of the samples exist within that interval.  
 
The sources of error in the drug release profile of 3D printed solid dosage forms was investigated in chapter 
3. The sources of error arose from each of the manufacturing steps and the measurement of the drug 
release at termination. The manufacturing steps included using hot melt extrusion (HME) coupled with 3DP. 
The drug release profile was measured by using a dissolution machine and subsequently a UV spectrometer 
and parametrised by the Peppas equation. Since the Peppas equation relates to the initial drug mass and 
sampled time drug, estimation of errors in drug mass or inferred drug mass from the equipment were 
substituted in the Peppas equation. The source of error in initial drug mass came from HME and 3DP and 
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the source of error in sampled drug mass at a sampling timepoint came from the entire process of 
dissolution and sampling using the UV spectrometer. Two cases arose for the initial drug mass: one was the 
direct error estimation from weighted 3DP samples and the other was the estimation of error in drug mass 
from the volume of the 3DP sample in the absence of direct weighing. In the latter case, the drug mass was 
inferred using the drug mass uniformity from HME technique while verifying that the 3DP process step did 
not significantly alter the drug mass.  
 
While identifying the sources of error, it was also possible to identify the types of errors in each step. The 
types of error were systematic and random error. The systematic error indicates the accuracy of the 
equipment while random error reflects the precision of the equipment. Modifications to the procedure can 
help minimize the systematic error. Some of the modifications were discussed in the chapter such as 
optimizing the residence time of HME or optimum temperature to achieve the optimum melt flowability of 
the filament for 3DP. Further suggestion can include making the HME-FDM a continuous one step process. 
This can help reduce systematic error observed for die shrinkage from two dies (HME and 3DP stage) to one 
die (3DP stage). A schematic of this is presented in Figure 7-1.  
 
Figure 7-1: HME-3DP as a continuous process. The die through which filament exits the HME is also the beginning of the 3D printing 
process. Adapted from reference (457). 
Systematic errors for dissolution machine that are process related can include sample introduction and 
multiple point sampling. Samples introduction in the dissolution vessel can be tricky and may not be able to 
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be performed reproducibly. Samples can have a dissolution rate that is position dependant. For example, if 
the sample is off-centre, the dissolution rate is high due to shear forces. Alternative, if it is in the centre, 
coning may occur and the dissolution rate will be lower (458). Such behaviour can be observed in the tori 
that were used for triplicate studies, which is shown in Figure 7-2. Multiple sampling time points are also an 
issue. A study conducted by Zhang et al of BCS Class II drug formulations determined that multiple sample 
pulls from the dissolution vessel when compared to a single-pull resulted in different dissolution rates (459). 
This could be caused by the additional insertions and residence of the sampling probe in the vessel during 
multi-point sampling which subsequently causes disturbance of fluid hydrodynamics in the dissolution 
vessel (458). Hydrodynamic conditions are crucial to the drug release rate (460, 461). 
 
Figure 7-2: The individual sample in different positions during the dissolution after the sample was introduced. The individual drug 
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Random errors that arise can be minimized with the technological advancement of equipment. More 
sophisticated HME, 3DP, UV that improve precision will reduce the random variation. Using the cumulative 
drug release equation, in terms of process error, obtained in chapter 3, the reduced error will lead to a 
more accurate and precise drug release error estimate which would be valid for any generic sample 
prepared using the HME-3DP coupled method. Table 7-1 summarises the two types of irreproducible 
behaviour, which are either manufacture or measurement related, observed in this thesis. 
Table 7-1: Summary of the types of irreproducibility and the proposed solution in each case. 
Irreproducibility Solutions 
Measurement 
• Calibration curves • Using multiple calibration curves (minimum three) 
• Number of samples • More than three samples if intra-sample variation is high 
• Sample position • More samples if inter-sample variation is high 
• Number of sampling pulls • Less multiple pulls recommended 
• 3D object drug content estimation 
• Estimate drug content from weighing samples compared 
to estimating from volume 
Machine 
• Sampling method • Automated sampling better than manual sampling 
• Manufacture process type 
• Continuous coupled process (HME+3DP) or (In Vitro+UV) 
reduces the irreproducibility 
• General improvement of machine  • Better precision of all readings across all machines 
 
Some areas can be further investigated for reproducibility of 3D printed samples. Currently, there is no data 
on an optimum temperature difference between the printing temperature and platform temperature. 
Further investigation of this which will cause an improvement of systematic error observed for the volume 
of 3DP sample fluctuating from the design specification. 
7.2 Predictability 
Predictability was the other key area of this work. Predictability can be divided into three parts. The first is 
being able to predict the behaviour of the carriers of the formulation, which are the polymers. Chapter 4 
investigated the hydration, swelling, and erosion of some common polymers used in 3D printing. The focus 
was to be able to predict the behaviour, using an ideal polymer mixture model, for a 50/50% w/w miscible 
and semi-miscible blend that was prepared from two of the individual polymers studied. It was found that 
ideal polymer mixture laws would only be able to predict a specific behaviour if the constituting polymers 
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exhibited the same characteristic behaviour in the solvent. For example, the erosion could be predicted for 
HPMCAS/PEO and HPMCAS/Soluplus blends since HPMCAS, Soluplus, and PEO erodes. Since PEO swells but 
HPMCAS does not swell, the swelling for HPMCAS/PEO blend could not be predicted.  
 
This approach highlighted the benefits and limitations. The benefit would be that if the ideal mixture laws 
are valid, then it would be valid for any proportion of the blend. The limitation was due to the 
parametrisation approach used wherein even if the blend behaviour could be predicted by the semi-
empirical model, the model does not yield any insights about the mechanisms of blend behaviour. Also, 
blend behaviour can only be predicted if the individual polymer behaviour is known. In cases where the 
approach of ideal polymer mixture laws is invalid, a different approach is required. An alternative approach 
such as using the solubility parameter could be used. However, an issue exists that there is no good theory 
that predicts the behaviour of polymer blends generally in the same way that there is no general theory of 
liquid mixtures so the hope of a unifying theory is unpropitious. 
 
The second part of attempting prediction is being able to predict polymer behaviour in the presence of 
drugs. Chapter 5 investigated polymer behaviours in the presence of selected drugs. The hypothesis was 
that ionisable drugs affected the polymer behaviour compared to non-ionised drugs. The effect of ionisation 
was summarized and, in some cases, significant differences were observed while in other cases, no 
significant differences were observed. Several limitations existed. It was assumed that drugs do not interact 
with a polymer to form any drug-polymer complex. Classification and clustering were used to deduce any 
trend that may exist between the drug release, types of drug, and polymer behaviour. The third part of 
predictability is to be able to use a mathematical equation that reliably parametrises the drug release. 
Based on the parametrisation, a model can be used to predict unexperimented drug release profile. 
Deducing better equations can better predict the drug release with more accuracy and precision but this 
was not the focus of this work. The Peppas-Korsmeyer equation was used in this work which explains the 
drug release reasonably well. All data gathered in chapters 4 and 5 were used to create a dataset.  
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Chapter 6 investigated any trend in drug release profiles and polymer behaviour based on the dataset 
created. This was achieved by using a classification based on clustering, and principal component analysis 
(PCA). The first step was the classification of polymer behaviour. PCA performed on the drug release profiles 
yielded the most distinct reduced curves amongst all formulation curves. This yielded a trend in the drug 
release profiles based on the quantity released in a given time. Once again, it was observed that drug 
release is dominated by polymers rather than drug types or drug ionisation. However, pH-sensitive HPMCAS 
did not follow a clear trend. K-mean clustering was further performed on the PCA drug release curves which 
deduced that HPMCAS formulations are loosely clustered to zein formulation in pH 1.2 but form a different 
cluster in pH 6.8. The reason for this is, in pH 1.2, HPMCAS is insoluble and shares drug release profile that 
resembles zein formulation, which is very slow to achieve half release or complete release of the drugs. In 
6.8, the HPMCAS formulation resemblance is less like zein and more to PEO formulation but still not close 
enough to be clustered together with PEO formulation. Although this was successful for the dataset used, a 
logical extension to this approach would be to be able to predict the desired release profile for any given 
drug. The bottleneck limitation of the approach occurred at this stage. To be able to predict drug release for 
any drug, the scale of the dataset has to be sufficiently large and contain a diversity of the drug types and 
the different polymers candidates, which is discussed next. 
7.3 Future works  
This section discusses some of the future research areas that can help build on the concepts. These include 
scaling, simulation, and their potential applications in the design of personalization. 
7.3.1 Scaling 
A problem that arises with a dataset that is less than optimum is that higher sensitivity to outliers or 
erroneous data points exists which lead to overfitting, poor generalization, large bias, and variance (462, 




Figure 7-3: Problems encountered with small datasets for analysis. Type I error is the rejection of a true null hypothesis while a type 
II error is the acceptance of a false null hypothesis, which occurs in statistical hypothetical testing. 
Several methods exist to handle small datasets such as data augmentation, regularization, using confidence 
intervals, using simpler fitting models to the data, using ensemble approach among others (464). Yet, it has 
been suggested that the most efficient method is to increase the dataset size (463). With a large, general 
diverse dataset, additional refinement for the drug release prediction can become possible through deep 
machine learning (335, 462, 465). An example of deep learning is the artificial neural network (ANN), which 
has already been applied in chapter 6 and other works predicting drug release profiles (336). Furthermore, 
ANN is more efficient in learning and predicting any given outcome with scaling up the dataset. ANN is 
designed to be trained with existing data and predict for new additional untested data. This type of growth 
of data over time across sectors is known as consortium approach (464). 
7.3.2 Simulation 
Finally, the simulation will put the prediction into a meaningful application and speed up the process of 
dosage form development. A possible pipeline is shown in Figure 7-4. 
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There are many levels of simulation with the smallest range dealing with angstrom (?̇?) to a larger range of 
meters. Angstrom level simulations are quantum level models (QM) and meter level simulations are 
multiscale models (MM). In principle, all systems can be simulated by QM but this is extremely time 
consuming and computationally complex, and thus is impractical. Therefore, depending on particle size, an 
appropriate level of simulation is chosen. Particles in matrices can be simulated using finite element method 
(FEM) (466). Such FEM simulation could have a visual animation of drug released from the matrix as well as 
the predicted drug release profile. Figure 7-5 illustrates a concept of this FEM for a torus geometry that was 
simulated as time progresses using Blender which is a simulation rendering software. 
   
 
 
Figure 7-5: Top) Animation of drug particle releasing from a torus using blender software. Three snapshots of the torus are shown at 
different times. The arrow shows the progression of time for the snapshots. Bottom) The accompanying generated drug release 
profile.  
7.3.3 Personalization 
A milestone of achieving desired release profile would be to achieve personalization of multiple drugs. 
Polypill was mentioned in chapter 1. In this work, the predictability of solid dispersions containing a single 
drug and a single polymer were investigated. Predictability of multiple drugs with one or more polymers 
Time Progression for animation 
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(polypill) is an area of future investigations with the wider application in personalised polypill development. 
Such a polypill can also be expected to achieve a more complex profile such as a periodic drug release 
profile (467). A periodic pulsive drug release profile is where there is a drug release for a certain duration 
followed by no drug release for a duration and followed by drug release for a duration again. This would 
require using different layers of polymers or compartmentalizing to control the drug release from the matrix 
at different times. Such a layered tablet has already been 3D printed (49). A polypill containing up to five 
compartments has also been printed (468). A concept of layered torus polypill containing two drugs to 
achieve a periodic drug release profile is shown in Figure 7-6. Simulation of polypills will present a different 
set of challenges such as highly accurate prediction of drug dissolution profile at a molecular level especially 
in the case where the drugs can have a drug-drug interaction. As more drugs are added in the polypill, it is 
expected that the controlled release duration will be longer, and therefore, more sophisticated computer 
power will be required which can run the simulations at a molecular lever for a longer duration. 
 
Figure 7-6: Concept of a torus polypill designed to have different release profiles. The drug release profile for drug 1 is an example of 
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